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ABSTRACT 
A neutral protease of the neutrophil surface: 
Role in the proteolysis of C-reactive protein and fibrinogen 
Both of the acute phase reactants, C-reactive protein and fibrinogen, as well as neutrophils have been 
shown to accumulate at sites of tissue injury or inflammation. The association of C-reactive protein 
with neutrophils and the concomitant degradation of this ligand by a phorbol 12-myristate 13 acetate-
activatable membrane-associated neutral protease has been shown in previous studies. Degradation of 
C-reactive protein by the neutrophil protease was shown to result in peptides with an ability to 
modulate various immune functions of the neutrophil. The aim of this study has been to investigate 
specific characteristics of the protease, with respect to cellular distribution and molecular size. The 
ability of this neutrophil membrane-associated protease to degrade the acute phase protein, fibrinogen 
was investigated. The mechanism of degradation of both C-reactive protein and fibrinogen during their 
association with the neutrophil was also examined. 
The neutrophil protease, capable of degrading C-reactive protein, was also associated with the 
cytoskeleton and was proposed to be a submembrane protease localised at sites of attachment of the 
membrane with the cytoskeleton. The protease was found to have a molecular mass of approximately 
600 kDa which, on sodium dodecyl sulphate polyacrylamide gel electrophoresis, separated into four 
bands which migrated to molecular mass values of 209 kDa, 316 kDa, 398 kDa and 501 kDa. This 
protease also possessed fibrinogenolytic activity. The fibrinogen degradation products generated by 
this neutrophil membrane-associated protease were distinct from the products generated by the 
fibrinogenolytic systems of plasmin, human neutrophil elastase and neutrophil lysosomal enzymes and 
were unclottable through cleavage of the Aa chain from the N-terminus and the B~ and y chains from 
the C-terminus. N-terminal cleavage of the Aa chain by the neutrophil membrane-associated protease 
generated the Aa 1-21 peptide, previously regarded as a unique consequence of elastase activity. 
Degradation of C-reactive protein and fibrinogen occurred as a result of their interaction with the 
neutrophil near to the CDl lc integrin receptor. This interaction resulted in the egress of proteolytic 
activity into the extracellular medium. The fibrinogen products generated outside the cell associated 
with the neutrophil via the ~2 integrin receptors and the IgG F c receptor. The interaction of the C-
reactive protein degradation products with the neutrophil could not be determined. Both C-reactive 
protein and fibrinogen are degraded by non-stimulated neutrophils but activation with phorbol 12-
myristate 13 acetate resulted in maximum degradation This upregulation of activity was achieved 
through activation of H7 and trifluoperazine inhibitable cellular kinases and changes in microfilament 
assembly. 
The generation of non-clottable fibrinogen together with possible modulation of neutrophil receptor-
mediated functions by the fibringen degradation products as well as the knowledge that the neutrophil 
protease generates C-reactive protein peptides with immunomodulatory activity implicates this 
neutrophil membrane-associated protease in the modulation of various inflammatory processes. 
Sharon Lesley Kelly 
MRCIUCT Liver Research Centre 
Department of Medicine, UCT Medical School 
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The acute phase response has been described as a complex series of events subsequent to tissue 
injury or infection. One such event is the alteration in the rate of synthesis and secretion of a 
number of so-called acute phase proteins/reactants by the liver (Schultz and Arnold, 1990; 
Baumann and Gauldie, 1994). This occurs within 24 hours following an inflammatory insult and is 
mediated by the action of mononuclear cell cytokines, including IL-1 and IL-6, on the hepatocytes 
(Taylor et al., 1990; Schultz and Arnold, 1990; Baumann and Gauldie, 1994). In man, both C-
reactive protein (CRP) and fibrinogen are acute phase proteins and their levels may increase 
several 1000 fold above the normal serum levels of 1 µg/ml and 4 fold above 2 mg/ml, respectively 
(Claus et al., 1976; Yen-Watson and Kushner, 1974; Mavier et al., 1990). 
The precise in vivo function of CRP has not been elucidated but due to its remarkable phylogenetic 
and evolutionary conservation this role is believed to be beneficial and of importance during the 
inflammatory process (Pepys, 1982). Various hypotheses have been put forward in this regard 
based on the results of in vitro experimentation. For example, the ability of CRP to bind to a 
number of exogenous ligands, which may be liberated during the inflammatory reaction, and the 
subsequent activation of the classical complement pathway, points to the ability of CRP to act as 
an opsonin (Kaplan and Volanakis, 1974; Siegel et al., 1974; Pepys, 1982). It has been suggested 
that clearance of these ligands from the circulation occurs via the C3b receptor as well as a CRP 
receptor, as yet unidentified, on both the neutrophils and mononuclear phagocytes (Buchta et al., 
1987; Zeller and Sullivan, 1993; Zahedi et al., 1989; Tebo and Mortensen, 1990; Egenhofer et al., 
1993). Evidence also exists that CRP and CRP peptides, which are generated by monocytic or 
neutrophil-mediated proteolytic processing, can modulate certain inflammatory functions of cells 
important in the immune response (Dobrinich and Spagnuolo, 1991, Buchta et al., 1987b; 
Shephard et al., 1986a; Shephard et al., 1988; Shephard et al., 1989; Shephard et al., 1990; Robey 
et al., 1990; Tebo and Mortensen, 1991; Foldes-Filep, 1992). CRP peptides, generated by 
proteases associated with the neutrophil lysosomes and membranes, have been shown to modulate 
neutrophil chemotaxis, oxidative metabolism, degranulation and phagocytosis (Shephard et al., 
1986a; Shephard et al., 1988; Shephard et al., 1989; Shephard et al., 1990; Robey et al., 1987). 
The inhibitory activity of these peptides was shown to be due to the inhibition of the glycolytic 
enzyme, enolase which results in the inhibition of glycolysis and a subsequent decrease in 
intracellular ATP levels (Shephard et al., 1992). This may play an important role in the 
modification of neutrophil function at inflammatory sites thus inhibiting the tissue destructive 
potential of neutrophils at these sites. 
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CRP peptides, derived from the proteolytic activity associated with the neutrophil membrane, have 
been shown to be produced during association of CRP with neutrophils which have been stimulated 
with the phorbol ester, phorbol 12-myristate 13 acetate (PMA), at a concentration that does not 
release proteases from the azurophilic granules (Shephard et al., 1989). The neutrophil membrane-
associated protease was found to be a PMA-upregulatable enzyme which is maximally activated in 
the presence ofCRP (Shephard et al., 1989; Shephard et al., 1991). Thus, CRP peptides, with the 
potential to modulate inflammatory functions, can be generated without intracellular processing, 
following the association of the intact ligand with the neutrophil surface at relatively low neutrophil 
activation states. 
The increased hepatic synthesis of fibrinogen, in response to various inflammatory cytokines, is 
considered to be a necessary requirement for adequate tissue repair (Doolittle, 1981; Lau et al., 
1993). At an inflammatory site, fibrinogen may be converted to fibrin via the action of the serine 
protease, thrombin (Bailey et al., 1951 ). Thrombin is generated from prothrombin at the final stage 
of a complex cascade of coagulation factor-mediated events. Tissue factor, expressed on the 
surface of activated endothelium and mononuclear cells in response to tumour necrosis factor and 
IL- I, is responsible for initiating this coagulation cascade (Edwards and Rickles, 1992). Thrombin 
has multi-functions including the recruitment of neutrophils to sites of inflammation. This is 
achieved through the ability ofthrombin to upregulate endothelial expression of P-selectin, which is 
a glycoprotein receptor capable of interacting with specific ligands, on the neutrophil surface 
(Zimmerman et al., 1992). This initial 'tethering' of the neutrophil to the endothelium is believed to 
result in further adhesion processes, mediated by the J32 integrin receptors on the neutrophil surface 
and members of the immunoglobulin superfamily on the endothelial cells (Zimmerman et al., 1992; 
Adams and Shaw, 1994). Neutrophil adhesion to the endothelium is thus strengthened and the cells 
are able to migrate from the vasculature toward the site of inflammation (Zimmerman et al., 1992). 
Once at the inflammatory site, neutrophils are believed to interact with fibrinogen via the J32 and J33 
(leukocyte response integrin [LRI]) neutrop1.i.l integrins (Wright et al., 1988; Loike et al., 1991; 
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Gresham et al., 1992). Soluble fibrinogen has also been shown to bind to the neutrophil ~2 
integrin, CD1 lb/CD18, via the sequence Gly 190-Val 202 which resides in a 30 kDa plasmin-
derived fibrinogen degradation product (Altieri et al., 1993). The consequence of this association 
was not evaluated. The interaction of immobilised fibrinogen with neutrophils has been shown to 
result in the activation of neutrophil oxidative metabolism and the release of neutrophil granules 
with subsequent degradation of the fibrinogen by elastase (Weitz et al., 1987). Fibrinogenolysis by 
elastase, as well as other neutrophil enzyme preparations, including cathepsin G and lysosomal 
enzymes, was shown to be distinct from that ofplasmin (Bilezekian and Nossel, 1977; Gramse et 
al., 1977, Plow, 1980; Weitz et al., 1987; Pizzo et al., 1972). The binding of soluble fibrinogen to 
the neutrophil LRI enhanced neutrophil Fe receptor-mediated phagocytosis (Brown et al., 1990; 
Zhou and Brown, 1993). Studies investigating the interaction of soluble fibrinogen with 
neutrophils, have not evaluated possible concomitant degradation of the ligand and the influence of 
such neutrophil-mediated fibrinogenolysis on the accumulation of fibrin at inflammatory sites. 
THE AIMS OF THIS STUDY 
From previous studies investigating the biological significance of the acute phase reactant CRP, it 
is apparent that the generation of biologically active CRP peptides, following the interaction of 
CRP with a neutrophil membrane-associated protease (Shephard et al., 1989), may have important 
consequences on the inflammatory process. It is tenable that other ligands may be degraded by this 
neutrophil membrane associated protease. Soluble fibrinogen has been shown to be degraded by 
neutrophil lysosomal enzyme preparations (Bilezikian and Nossel, 1977; Gramse et al., 1977; 
Weitz et al., 1986; Gramse et al., 1980) but the ability of these proteases or proteases associated 
with the neutrophil membrane to act as fibrinogenolytic agents during the interaction of fibrinogen 
with intact neutrophils has not been investigated. The consequences of such degradation of 
fibrinogen may well influence the deposition of fibrin at inflammatory sites. 
The aim of this study will thus include: 
a) an investigation of the mechanisms involved in the neutrophil mediated processing of CRP, 
b) characterisation of the membrane associated protease with respect to CRP and fibrinogen as 
substrates, 
c) characterisation of the neutrophil protease with respect to cellular distribution and molecular 
size, and 
d) an investigation of fibrinogenolysis by this neutrophil membrane-associated protease. The 
relative role of neutrophil membrane and lysosomal proteases in fibrinogenolysis during the 
interaction of fibrinogen with intact neutrophils will be investigated. 
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2.A. C-REACTIVE PROTEIN (CRP) 
2.A.1. INTRODUCTION 
CRP is present in trace amounts in normal plasma (±70 ng/ml in neonates and ±600 ng/ml in 
adults) and is described as a classical acute phase reactant in man. Following acute tissue injury, 
infection or inflammation hepatic synthesis of this protein occurs and its concentration may rise to 
as much as 1000 µg/ml within 24-48 hr (Claus et al., 1976; Yen-Watson and Kushner, 1974). 
Serum levels of CRP have been used as an important indicator of the presence, extent and activity 
of disease (Pepys, 1982). 
CRP is one of two members of the pentraxin family of proteins, the other being serum amyloid 
protein (SAP). SAP is a normal plasma glycoprotein in man and the circulating levels (30 mg/ml) 
are not altered by inflammatory processes (Pepys and Baltz, 1983; Dyck et al., 1980; Breathnach 
et al., 1981 ). CRP is composed of five identical, non-glycosylated, non-covalently associated 
polypeptide subunits which are arranged in a disc-like configuration with cyclic pentameric 
symmetry (Pepys, 1982). SAP is composed often identical glycosylated polypeptide subunits that 
are non-covalently associated in two pentameric disc-like rings which interact 'face to face' (Pepys 
and Baltz, 1983). The genes for both CRP and SAP are located on chromosome 1 (Floyd-Smith et 
al., 1986) suggesting that these genes are derived from a single gene duplication event. Both 
proteins share approximately 60% sequence homology and both bind, calcium dependently, to 
specific ligands. This binding specificity is presumably related to their function although their 
precise biological role remains uncertain. Since both CRP and SAP exhibit highly stable 
evolutionary conservation it is presumed that their function is one of importance and is beneficial 
to the organism. Various hypotheses have been put forward regarding CRP function and these 
include the ability of CRP to precipitate and agglutinate its ligands e.g. foreign pathogens and 
toxic materials released into the circulation from dead or damaged cells and tissue. This leads to 
the activation of the classical complement cascade, facilitating the clearance of these ligands from 
plasma via phagocytic processes (Pepys, 1982). CRP has thus been described as a pro-
inflammatory mediator of non-specific host resistance. CRP has also been shown to stimulate the 
production of various inflammatory mediators e.g. the interleukins, IL- la, IL-1 ~' IL-6 and 
tumour necrosis factor (TNF) and conversely, has been found, at higher concentrations, to 
stimulate the production of the IL-1 receptor antagonist, thus assisting in the downregulation of 
the inflammatory effects ofIL-1 (Tilg et al., 1993). CRP may serve a dual role of initially 
amplifying the inflammatory response when, for example, a pathogen is present, and down-
modulating the response when the pathogen has been eradicated. This may prevent the 
development of pathological inflammatory disorders. 
15 
SAP is known to associate with the amyloid fibrils during amyloidosis and is presumed to be 
involved in its pathogenesis (Pepys, 1982). SAP is also believed to be the predominant chromatin 
and DNA-binding protein thus facilitating opsonisation and subsequent clearance of the nuclear 
material from dead or damaged cells and consequently preventing the generation of autoimmune 
products (Pepys et al., 1994). SAP has been shown to bind Ca2+ dependently to immobilised CRP 
and this may allow the localisation of SAP to sites of tissue damage or repair or sites where CRP 
is selectively deposited (Swanson et al., 1992). 
Recently a third member of the pentraxin family has been identified as PTX3 (Brevario et al., 
1992). PTX3 was cloned as an IL-I inducible gene in endothelial cells with significantly 
homologous C-terminal sequences to CRP and SAP. PTX3 expression and secretion was 
subsequently found to be inducible in fibroblasts by IL-1 (Lee et al., 1993) and in mononuclear 
phagocytes by lipopolysaccharide (LPS) and to a lesser extent TNF (Alles et al., 1994). 
2.A.2. THE ACUTE PHASE RESPONSE 
Acute infections or tissue damage, together with various inflammatory stimuli, result in several 
dramatic humeral and cellular changes and this is referred to as the acute phase response (APR). 
Major changes which may occur during the APR include fever, vaso-active amine and arachidonic 
acid pathway-induced vascular permeability increases, neutrophilia, anaemia, changes in plasma 
steroids, hormones and metal ion concentrations, negative nitrogen balance and increased de novo 
synthesis and catabolism of a wide variety of proteins (Schultz and Arnold, 1990; Baumann and 
Gaul die, 1994). These changes are believed to promote survival during the period immediately 
following injury or infection, possibly resulting in the removal of infectious agents, removal of 
damaged tissue, protection against further damage and repair of affected organs. 
The liver is the major organ involved in the APR with respect to the production of the acute phase 
proteins. This synthesis is the result of a co-ordinated interaction between the hepatocytes and 
various stimulatory cytokines e.g. IL-6, IL-1, TNF-a, Transforming growth factor S (TGF-S), y-
interferon (y-IFN), epidermal growth factor (EGF) and leukemia inhibitory factor (Taylor et al., 
1990; Schultz and Arnold, 1990). The inflammatory mediators or cytokines are predominantly 
produced by the tissue macrophages or blood monocytes (Baumann and Gauldie, 1994). It has, 
however, been demonstrated that leukocytes may synthesise and release their own particular set of 
cytokines within the target tissue (from Baumann and Gauldie, 1994). 
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The serum levels of the acute phase proteins may vary considerably during the APR as some may 
increase while others decrease. The levels of these proteins may also vary between different 
species (Schultz and Arnold, 1990). It is, however, difficult to quantitate the changing levels of 
some acute phase reactants as an increase in serum levels may be accompanied by a parallel 
increase in the catabolic rate of these proteins. Acute phase proteins which increase approximately 
50% above normal levels in human serum include ceruloplasmin and the complement protein C3, 
while CRP and serum amyloid A protein (SAA) increase dramatically (up to 1000 fold) above 
normal levels (McAdam et al., 1978). Fibrinogen, haptoglobin, a.1-acid glycoprotein, a.1-
antitrypsin ( a.1 AT) and a.1-antichymotrypsin increase approximately two to four fold during the 
acute phase response (Mavier et al., 1990). Other proteins which increase in concentration include 
the complement compounds C2, C5, C6, C9, factor B and total haemolytic C activity (Takahashi 
et al., 1974; Bamberger et al., 1978). On the other hand, the serum concentration of albumin, 
transferrin and a.2-Hs glycoprotein decrease during the acute phase response and are referred to as 
negative acute phase reactants (Lebreton et al., 1979). 
2.A.3. PHYLOGENETIC CONSERVATION OF CRP 
CRP demonstrates significant phylogenetic conservation. Many different species contain CRP-
like molecules where CRP-likeness is evaluated mainly by its ability to specifically bind 
phosphorylcholine (PC) (see 2.A.6. Ligand specificity of CRP). Examples of the numerous species 
shown to contain CRP-like molecules include a living fossil, the horseshoe crab or Limulus 
polyphemus (Robey and Liu, 1981; Mandal et al., 1991), the Japanese eel (Nonomura, 1991), the 
snail (Manda! et al., 1991), the bony fish (plaice and the lumpsucker) (Baldo and Fletcher, 1973), 
Xenopus laevis (Seery et al., 1993), rabbits (Dougherty et al., 1991 ), chickens, mice (Patterson 
and Mora, 1964), hamsters (Coe et al., 1981), dogs (Riley and Coleman, 1970; Yamamoto et al., 
1992)), horses (Takiguchi et al., 1990) and monkeys (Abernethy, 1937). The guinea pig is the only 
species studied thus far in which CRP has not been detected (Maudsley et al., 1986). 
Despite various functional and broad structural similarities between CRP-like molecules of 
different species Ying et al. ( 1992a) have shown that a monoclonal antibody reactive with the PC 
binding site of human CRP (hCRP) does not react with Limulus or rat CRP and is 100 times less 
reactive with rabbit CRP. Similarly, a polyclonal antibody directed against the calcium binding site 
of Limulus CRP reacts only weakly with hCRP and rabbit CRP and not at all with rat CRP and 
hamster female protein (see below). Limulus CRP contains the highly conserved PC and
 Ca2+ 
binding regions, but it demonstrates only 25% sequence homology with hCRP and e
xists as two 
trimers of similar but non-identical subunits to form a hexagonal ring structure, rathe
r than the 
characteristic pentamer of CRP (Myles et al., 1990). On the other hand, the mouse CRP
 gene has 
been cloned and shown to have 71 % sequence similarity with the hCRP gene as wel
l as a similar 
structural organisation (Ku and Mortensen, 1993). 
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Differences between the CRP-like molecules also exist in their acute phase behaviou
r where, for 
example, levels of Limulus, rat and cow CRP are constitutively high and only a margina
l or no 
inducible response to the acute phase occurs (Pepys and Baltz, 1983) while mouse C
RP is a minor 
plasma protein and its levels increase marginally from ±0.1 to 1 or 2 µg/ml during in
flammation 
(Ku and Mortensen, 1993). On the other hand, hCRP (McAdam et al., 1978), rabbit (D
ougherty et 
al., 1991) and horse CRP (Takiguchi et al., 1990) show very low resting levels which i
ncrease 
dramatically following tissue injury or disease. 
An interesting CRP-like molecule has been identified in female Syrian hamsters by Coe e
t al. 
(1981) termed hamster female protein (FP). It was so named as its synthesis appears to 
be under 
dual sex steroid and acute phase control. The resting FP levels are low in males but h
igh in females 
and following an acute phase response there is a rise in the levels in the male hamste
rs but a drop in 
the FP levels of the females. Despite the ability ofFP to bind PC and activate the cla
ssical 
complement pathway, it has since been suggested that FP is in fact the counterpart o
f SAP in 
humans, due to its localisation in amyloid deposits and its amino acid sequence homo
logy with SAP 
(Tennent et al., 1993; Rudnick and Dowton, 1993). It was also suggested that a true CR
P 
counterpart, apart from FP, may exist in the hamster. 
2.A.4. THE CRP GENE 
The genes encoding both CRP and SAP are located on the proximal long arm of chr
omosome 1 
between bands ql2 and q23 (Floyd-Smith et al., 1986). Due to their similarities in basic
 structure 
and amino acid sequence and their location on chromosome 1, it has been suggested
 that CRP and 
SAP are the products of an ancestral gene duplication event and have maintained a l
inkage 
relationship throughout evolution (Yunis and Whitehead, 1990). 
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The same region on chromosome 1 has also been shown to contain genes for apolipoprotein A-II, 
a-spectrin, peptidase C, antithrombin 3, complement factor H, CR-2 receptor, several Fe 
receptors, H4 and possibly H3 histones and selectins (Yunis and Whitehead, 1990; Bevilacqua, 
1993). There appears, therefore, to exist a complex of linked genes, the products of which have 
immune and inflammatory associated roles as well as the capacity to interact with DNA (see 
2.A.7.3. Interaction with chromatin). 
The complete amino acid sequence ofhCRP has been determined (Oliviera et al., 1979) (Fig IA). 
The mature protein contains 206 amino acids including a leader sequence of 19 amino acids which 
is typical of a secreted protein (Lei et al., 1985). Nucleotide sequence analysis of the coding region 
for CRP shows it to be typical for eukaryotic genes, namely non-linear. The 5' and 3' non-coding 
sequences have also been determined (Lei et al., 1985). Typical promoter regions described as a 
TATA box and CAAT box, are located 29 and 81 nucleotides upstream of the CAP site but 
Toniatti et al. ( 1990) have described an unusual feature of the CRP promoter region. It comprises 
two distinct, so-called acute phase responsive elements (APRE's) which contain the information 
for both liver specific/constitutive and IL-6 inducible expression. Both of these APRE's contain 
low affinity binding sites for the liver specific transcription factor HNF-1/LFBI (HNF 1). Low 
level or constitutive expression of CRP requires weak interaction of both APRE's with HNF 1 
while acute phase expression of CRP requires the interaction of the APRE's with an IL-6 inducible 
transcription factor H-APF-2/IL6DBF (H-APF-2). Both APRE's have been shown to contain 
binding sites for H-APF-2 downstream of the HNF-1 binding sites. HNF-1 thus ensures liver 
specific, constitutive expression of CRP whereas H-APF-2 confers acute phase, IL-6 inducible 
expression. 
2.A.5. SYNTHESIS AND SECRETION OF CRP 
It was initially believed that CRP was synthesised exclusively by hepatocytes (Hurlimann et al., 
1966). Since then, extrahepatic transcription of CRP has been reported in, for example, human 
peripheral blood lymphocytes (Kuta and Baum, 1986) and peripheral blood mononuclear cells 
(PBMC's) (Ikuta et al., 1986) which synthesise a peptide that is recognised by anti-CRP. Murphy 
et al. (1991) also demonstrated the ability ofPBMC's to transcribe the CRP gene. However, while 
hepatocytes express secreted CRP, peripheral blood cells express a membrane bound form of the 
protein (Baum et al., 1983; Kuta and Baum, 1986). Kempka et al. (1990) initially demonstrated 
that CRP may be constitutively expressed as a galactose specific binding protein situated 
peripherally in the membrane of rat liver macrophages (mCRP). 
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PCA - Thr -Asp -Met -Ser -Arg -Lys -Ala -Phe -Val - Phe -Pro -Lys -Glu -Ser- 15 
Asp - Thr - Ser - Tyr -Val -Ser - Leu -Lys -Ala -Pro -Leu -Thr -Lys -Pro -Leu 30 
Lys - Ala - Phe -Thr -Val -Cys -Leu - His -Phe -Tyr -Thr -Glu -Leu -Ser -Ser 45 
Thr - Arg - Gly -Tyr -Ser - Ile - Phe - Ser -Tyr -Ala -Thr -Lys - Arg -Gln -Asp 60 
Asn - Glu - Ile -Leu - Ile - Phe -Trp -Ser -Lys -Asp - Ile - Gly -Tyr - Ser -Phe 75 
Thr - Val - Gly -Gly - Ser -Glu - Ile - Leu -Phe -Glu - Val -Pro -Glu -Val -Thr 90 
Val - Ala - Pro -Val - His -Ile - Cys -Thr -Ser - Trp - Glu -Ser -Ala - Ser -Gly 105 
Ile - Val - Glu -Phe -Trp -Val -Asp -Gly -Lys -Pro - Arg -Val -Arg -Lys -Ser 120 
Leu - Lys -Lys -Gly - Tyr -Thr -Val - Gly-Ala - Glu - Ala -Ser - Ile - Ile - Leu 135 
Gly - Gln - Glu - Gln - Asp -Ser -Phe -Gly -Gly -Asn - Phe -Glu -Gly -Ser -Gln 150 
Ser - Leu - Val -Gly- Asp -Ile- Gly-Asn -Val-Asn - Met -Trp -Asp -Phe -Val 165 
Leu - Ser - Pro -Asp -Glu - Ile - Asn -Thr- Ile - Tyr - Leu -Gly-Gly - Pro -Phe 180 
Ser - Pro - Asn -Val -Leu -Asn -Trp -Arg -Ala -Leu - Lys -Tyr -Glu - Val -Gin 195 
Gly - Glu - Val - Phe -Thr-Lys - Pro -Gln -Leu -Trp -Pro - OH 206 
Figure IA. The Structure of Human C-reactive protein. The amino acid sequence of human 
CRP from residues 1-206 (from Fiedel, 1988) 
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Egenhofer et al. (1993) subsequently provided evidence that this membrane bound CRP was 
synthesised·by macrophages and was not acquired externally. They also showed that this membra
ne 
form of CRP does not exist as a pentamer, as does the soluble form, but exists as subunits with 
neo-CRP antigenicity within the macrophage membrane. Neo-CRP has been described as an 
antigenically distinct form of CRP which arises under certain conditions of adsorption or 
modification such that the native CRP undergoes conformational alterations and results in the 
release ofCRP subunits from the pentamer (Bray et al., 1987; Potempa et al., 1987). Neo-CRP 
may also be observed during CRP biosynthesis before aggregation of the subunits. The free 
subunits have reduced solubility, altered electrophoretic mobility (molecular mass 22 kDa) and 
unique surface characteristics due to exposed antigen epitopes which would otherwise be hidden 
in 
the pentameric configuration. The biological activity of the neo-CRP is consequently different to 
that of native CRP. It appears that neo-CRP preferentially activates the elements in the blood 
important in the inflammatory response (see 2.A. 7. Biological significance of CRP) and is unable 
to 
activate the complement system. Native CRP, complexed with C-polysaccharide (CPS), on the 
other hand, shows preferential activity in the humoral complement system (Bray et al., 1987; 
Potempa et al., 1987). Neo-CRP is found in the acute phase plasma and is preferentially expressed 
in inflammatory and necrotic tissues (Bray et al., 1987; Potempa et al., 1987). It may be that 
hepatocytes synthesise and release pentameric CRP which remains inactive until it reaches sites of
 
inflammation while peripheral blood cells at sites of inflammation might express a conformationall
y 
active form ofCRP (Murphy et al., 1991). This would support suggestions ofCRP being involved 
in cell-mediated immunity. 
In the case of hepatic synthesis ofCRP, the first cells to produce CRP are adjacent to the portal 
areas. During a sustained inflammatory response cells closer to the centre of the lobules become 
involved (Kushner and Feldmann, 1978). This suggests the action of a circulating mediator which
 
acts initially at the portal areas and extends into the lobule with time. It was originally thought that 
IL- I was the circulating mediator solely responsible for the induction of CRP synthesis (Darlingto
n 
et al., 1986) but there have since been reports that IL-6 may in fact be the principle mediator 
(Schultz and Arnold, 1990). Much conflicting evidence.has been produced in this regard, all of 
which seems to point to a complex co-operation between different soluble mediators. Ganapathi e
t 
al. (1991) as well as Smith and McDonald (1992) have demonstrated that induction of CRP in the 
Hep 3B cell line required the co-operative interaction of IL-1 and IL-6. This was potentiated by th
e 
synthetic corticosteroid dexamethasone and neither IL-1, IL-6 nor dexamethasone could elicit 
synthesis on their own. It was shown that either II -1 or IL-6 could induce CRP synthesis as long 
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as minimal amounts of the other cytokine were available. On the other hand Yap et al. (1991) and 
Taylor et al. (1990) both showed that IL-1 and IL-6 could stimulate CRP synthesis on their own 
using primary hepatocyte cell cultures and a hepatoma cell line, respectively. Castell et al. ( 1990) 
showed that in primary hepatocyte cultures only recombinant IL-6 and not IL-1 ~ could induce 
CRP production which could be augmented by dexamethasone. It was suggested by Ganter et al. 
(1989) that the transcription of CRP is controlled by IL-6 and the translation by IL-1. Other 
inflammatory mediators have been implicated in the modification of CRP production. TNF-a has 
been shown to inhibit the stimulatory activity of IL-1 and IL-6 on primary hepatocyte cultures 
(Yap et al., 1991). TGF-~ was found to be a potent regulator of CRP synthesis by hepatocytes at 
the post-transcriptional level, but this effect was found to be very much dose dependent (Taylor et 
al., 1990). High concentrations ofTGF-~ (>0,1 pg/ml) caused inhibition ofCRP accumulation in 
NPLC/PRF/5 cells treated with both IL-1 and IL-6. Low concentrations ofTGF-~, on the other 
hand, resulted in stimulation of CRP accumulation. Ganapathi et al. (1990) showed that the 
induction of CRP synthesis by the conditioned medium ofLPS stimulated monocytes and IL-1 and 
IL-6 stimulated hepatoma cell lines, Hep 3B and NPLC/PRF/5, was potentiated 3-6 fold by the 
methylxanthine, caffeine. Yiangou et al. ( 1991) demonstrated that heavy metals, especially Hg, 
stimulated CRP production in mouse liver and in the Hep G2 cell line, in the presence of 
glucocorticoids. It has also been proposed that the production of rat CRP may be partly under 
hormonal control as serum estradiol-17~ was shown to have an inhibitory effect on CRP 
production and testosterone stimulated it (Nunomura, 1990). 
One may conclude from these studies that CRP production may be under varying control in cells 
or cell lines of differing origin and is ultimately the result of a complex interaction of a number of 
inflammatory mediators. Macintyre (1992) also described the upregulation of CRP production in 
the hepatocyte during the acute phase response to occur at a posttranslational level. This appears 
to occur via preferential retention or secretion of CRP from the endoplasmic reticulum (ER) due 
to the presence of both high and low affinity CRP binding sites in the ER of normal hepatocytes 
and the loss of the high affinity CRP binding site in hepatocytes under acute phase control. 
Consequently, the half-time for CRP secretion by the hepatocyte decreases markedly in association 
with increased synthesis during the acute phase response. 
2.A.6. LIGAND SPECIFICITY OF CRP 
The ability to bind to phosphorylcholine (PC) is considered a common functional characteristic 
of CRP molecules from all species (Pepys and Baltz, 1983). PC forms part of the pneumococcal 
CPS cell wall, is present in many other bacteria, parasites, fungi and plant extracts and is also an 
integral component of cells which is likely to be abnormally exposed or released from damaged 
tissues (Pepys, 1982; Baldo and Fletcher, 1973). 
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Each CRP molecule binds 2 ca2+ ions and the Ca2+ binding site was initially believed to reside in 
a four amino acid acidic region within the highly conserved region between amino acids 133-147 
(Swanson et al., 1991) (Fig IA). A second Ca2+ binding site has subsequently been identified in 
the amino acid residues 152-176 (Mullenix and Mortensen, 1994) (Fig IA). Following Ca2+ 
binding these two, nearly adjacent sites, cooperate to exert a conformational change which 
promotes binding to PC as well as other ligands (see below). 
The PC binding site on the CRP molecule is believed to reside between amino acids 4 7 and 63 (Fig 
lA). The anion residues Lys-57 and Arg-58 are thought to bind (but not solely) to the phosphate 
ester while Trp-67 binds to the choline group (Swanson and Mortensen, 1990; Agrawal et al., 
1992). It is believed that the phosphate group of PC is critical for binding (Gotschlich, 1982). 
Apart from it's PC specificity CRP can bind to a number of other ligands e.g. the polycations. 
These include L-lysine and L-arginine polymers, protamine, myelin basic protein, leukocyte 
cationic protein and histone protein (Potempa et al., 1981; Shephard et al., 1991; Du Clos et al., 
1991 a). This binding is inhibited by Ca2+ alone but is promoted in the presence of CPS and ca2+ 
suggesting that the polycation binding site closely approximates the PC binding site and ca2+ may 
function as an allosteric modulator (Oliviera et al., 1980; Young and Williams, 1978). Other 
ligands for CRP lack both phosphate and choline. CRP binds to, for example, depyruvylated type 4 
polysaccharide (Heidelberger et al., 1972), agarose (Pepys et al., 1977) and galactose residues 
present in various glycans (Kempka et al., 1990; Kottgen et al., 1992). This binding specificity 
may be physiologically relevant as Kempka et al. (1990) demonstrated that CRP can exist as a 
galactose-specific binding protein in the membrane of rat liver macrophages (see 2.A.5. Synthesis 
and secretion of CRP). The membrane bound CRP may thus act as a receptor for mediating 
galactose specific endocytosis of particulate ligands at sites of inflammation. The fact that the 
optimum pH for binding was 6. 0 further validated this theory as this pH is representative of 
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inflammatory sites. Binding of CRP to sugars is Ca2+ dependent, inhibitable by PC and is thus 
believed to involve the PC binding site in the CRP molecule. CRP may also bind to extracellular 
matrix proteins e.g. aggregated or surface bound fibronectin and laminin (Swanson et al., 1989). 
This binding is Ca2+ dependent and is believed to occur via the PC binding region although Mori 
et 
al. (1991) indicated it to be PC independent. CRP binds to the phosholipids lecithin and 
sphingomyelin (Volanakis and Narkates, 1981) as well as low density lipoprotein (LDL) and trace
s 
of very low density lipoprotein (VLDL) (De Beer et al., 1982). 
Neo-CRP (as described above in 2.A.5. Synthesis and secretion of CRP) has distinct surface 
properties from the native pentameric CRP and is unable to bind PC or Ca2+ (Bray et al., 1987). 
2.A.7. BIOLOGICAL SIGNIFICANCE OF CRP 
In summary, the biological significance of CRP activity includes activation of the complement 
cascade (Kaplan and Volanakis, 1974; Siegel et al., 1974) following opsonisation ofligands 
through the Ca2+ dependent binding of CRP with PC moieties within the various CRP ligands 
(Mortensen and Dusciewicz, 1977). This leads to the clearance of the ligand by phagocytic cells. 
CRP has also been shown to lead to the direct activation of macrophages and neutrophils (Zahedi 
and Mortensen, 1986; Barna et al., 1987; Kilpatrick and Volanakis, 1985; Zeller et al., 1986a; 
Zeller et al., 1986b). 
2.A.7.1. Interaction with complement 
Human CRP, aggregated with itself, CPS or other ligands, activates the classical complement (C) 
pathway as efficiently as the immunoglobulin IgG (Kaplan and Volanakis, 197 4). Activation of C 
was observed preferentially with CRP ligand complexes or CRP aggregates where the native 
conformation of CRP and the expression of native CRP antigenicity was maintained (Jiang et al., 
1991). Neo-CRP (as described in 2.A.5. Synthesis and secretion of CRP) is unable to activate the 
complement system, as is the native, pentameric CRP. 
Whereas IgG consumes all components of C, CRP only consumes 80% of the haemolytic 
components Cl, C4 and C2 and 42-66% ofC3. The membrane attack complex of C5-C9 is not 
consumed by CRP at all. The binding of CRP to a ligand thus results in the activation of early 
components of the classical complement pathway (Berman et al., 1986; Osika et al., 1983). The 
required human serum factor was found to be Clq for both CRP ligand complexes and IgG (Claus
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et al., 1977), however, Jiang et al. ( 1991) demonstrated that IgG binds to the globular region ( GR) 
of Clq and CRP binds to the collagen-like region (CLR). More specifically, CRP binds to the 
peptides 76-92 and 14-26 of the A chain of reduced Clq whereas IgG binds to the C chain of 
reduced Clq. It is believed that Clq binding and subsequent activation occurs via a conformation 
rather than sequence specific site on CRP (Jiang et al., 1991). The optimum pH for binding is 6.3, 
which is within the physiological range normally found at inflammatory sites (Miyazawa and Inoue, 
1990). CRP may thus undergo a pH dependent conformational change which effects its binding 
with Clq. Miyazawa and Inoue suggested the binding site on CRP for C to be the PC binding site 
but this was disputed by Jiang et al. (1991). This controversy may be due to the fact that the 
studies of Jiang et al. were conducted in normal human serum while those of Miyazawa and Inoue 
were performed in vitro at pH 6.3, representative of inflammatory conditions. This may imply a 
mechanism for the clearance of foreign and unwanted ligands at sites of inflammation. A study by 
Agrawal and V olanakis ( 1994) indicated, by site-directed mutagenesis, that the C binding site is 
dependent on the negative charge of Asp-112 which is unique as it appears to be modulated by the 
positively charged Lys-114 (Fig IA). 
2.A. 7 .2. Interaction with lipids 
As mentioned, CRP binds to certain lipids, phosholipids as well as LDL and traces of VLDL 
(Volanakis and Wirtz, 1979; De Beer et al., 1982). Nunomura and Hatekeyama (1990) have 
shown that LDL binds to CRP via the Arg residues of the PC binding site of the CRP molecule. 
Despite the fact that the activity of plasma lipoprotein lipase (LPL) and hepatic lipase (HL) falls 
during the acute phase response, LDL and VLDL triglycerides also fall during the acute phase 
(Sammalkorpi et al., 1990). It is proposed that the binding of CRP during the acute phase to 
VLDL and LDL may enhance their metabolism and facilitate their removal (see 2.A.7.7. 
Interaction of CRP with monocytes and macrophages) during infection and inflammation. 
Mookerjea et al. ( 1993) suggested that the association of rat CRP with LDL results in a charge 
modification of the LDL molecule which leads to the stimulation of its degradation by 
macrophages. Substantiation for the physiological role of CRP binding to lipids was demonstrated 
when CRP was able to interact with liposomes containing dimyristoylphosphatidylcholine : 
cholesterol : galactocylceramide, resulting in complement activation of the classical pathway, 
followed by membrane lysis of the liposome membrane (Mold et al., 1981). 
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2.A. 7 .3. Interaction with chromatin 
In 1984 Robey et al. demonstrated the binding of CRP to the nuclei of fibroblasts damaged in 
culture. They also demonstrated rabbit CRP binding specifically to chromatin in the presence of 
ca2+ with an approximate stochiometry of 1 CRP molecule/160 base pairs of DNA. They 
subsequently showed binding of CRP to the nucleosome core particles but these studies were done 
in non-physiological saline and were disproved by Du Clos et al. (1991a) using hCRP. Du Clos et 
al. (1991a) did, however, validate the ca2+ dependent binding ofhCRP to chromatin. 
It was originally thought that CRP could not bind to the histones alone (Tanaka and Sueishi., 
1983) but Du Clos et al. (1991a) demonstrated that human CRP could bind the H3-I4 tetramer, 
the H2A-H2B dimer as well as the individual histones H2A, H2B and H l · CRP binding to H 1 was 
abolished upon addition of DNA, possibly indicating that binding of CRP to chromatin differs to 
that of binding to H 1 alone (Du Clos et al., 1991a). Minota et al. (1993) subsequently 
demonstrated the presence of two CRP binding sites on the H 1 molecule. One of these CRP-
binding sites was found to be approximately 20 amino acids long, Ca2+ independent and 
corresponded to the DNA-binding site ofH l · The addition of DNA might, therefore, sterically 
inhibit the binding of CRP to this site. The second CRP binding site on H 1 was found by Minota et 
al. (1993) to be approximately 25 amino acids in length, Ca2+ dependent, PC inhibitable and did 
not correspond to the DNA-binding region of H 1 or an autoepitope of H l · This Ca2+ dependent 
CRP-binding site may thus represent the CRP-binding site of H 1 within the chromatin molecule. 
These results correlated with those of Du Clos et al. (1991b) who demonstrated that the Ca2+ 
dependent binding of CRP to histones was PC inhibitable and involved sequence specific residues 
in the C-terrninal fragment of H l · They also demonstrated a Ca2+ dependent, PC inhibitable CRP-
binding site in the N-terminal fragment ofH2A. Shephard et al. (1991), however, showed Ca2+ 
dependent binding ofhCRP to H4 only. 
CRP may also bind the small ribonuclearproteins (snRNP) (Du Clos, 1989) and more specifically a 
70 kDa protein of snRNP (Jewell et al., 1993). The hamster FP also binds histones and chromatin 
in a Ca2+ dependent and PC inhibitable manner (Saunero-Nava et al., 1992). 
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Binding of CRP to the C-tenninal fragment of H 1 is significant as this region is respon
sible for 
maintaining the compact structure of condensed chromatin (from Minota et al., 1993). 
CRP 
binding could thus potentially unfold the chromatin allowing endogenous nucleases to
 degrade the 
DNA. This may be important for the clearance of nuclear material from dead or dama
ged cells and 
particularly as nuclear accumulation following cell death, can lead to the generation o
f autoimmune 
products, for example, in patients with systemic lupus erythematosus (SLE) (Minota et
 al., 1993). 
Shephard et al. (1986b) showed enhanced micrococcal nuclear digestion following CR
P binding as 
well as an inhibition of transcription of the damaged chromatin. It is important to note h
ere that 
while CRP has been shown to bind chromatin and may play an important role in vivo, 
SAP has 
been demonstrated to be the main chromatin binding protein (Butler et al., 1990) and 
also, unlike 
CRP and FP, may bind to naked DNA (Pepys and Butler, 1987). Despite this, Robey 
et al. (1984) 
claimed that the amount of CRP present was directly proportional to the amount of ch
romatin 
solubilised. They believed that this solubilisation took place via the activation of the cl
assical 
complement cascade by the CRP-chromatin complex. These results were, however, di
sputed by 
Butler et al. (1990) who could show no activation of complement by the CRP-chromat
in complex. 
They suggested the findings of Robey et al. (1984) to be due to the presence of other n
uclear 
materials e.g. phospholipids or UlRNP, to which CRP also binds. Pepys et al. (1994) 
have 
subsequently claimed that in physiological conditions CRP binds only to the snRNP's a
nd does not 
bind to chromatin. They showed that only SAP binds to chromatin and nucleoli in situ
 and 
suggested previous studies showing CRP binding to chromatin to be erroneous due to
 non-
physiological conditions. 
A major question which arises from some of the results described above is, how the C
RP binds to 
the nuclear components as, theoretically, it would be excluded from the nucleus. Du C
los et al. 
(1990) found that CRP was structurally and functionally very similar to a well defined
 nuclear 
transport protein, nucleoplasmin. They subsequently identified a nuclear localisation s
ignal (NLS) 
sequence within CRP which was capable of transporting human serum albumin (HSA)
 into the 
nucleus and also demonstrated in vivo nuclear localisation of CRP in intact VERO cell
s ( a cell line 
of African green monkey kidney cells). SAP has also been shown to contain this NLS 
and is equally 
capable of nuclear localisation (Du Clos et al., 1990). Shephard et al. (1991) demonst
rated binding 
of human CRP to nuclear envelope proteins with molecular mass values of 43 kDa, 46
 kDa, 52 
kDa and 70 kDa. A 46 kDa envelope protein was previously implicated in the nuclear
 transport of 
RNA and may be a component of the nuclear pore complex (Sabbatini and Van Holt, 
1987). 
In summary, the results of these studies suggest that a function of CRP may be to clea
r endogenous 
nuclear mateiial from dead or dying cells. 
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2.A. 7.4. Interaction with lymphocytes 
An interaction between CRP and lymphocytes was first suggested b
y Abernethy and Francis in 
1937. Since then Hokama et al. (1973) have demonstrated an interacti
on between CRP and 
peripheral blood lymphocytes (PBL's) and Mortensen et al. (1975) sh
owed selective binding of 
CRP to T-lymphocytes with subsequent inhibition of certain T-cell
 functions. It has since been 
shown, however, that purified CRP does not bind to PBL's (Ballou
 et al., 1989) and aggregated or 
complexed CRP only binds to a small population of the PBL's (3-5
%) (James et al., 1983; Lozanski 
et al., 1991). This binding occurs only after prolonged (up to 18 hr) in
cubation in vitro, and 
requires concentrations of CRP over 25 µg/ml. It would seem that 
CRP only binds to a specific 
population of lymphocytes bearing specific membrane receptors. B
oth James et al. (1982) and 
Muller and Fehr (1986) suggested a correlation between lymphocy
tes bearing IgG Fe receptors and 
those that bind CRP. This would present a number of possibilities: 
i) CRP may bind to the same 
receptor as IgG, ii) CRP may bind to one of the heterogeneic IgG r
eceptors, iii) binding may occur 
via a distinct epitope on the Fe receptor, or iv) to a distinct recepto
r that is expressed primarily on 
IgG Fe receptor bearing cells. It has also been suggested that CRP on the
 lymphocyte is not 
acquired passively from the serum but is rather synthesised by the l
ymphocyte itself and expressed 
on the surface (Kuta and Baum, 1986; Ikuta et al., 1986). 
Bray et al. (1987) and Samberg et al. ( 1988) suggested, following a stu
dy using antibodies directed 
against both native CRP and neo-CRP (see 2.A.5. Synthesis and se
cretion of CRP), that neo-CRP, 
but not native CRP, is able to bind PBL's. 
Not much evidence exists regarding the effects of CRP on lymphoc
yte function. James et al. (1982) 
showed only slightly enhanced blastogenesis of resting lymphocyte
s and responsiveness of 
allogeneic cells in a mixed lymphocyte reaction. 
2.A. 7.4.1. Interaction with natural killer (NK) cells 
Binding of CRP to NK cells has been observed (Timonen et al., 1981)
 although this was shown 
to have no affect on NK activity. CRP bearing PBL's have, howeve
r, subsequently been shown to 
deplete NK activity (Baum et al., 1983). Khattri et al, (1994) have de
monstrated, with the use of 
anti-CRP, the ability of CRP on large granular lymphocytes to mod
ulate the NK cell lytic function. 
This modulation ofNK cell activity by anti-CRP was achieved by a
ltering the cytoskeletal 
rearrangement of the NK cells and subsequent release of lytic facto
rs. Contrary to previous reports 
(Hamoudi and Baum, 1991), the modulation ofNK cell activity by
 anti-CRP was independent of an 
alteration in ca2+ flux. 
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2.A. 7 .5. Interaction with platelets 
Initially Fiedel et al. (1977) obtained inconsistent results where the majority of CRP preparations 
(>87%) inhibited platelet activation but a limited number of CRP preparations (<13%) were not 
inhibitory. Subsequently, Fiedel et al. (1982) found the inhibition to be due to a contaminating 
inhibitory factor, described as LMF, with a molecular mass of 8.5-12 kDa. It was then 
demonstrated that LMF was in fact a degradation product of CRP (Fiedel and Gewurz, 1986). 
With the use of synthetic peptides Fiedel (1988) showed that the cleavage ofCRP by neutral 
proteases of the polymorphonuclear leukocytes resulted in products with the potential to depress 
platelet activation. This inhibition was speculated to be due to a tuftsin sequence Gly-Lys-Pro-Arg 
at residues 113-116 of the CRP molecule (Fig lA), as a synthetic peptide modelled on this 
sequence, described as CRP II, mimicked this inhibitory activity. CRP II has homology with the 
tetrapeptide Gly-Pro-Arg-Val resident in the Aa chain offibrinogen. This tetrapeptide becomes the 
N-terminal aspect of the Aa chain of fibrinogen following the action of thrombin and represents 
the fibrin polymerisation site (see 2.B.5. Fibrin formation). It may be possible, therefore, that 
through sequence homology with the fibrin polymerisation site, CRP or CRP peptides may 
modulate platelet coagulation or clotting processes. 
It has been demonstrated that neo-CRP (see 2.A.5. Synthesis and secretion of CRP) is able to 
induce reactions of aggregation and secretion from isolated platelets as well as to potentiate 
platelet activation by ADP in platelet rich plasma (PRP) (Potempa et al., 1987). 
2.A.7.6. Interaction with neutrophils 
CRP has been shown to bind to neutrophils in a specific, saturable and rapid manner at pH 7.4 
and 220c (Buchta et al., 1987a; Dobrinich and Spagnuolo, 1991; Shephard et al., 1989). Binding 
requires Ca2+ and Mg2+ and appears to involve the PC binding site. Results from Muller and Fehr 
(1986) indicate approximately 30 µg/ml CRP is required for saturable binding while those of 
Buchta et al. (1987a) found that <5 µg/ml was sufficient. Of significance is the fact that this is 
within the range at which CRP exerts maximal effects on neutrophil function (Dobrinich and 
Spagnuolo, 1991). It was then suggested that there may exist both a high and a low affinity 
receptor for CRP on the neutrophil and that Muller and Fehr (1986) did not pick up the high 
affinity receptor as they did not look at binding at low enough concentrations of CRP. Buchta et 
al. (1987a) showed that aggregated IgG displaced CRP binding to the neutrophil and suggested 
that the CRP receptor is related to the IgG receptor. It may be, however, that the CRP receptor is 
physically associated with, but distinct from, the IgG Fe receptor. Zeller and Sullivan (1992) 
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showed that although aggregated CRP (I 00 µg/ml) alone had no affect on the 
respiratory activity 
of neutrophils, this form of CRP (I 00 µg/ml) was able to stimulate the intracell
ular respiratory 
burst of aggregated lgG-stimulated neutrophils. Zeller and Sullivan subseque
ntly (1993) showed 
that the lgG FcyRII was involved in the aggregated CRP-mediated upregula
tion of the IgG-
induced respiratory burst of the neutrophil but that this did not involve bindi
ng of CRP to the Type 
II Fe receptor. This may suggest that the CRP receptor is physically associat
ed with the IgG 
receptor. A similar association has been suggested for the CRP receptor on m
acrophages and 
monocytes (see 2.A.7.7. Interaction with monocytes and macrophages) (Zah
edi et al., 1989; Tebo 
and Mortensen, 1990). 
While examining the interaction of CRP with neutrophils Shephard et al. ( 1989
) demonstrated the 
existence of a neutrophil membrane associated protease which is capable of 
cleaving CRP to 
smaller peptides. These CRP degradation products were found to bind to the
 neutrophil surface 
and may be responsible for the high percentages (50%) of non-specific bindi
ng encountered in 
many CRP/neutrophil binding studies (Muller and Fehr, 1986; Buchta et al., 19
87a). The low 
molecular mass CRP peptides (<14 kDa) generated by the neutrophil membr
ane associated 
protease were shown to inhibit neutrophil function (see 2.A.8. Proteolysis o
f CRP). 
Although Shephard et al. (1986a) have shown that pure CRP had no effect on
 neutrophil function, 
other studies have demonstrated a CRP concentration effect on neutrophil fu
nction (Dobrinich and 
Spagnuolo, 1991). For example, at concentrations of CRP which would be e
xpected to completely 
saturate the high affinity receptor ( <50 µg/ml), the predominant effect appea
red to be inhibition of 
neutrophil superoxide production. High concentrations of CRP (> 100 µg/ml) 
led to antioxidant 
activity and at very low concentrations of CRP ( <5 µg/ml), modest stimulati
on of neutrophil 
superoxide production was observed (Buchta et al., 1987b). Chemotaxis was i
ncreased at CRP 
concentrations up to 1 µg/ml but higher concentrations were inhibitory (Buc
hta et al., 1987b). 
Phagocytosis was enhanced by CRP at concentrations between 1 and 50 µg/
ml and cyclic 
adenosine monophosphate ( cAMP) was markedly and rapidly elevated by CR
P at 50-100 µg/ml. 
Lysozyme release was slightly inhibited by CRP alone; at all concentrations, 
but specific granule 
release was not affected by CRP alone and was inhibited by CRP in the prese
nce of phorbol 12-
myristate 13 acetate (PMA) or Conconavalin A (Con A) (Buchta et al., 1987b
). This alternative 
inhibition and stimulation of various neutrophil functions by differing concen
trations of CRP may 
be physiologically important as a mechanism for the prevention of 'super-act
ivation' of the 
neutrophil and subsequent tissue toxicity during inflammation. 
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Saturation of the high affinity CRP receptor occurs at <5 µg/ml (Buchta et al., 198
7a) and 
subsequent inhibition of neutrophil function following further binding to the 
receptor may be due 
to, i) degradation of the bound CRP (Shephard et al., 1989) or dissociation of
 the CRP receptor 
complex, ii) the CRP degradation products may themselves have specific bio
logical functions and 
iii) binding of CRP to different high and low affinity receptors may elicit diff
erent biological 
responses. It has also been found that modified CRP with 'neo-CRP' epitope
s (see 2.A.5. Synthesis 
and secretion of CRP) preferentially activates or potentiates activation of leu
kocytes and platelets 
(Potempa et al., 1987; Ying et al., 1992b; Zeller et al., 1986a; Zeller et al., 1986
b ). The actual 
mechanism for the influence of CRP on neutrophil function may be related to
 the phosphorylation 
of various proteins. Buchta et al. (1988) showed that neutrophils preincubated
 with CRP and 
stimulated with PMA or N-formyl-methionyl-leucyl-phenylalanine (FMLP) s
howed marked 
inhibition of phosphorylation of various proteins with molecular mass values
 of 43, 47, 54, 66 and 
85 kDa. The extent of inhibition exceeds, however, the degree of inhibition o
f neutrophil functions. 
This is in accordance with the hypothesis that neutrophil activation may invo
lve the activation of 
other pathways beside the protein kinase C (PKC) pathway (Buchta et al., 198
8). 
2.A.7.7. Interaction with monocytes and macrophages 
CRP has been shown to have an opsonic role for the phagocytic and tumoric
idal functions of 
monocytes and macrophages (Barna et al., 1984; Miyagawa et al., 1988; Thom
assen et al., 1993; 
Zeller and Sullivan, 1993; Tebo and Mortensen, 1990) and this would imply 
a requirement for 
binding of CRP to these cells. Specific binding of CRP to monocytes (Ballou
 et al., 1989; Ballou 
and Cleveland, 1991; Crowell et al., 1991; Zeller and Sullivan, 1993) and macr
ophages (Zahedi et 
al., 1989; Nagpurker, 1993) has been observed. Binding appeared to be reversib
le, rapid and Ca2+ 
dependent although Zahedi et al. (1989) showed Ca2+ independent binding to
 macrophages, thus, 
apparently not involving the PC binding site. Similarly, Crowell et al. ( 1991) co
nfirmed a ca2+ 
independent binding of CRP to monocytes with the use of the human monoc
ytic U93 7 cell line. In 
accordance with this controversy, Ballou et al. (1989) demonstrated only one 
binding site for CRP 
on the monocyte whereas others have found both a hi·gh and a low affinity re
ceptor on both 
monocytes (Tebo and Mortensen, 1990) and macrophages (Zahedi et al., 1989
). Tebo and 
Mortensen (1990) showed the two CRP receptors on monocytes to have mo
lecular mass values of 
60-62 kDa and 3 8-41 kDa. 
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A CRP receptor from the macrophage was found by Zahedi et al. (1989) to have a molecular mass
 
of 57-60 kDa and by Egenhofer et al. (1993) to have a molecular mass of 59-61 kDa. Crowell et 
al. (1991) identified a CRP receptor from U937 cells with a molecular mass identical to that of the
 
IgG Fey receptor, namely 43-45 kDa. It was suggested that the high affinity receptor may be CRP
 
specific and the low affinity receptor may be the IgG Fe receptor with a weak affinity for CRP. 
There is much controversy over whether the IgG Fe receptor is a CRP receptor or not. Inhibition 
ofCRP binding to monocytes and macrophages by lgG has been observed (Tebo and Mortensen, 
1990; Crowell et al., 1991; Zahedi et al., 1989) but, conversely, CRP has not been shown to inhibit
 
lgG binding. Also, in some cases inhibition of CRP binding to both monocytes and macrophages 
was not inhibited by IgG (Ballou et al., 1989; Ballou and Cleveland, 1991; Nagpurkar, 1993). 
Further complications arise from the fact that there are three different types of Fey receptors. 
Monocytes possess FeyRI and FeyRII. Monoclonal antibodies against these two receptors did not
 
effect CRP binding (Tebo and Mortensen, 1990; Crowell et al., 1991; Zeller and Sullivan, 1993) 
but this does not exclude CRP binding to a distinct epitope on the Fe receptor. Tebo and 
Mortensen (1990) showed, however, that upregulation ofFeyRI by IFN-y and PMA did not affect 
CRP receptor expression. Despite the fact that aggregated CRP does not appear to bind to 
phagocytic cells via the FeyRII, it was shown that CRP potentiated the IgG mediated respiratory 
burst via this receptor. A monoclonal antibody against FcyRII, mAb IV.3, significantly suppressed
 
the enhancement of IgG induced chemilluminescence by aggregated CRP but did not affect the 
binding ofCRP (Zeller and Sullivan, 1993) (see 2.A.7.6. Interaction with neutrophils). It appears 
from the above studies that, as in the case of neutrophils, the CRP receptor on monocytes and 
macrophages is chemically distinct but possibly topographically or physically associated with the 
lgG F c receptor. 
An interesting observation regarding the interaction of CRP with macrophages is that of Kempka et
 
al. (1990) who demonstrated the existence of CRP as a specific galactose receptor within the 
macrophage membrane (mCRP) (see 2.A.5. Synthesis and secretion of CRP). This mCRP was 
found to mediate the uptake of particulate material with exposed galactosyl groups (Kolb-
Bachofen, 1991 ). 
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Following CRP binding to U937 cells, the IgG mediated respiratory burst is enhanced (Zeller and 
Sullivan, 1993). Barna et al. (1984) and Miyagawa et al. (1988) also demonstrated that CRP 
enhanced tumoricidal activity and superoxide generation in murine and guinea pig peritoneal 
macrophages, respectively. It is possible that the observed effects on monocyte function may have 
been elicited by CRP peptides as these peptides have previously been shown to lead to monocyte 
activation (Robey et al., 1987). It has also been demonstrated that following binding ofrat CRP to 
macrophages there is internalisation into the lysosomes and subsequent degradation (Nagpurkar et 
al., 1993). The biological role of the peptides were not investigated. Tebo and Mortensen (1991), 
however, demonstrated that upon binding of CRP to U937 cells and subsequent internalisation of 
CRP into an endosomal compartment followed by degradation there was enhancement of the 
monocytes' H202 production and tumoricidal activity. Thomassen et al. (1993) identified a CRP 
peptide, described as RS-83277 (amino acids 174-185) (Fig IA), which specifically enhanced 
monocyte and macrophage tumoricidal activity (see 2.A.8. Proteolysis of CRP). 
As in the case of neutrophils (see 2.A.7.6. Interaction with neutrophils), neo-CRP (see 2.A.5. 
Synthesis and secretion of CRP) was found to potentiate the activation of monocytes and 
macrophages (Potempa et al., 1987; Zeller et al., 1986a; Zeller et al., 1986b ). 
Cermak et al. (1993) have shown that CRP could induce monocytes to express tissue factor which 
is a potent procoagulant and initiator of the extrinsic coagulation pathway. CRP may thus play a 
role in altered micro-circulation in inflammatory and necrotic tissue. 
A dodecapeptide within the CRP molecule (27-38) (Fig IA) has been described as a cell binding 
peptide (CB-Pep) as it supports cell adhesion in vitro (Fernandez et al., 1992). Mullenix et al. 
(1994) have identified the critical sequence within this peptide to be Phe-Thr-Val-Cys-Leu which is 
not similar to any of the known adhesive recognition sequences and does not mediate adhesion via 
the integrin receptors. 
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2.A.8. PROTEOLYSIS OF CRP 
- Effect of CRP peptides on leukocyte function 
Various studies have indicated that degradation of CRP gives rise to biologically active peptides 
with specific immunomodulatory activity (Shephard et al., 1986a; Shephard et al., 1988; Shephard 
et al., 1990; Robey et al., 1987). 
It was initially described that, although native CRP could not induce phagocytic leukocytes to 
chemotax or produce superoxide, treatment of the purified CRP with human neutrophil derived 
acid proteases resulted in peptides with potent effects on leukocyte function (Shephard et al., 
1986a; Robey et al., 1987). Robey et al. (1987) subsequently demonstrated that three synthetic 
CRP peptides containing the tuftsin-like sequences in the CRP molecule, Thr-Lys-Pro-Leu (27-30), 
Gly-Lys-Pro-Arg (113-116) and Thr-Lys-Pro-Gln (200-203) (Fig IA) could stimulate phagocytic 
leukocyte chemotaxis and superoxide and IL-1 production. In contrast, Shephard et al. (1988) 
showed that the CRP peptides, derived from the degradation of CRP by neutrophil lysosomal 
enzymes, inhibited neutrophil chemotaxis, superoxide production, degranulation and phagocytosis. 
Discrepancies may have arisen from very slight differences in the amino acid sequences of the 
synthetic peptides. 
Subsequent studies by Shephard et al. (1990) showed another three synthetic CRP peptides, 
generated by the action of a neutrophil membrane associated protease and corresponding to 
residues 201-206 or Lys-Pro-Gln-Leu-Trp-Pro (CRP III - contains a tuftsin-like sequence), 83-90 
or Leu-Phe-Glu-Val-Pro-Glu-Val-Thr (CRP IV) and 77-82 or Val-Gly-Gly-Ser-Glu-Ile (CRP V) 
(Fig IA), significantly inhibited neutrophil superoxide production at 50 µM. CRP III and V were 
also able to inhibit neutrophil chemotaxis at 50 µM. These concentrations may appear high but 
CRP is known to accumulate at inflammatory sites and may reach such concentrations at these 
sites. It may be of interest to note that CRP IV has no homology with any other known bioactive 
peptides. These inhibitory activities of CRP peptides may represent a significant mechanism for the 
prevention of 'super-activation' of neutrophils and subsequent tissue destruction at inflammatory 
sites. The kinetics of CRP production support this hypothesis as maximal CRP production occurs 
approximately 50 hours post acute phase initiating events (Shephard et al., 1989). It is at this time, 
when host mechanisms to limit tissue destruction are required, that degradation and subsequent 
release of neutrophil modulating peptides would be maximal. 
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Thomassen et al. (1993) identified a CRP peptide, described as RS-83277 (amino acids 174-185) 
(Fig IA), which specifically enhanced monocyte and macrophage tumoricidal activity. This CRP 
peptide, contained within multimellar vesicles, was later demonstrated to have immunotherapeutic 
activity in preclinical tumour models and especially when administered together with IL-2 (Barna et 
al., 1993; Barna et al., 1994). 
Internalisation and degradation of CRP by the human monocytic cell line, U93 7, has been 
demonstrated and the peptides formed were able to activate monocytes (Tebo and Mortensen, 
1991). Rat peritoneal macrophages were also shown to degrade CRP but the biological function of 
the peptides formed was not investigated (Nagpurkar et al., 1993). Foldes-Filep (1992) showed 
inhibition of platelet activating factor (P AF), FMLP and PMA stimulated guinea pig macrophage 
superoxide production by CRP. Platelets appear to be modulated by CRP peptides but are, 
themselves, incapable of degrading CRP (Fiedel, 1988). 
2.A.9. PROPOSED FUNCTION OF CRP 
In summation, it appears that CRP has multi functions during the acute phase. Besides the ability 
of CRP to bind to, neutralise, detoxify and opsonise harmful or foreign substances within the 
circulation, an immunomodulatory role for CRP at sites of inflammation has been suggested. 
Vigushin et al. (1993), however, investigated the metabolic fate of CRP, as well as its tissue 
localisation in normal and diseased patients, and found that in all cases the clearance of CRP took 
place at a constant maximal rate. They could also not demonstrate tissue localisation of CRP which 
would seem to negate the hypothesis for a role of CRP at inflammatory sites. 
The exact function of CRP remains a mystery as one would expect its role to be critical, due to the 
significant phylogenetic and evolutionary conservation of CRP. It appears, however, that the 
functions which have been observed to be performed by CRP are not unique to it and the guinea 
pig, which has no CRP-like molecule at all, does not appear to exhibit any deleterious side effects 
from its absence. It seems, therefore, that despite numerous studies which have demonstrated many 
possible functions of CRP, the search is still on to find the raison d'etre for its presence and 
preservation in all organisms, but one, studied thus far. 
2.B. FIBRINOGEN 
2.B.1. INTRODUCTION - FIBRINOGEN STRUCTURE 
Fibrinogen (fbg) is a large, heterodimeric plasma glycoprotein which is essential for blood 
coagulation and platelet aggregation. 
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The structure offbg was first described in 1959 by Hall and Slayter (from Doolittle, 1984). Fbg 
consists of three pairs of non-identical polypeptide chains (Aa, B~ and y) held together by 29 
disulphide bonds with no free sulphydryl groups (Fig 1 ). The Aa chain has a molecular mass of 67 
kDa (610 residues), the B~ chain 56 kDa (461 residues) and they chain 47 kDa (411 residues), 
thus forming a molecule with a molecular mass of 340 kDa (±3000 amino acids). During 
biosynthesis of fbg, posttranslational modifications include glycosylation of the B~ and y chains, 
phosphorylation of the Aa chain and sulphation of the tyrosine in they chain (Doolittle, 1984; 
Mosesson, 1992). The molecule exists as a trinodular structure ( of 450 ° A) with two terminal, 
globular, carboxyl domains (D-domains) tethered to a central, N-terminal, disulphide knot (E-
domain) by "coiled coil" a-helical regions. The central region of fbg contains the amino terminals 
of all six chains as well as 11 disulphide bonds. Three of these bonds hold the dimeric halves 
together, two are between the Aa and B~ chains and the other six are thought to be situated at the 
junctions of the central region and the distal region and are described as disulphide rings. The distal 
D-domains contain the carboxyl terminal portions of the B~ and y chains while the carboxyl-
terminal halves of the Aa chains extend out from this region and have been described as the a 
chain protuberances (Doolittle, 1984; Mosesson, 1992). The exact positioning of the Aa chain 
protuberances is still uncertain but recent studies indicate that they form part of the central globular 
domain (Veklich et al., 1993 ). These a chain protuberances appear to interact intramolecularly in 
the fbg molecule but, with the formation of fibrin, dissociate from each other and the central 
domain in order that they may associate intermolecularly. The intermolecular association of the 
carboxyl termini of the Aa chains is known to occur during fibrin formation following the action of 
transglutaminase factor XIIIa (see 2.B.5. Fibrin formation) (Veklich et al., 1993). Due to their lack 
of defined structure the a chain protuberances are desribed as random coils and due to their 
exposed nature are very susceptible to proteolytic attack (Farrell et al., 1993). 
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13 Fibrinogen y 
E Domain 
Figure 1. Schematic model of the fibrinogen molecule. Fbg consists of three pairs of polypeptide chains, Ao., B~ 
and y. The amino terminal regions of all three chains are joined in the central domain (E domain) by 
disuphide bonds and form a dimeric structure. This domain contains the fibrinopeptide A (FP A) and 
fibrinopeptide B (FPB) sequences that are cleaved by thrombin. The carboxyl termini of the BP and y 
chains form the globular D domains, while the Ao. chain extends out from this region as an o. chain 
protuberance. The D-domains are joined to the central E domain by the 'coiled-coil' a. helices (from 
Mosesson, 1992). 
2.B.2. PHYLOGENETIC CONSERVATION OF FIBRINOGEN 
All vertebrates contain similar fbg's, the most primitive being that of the lamprey, which is 
however, still remarkably similar to its mammalian counterparts (Doolittle, 1984). 
2.B.3. THE FIBRINOGEN GENE 
There is a single copy of each gene for all three fbg chains. All three of these human genes have 
been cloned and sequenced and the B~ and y chains have been found to be 33% identical and are 
similar enough to the Aa chain to suggest a common ancestry (from Doolittle, 1984). The 
homology between the chains is exemplified by the location of the cysteines. 
The order of synthesis of the three gene products appears to be the B~ chain first followed by the 
Aa and then the y chain. All three chains are synthesised in a precursor form with extended amino 
terminal regions (signal peptides). These signal peptides are removed before or during secretion of 
fbg from the hepatocyte (Doolittle, 1984). Farrell et al. (1993) investigated the fact that the cDNA 
for human fbg encodes a 15 amino acid portion of the carboxyl terminus of the Aa chain which is 
not found in the native plasma protein. The exact function of this carboxyl extension is not known 
but it was found not to be involved in the assembly and secretion of fbg and removal of this 
extension appeared to be a normal post-translational event, although the exact means of removal 
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was not ascertained. Glycosylation of they chain occurs as an early co-translational event but Bl3 
chain glycosylation occurs a bit later and the Aa chain is not glycosylated at all. Phosphorylation 
and sulphation occur in translocational events subsequent to the ER but prior to secretion from the 
cell (Doolittle, 1984). 
2.B.4. FIBRINOGEN BIOSYNTHESIS 
Fbg is produced by the hepatocytes in the liver with its synthesis being under the overlapping 
control of a number of stimuli e.g. defibrination, hormones and trauma leading to an acute phase 
response. The release of fragments D and E, following plasmic digestion, affects the release of 
hepatocyte stimulating factor (HSF) from leukocytes which brings about increased fbg and acute 
phase protein synthesis (Doolittle, 1984). 
The intracellular assembly of the three peptide chains into fbg is a stepwise process in the ER, 
involving a number of probable intermediates although there are conflicting reports regarding these 
intermediates and the pathway of assembly. A study by Roy et al. (1991) showed that COS-I cells 
(a monkey kidney fibroblast cell line) transfected with all three fbg chain cDNA's were capable of 
assembling and secreting a functional fbg molecule. The predominant intermediates were Aay, free 
y and Aa chains with AaBl3 and Bl3y intermediates also being found to a lesser degree. It was 
proposed that surplus amounts of Aa and y chains are maintained in the pre-golgi of the 
hepatocytes, either singly or complexed to each other, and production of the Bl3 chain leads to the 
synthesis and secretion of fbg. Following production of the Bl3 chain, Bl3y and AaBl3 complexes 
are released into the rough ER where they acquire the third chain to form half-molecules. Two half 
molecules are then joined via disulphide bonds to form dimeric fbg. Thus, from the results of Roy 
et al. (1991), the production of the Bl3 chain is a rate limiting factor in the assembly offbg. The 
sequence within the Bl3 chain which is critical for fbg assembly was found to be between amino 
acids 73 and 93, or the start of the "coiled-coil" region (Zhang and Redman, 1992). The exact 
function of the Aay intermediate is not certain as, although it is formed prior to fbg, it does not 
appear to be a direct precursor. In conflict with the results of Roy et al. (1991) a study using Hep 
G2 cells and transfected baby hamster kidney cells showed that Aay and Bl3y dimers as well as 
AaBl3y half molecules were formed as intermediates during the assembly and biosynthesis of fbg 
but disulphide-linked AaBl3 complexes were not found (Huang et al., 1993a). This may indicate 
that the interaction of the Aa and Bl3 chains, which become linked via three disulphide bonds, may 
only occur later on in the assembly of fbg. Thus, the disulphide bonds between the Aa and Bl3 
chains most likely only occur when AaBJ3y half molecules are formed between Aay and BJ3y 
intermediates and/or when AaBJ3y half molecules dimerise to generate the whole molecule. 
Doolittle (1984), on the other hand, suggested the formation of a homotrimer Y3 followed by 
stepwise displacement of two of the y chains and subsequent formation of the heterotrimer 
intermediates Aay2 and BJ3y2. In this way a pool ofy chains is generated. Conflicting results may 
be explained by the observation of Oddoux and Greininger ( 1994) that differences in fibrinogen 
assembly may be species specific. For example, they found that in chicken hepatocytes, the Aa 
chain plays a critical role in fbg assembly, rather than the BJ3 chain in human hepatocytes. 
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A common feature of all the studies described above is the observation that the dimerisation of t
wo 
half molecules, via disulphide bonds, is one of the final steps in the assembly of fbg with the 
disulphide bonds in the amino terminal region of the Aa and y chains holding the two AaBJ3y ha
lf-
molecules together (Huang et al., 1993b). For this, the Aa28-Cys residue interacts with the same 
residue on the other Aa chain, and the cysteine residues at positions 8 and 9 in the y chain pair with
 
their counterparts in an anti-parallel or reciprocal fashion. It has been suggested that this would 
allow the dimeric half-molecules to orientate in an anti-parallel manner (from Mosesson, 1992). 
A 
bond between Aa36-Cys and BJ365-Cys of the other half molecule also appears to be critical for
 
linking the two AaBJ3y half-molecules together (Huang et al., 1993b ). The disulphide rings which 
flank the "coiled-coil" region may also play an important role in dimer assembly (Zhang and 
Redman, 1994). These rings may be necessary for maintaining the "coiled-coil" structure and ma
y 
be critical in aligning the four cysteines of the amino terminus of one half molecule with the 
corresponding four cysteines of the other half molecule, thus promoting disulphide linkage and 
dimer formation. The residues involved in the formation of these disulphide rings at the amino 
terminus include BJ376-Cys, BJ380-Cys, yl9-Cys and y23-Cys (Zhang and Redman, 1994). The 
disulphide rings at the carboxyl terminus of the "coiled-coil' are believed to be important for 
secretion of fbg. It was suggested that there is a co-operative effect where some of the disulphide 
bonds may influence the formation of other disulphide bonds on different domains of the molecu
le 
(Zhang and Redman, 1994). 
An interesting observation derived from these studies (Huang et al., 1993 a; Roy et al., 1991) was 
that fbg assembly, intracellular transportation and secretion does not require the hepatocyte 




2.B.5. FIBRIN FORMATION 
Blood clotting is a complex series of events involving many sequential cascades of zymogen 
activation where a serine protease, thrombin, ultimately converts fbg into an insoluble cross-linked 
fibril network, described as fibrin (from Esmon, 1993). Thrombin elicits the release of 
fibrinopeptide A (FPA, Aa.1-16) and then fibrinopeptide B (FPB, Bf31-14) from the Aa. and Bf3 
chains of fbg, respectively (Fig 1) (Bailey et al., 1951 ). Spontaneous polymerisation between tbg 
molecules occurs through electrostatic interactions of the newly positively charged central domains 
with the slightly negatively charged terminal domains (see 2.B.5.1. Polymerisation sites). Different 
polymerisation paths may develop depending on the relative rates of release of FPA and FPB 
(Doolittle, 1984). Initially, two stranded protofibrils (trimers and tetramers) are formed in a half 
staggered overlap conformation. Following protofibril formation, end to end cross-linking occurs 
and the formation of fibrin polymers with y dimers is observed. Crosslinking of the y chains is 
initiated by the plasma transglutaminase factor Xllla and gives rise to a covalent bond between the 
two y chains providing structural stability and integrity to an otherwise easily deformable clot 
(from Mosesson, 1992). Aa. chain crosslinks between the carboxyl termini are also observed, 
during prolonged clot formation, and are also initiated by the transglutaminase factor XIIIa 
(Veklich et al., 1993). Crosslinks may occur between Aa. and y chains and are initiated by human 
erythrocyte transglutaminase (Murthy et al., 1991). 
Release of FPB occurs more slowly than the release of FP A and gives rise to lateral associations 
and branching. The coarseness of a clot appears to relate to the release of FPB and, more 
importantly, a delay in release of FPB (after protofibril formation) appears to be necessary for 
normal fibre assembly with lateral branching (Weisel et al., 1993). Removal ofFPA thus allows the 
formation of linear polymers, which are described as fibrin I or desA fibrin, whereas the delayed 
release ofFPB allows lateral involvement and the formation of thick fibres, described as fibrin II or 
desAB fibrin, which is more resistant to proteolysis (Doolittle, 1984). 
2.B.5.1. Polymerisation sites 
The active site ofthrombin consists of two separate domains, namely the catalytic site and an 
extended tbg recognition sequence (FRS). Aa.7-16 of fbg interacts with the catalytic site of 
thrombin and residues Aa.27-50 are involved in binding the FRS ofthrombin (Martin et al., 1992). 
The release of the second FP A from the fbg molecule by thrombin occurs 16 times faster than that 
of the first and is suggested to be due to a co-operative effect of thrombin which is assisted by the 
close orientation of the amino terminals of the two Aa chains within the tbg molecule (from 
Mosesson, 1992). Less is known of the interaction of the B~ chain with thrombin although it has 
been suggested that B~l5-42 may interact with the FRS (Binnie and Lord, 1993). 
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Removal of FP A from the central amino terminal domain uncovers the peptide sequence Gly-Pro-
Arg (G-P-R) which interacts, ca2+ and conformation dependently, with the carboxyl terminal 
residues y357-373 (Laudano and Doolittle, 1981; Cierniewski and Budzynski, 1993; Shimuzu et 
al., 1992). A critical residue within this sequence was found to be the Tyr ofy363 (Yamazumi and 
Doolittle, 1992). Peptides beginning with the sequence G-P-R, or containing the G-P-R sequence
 
only, are very effective inhibitors of fibrin polymerisation (Laudano and Doolittle, 1980; Kawasak
i 
et al., 1993). Slight variations in the peptide sequence may, however, alter its affinity e.g. G-P-R-V 
(which is the actual sequence in tbg) has a much reduced affinity for the carboxyl region of they 
chain when compared with G-P-R-P (Laudano and Doolittle, 1980). 
Release ofFPB exposes the sequence Gly-His-Arg (G-H-R) which interacts Ca2+ dependently 
with the distal domain of the B~ chain of another tbg molecule (Laudano and Doolittle, 1981 ). 
Peptides beginning with the sequence G-H-R do not, however, inhibit fibrin formation although, G
-
P-R and G-H-R in combination, offer the most effective inhibition of clotting under physiological 
conditions with thrombin (Laudano and Doolittle, 1981 ). 
Formation of the y-y cross-link involves reciprocal binding of a donor Lys at position 406 and an 
acceptor Gly at the carboxyl termini of the respective y chains, at position 398 or predominantly 
399 (Purves, 1988). 
2.B.6. INTERACTIONS OF FIBRINOGEN 
Fibrinogen has been shown to interact with a number of ligand substrates and cells with 
important physiological consequences. 
2.B.6.1. Interaction of fibrinogen with plasminogen 
Plasminogen (plg) binds to tbg via lysine side chains on the tbg molecule and this has been 
indicated to be important for plg activation (Yonekawa et al., 1992; Gron et al., 1992) (see 2.B.7. 
Fibrinogenolysis ). 
2.B.6.2. Interaction of fibrinogen with thrombin 
Interaction of thrombin with fbg leads to the release of FP A and FPB and subsequent clot 
formation (see above). 
2.B.6.3. Interaction of fibrinogen with calcium 
There are three high and 10-12 low affinity ca2+ binding sites on the fbg molecule. Two of the 
high affinity binding sites are found on the D-domain (Fig 1) while no high affinity binding sites 
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were found on the E-domain (Lindsey et al., 1978). One of the Ca2+ binding sites involved in clot 
formation is on they chain between residues 303 and 3 56 (Varadi and Scheraga, 1986). Removal 
of the tightly bound Ca2+ renders fbg more susceptible to thermal and alkali danaturation and 
plasmin digestion. In the absence of Ca2+ fibrin formation is much slower and the rigidity of the 
resultant clot is much diminished (from Hermans and McDonagh, 1982). Ca2+ binding may 
upregulate the affinity of a polymerisation site on the B~ chain following removal of the FPB and is 
also essential for the binding oftransglutaminase factor XIIIa to fbg (Laudano and Doolittle, 
1981). 
2.B.6.4. Interaction of fibrinogen with leukocytes 
Fbg has been shown to bind rapidly, ca2+ dependently and reversibly to neutrophils and purified 
monocytes but not lymphocytes (from Trezzini et al., 1988). This association is generally believed 
to occur via the ~2-integrin which is ubiquitously expressed on all leukocytes of lymphoid and 
myelo-monocytic lineage and which may recognise multiple ligands (see 2.C.7.3. The integrins). 
The interaction of fbg with leukocytes has pathophysiologic consequences. Intra vascular 
accumulation of leukocytes may severely contribute to the onset and development of 
atherothrombotic lesions while local activation of coagulation and fbg deposition on the leukocyte 
surface invariably contributes to thrombus organisation in the atherosclerotic plaque (from Altieri 
et al., 1993). On the other hand, fbg association with leukocytes may play a role in specific 
mechanisms of host defence and inflammation. This is. indicated by the ability of fbg binding to 
CDI 1/CD18 and the leukocyte response integrin (LRI, see 2.C.7.4.1. Neutrophil integrins) to 
modulate monocyte oxidative responses (Trezzini et al., 1988), Fe-mediated phagocytosis of 
complement-opsonised particles (Gresham et al., 1989), neutrophil chemotaxis (Senior et al., 
1992) and hydrogen peroxide (H202) production by neutrophils in the presence of stimulators, 
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TNF and PMA (Nathan et al., 1989; Zhou and Brown, 1993). Binding offbg via they chain C-
terminal sequence, Lys-Gln-Ala-Gly-Asp-Val (K-Q-A-G-D-V), to the CD1 lb/CD18 receptor on 
monocytes has been shown to decrease monocyte induced lymphocyte responsiveness (Robson et 
al., 1994). Leukocyte interactions with fbg may also play a role in the localisation and diapedesis of 
monocytes and neutrophils in the extravascular compartment as a result of a collaborative network 
of neutrophil interactions with endothelial cells and endothelial associated fbg (from Altieri et al., 
1988, see 2. C. 7 .1. Endothelial-neutrophil interaction). The binding of fbg to the monocyte has also 
been implicated in the differentiation of monocytes into macrophages (Trezzini et al., 1988). 
2.B.6.5. Interaction of fibrinogen with platelets 
Platelets bind to and contain fbg, as well as other factors involved in clot formation, and the 
overall phenomenon of normal haemostasis depends on their mutual interaction (Bennett et al., 
1983). In particular, fbg enhances the agonist induced platelet aggregation response and platelets in 
tum cause the fibrin clot to retract (Bennett et al., 1983). Fbg binds to platelets via the f33 integrin 
of the cytoadhesin family, namely the aIIbf33 receptor, or more commonly the gpIIb/Illa 
glycoprotein complex (see 2.C.7.3. The integrins) (Bennett et al., 1983). Like fbg binding to the f32 
integrins, binding to the f33 integrin is divalent cation dependent (Peerschke, 1993). The platelet 
receptor must be activated in order to bind soluble fbg and this is achieved with adenosine 
diphosphate (ADP) or thrombin, although the binding of small fbg peptides to aIIbf33 does not 
require activation (Tomiyama et al., 1992). This may indicate a conformational change in the 
receptor, following activation, thus allowing access for the binding of macromolecules. The binding 
of fbg to the gpIIb/Illa complex thus leads to the bridging of these receptors between adjacent 
platelets as well as receptor modification, neoantigen exposure and subsequent signal transduction 
giving rise to intracellular second messengers and the ultimate result of platelet adhesion and 
aggregation (Perutelli and Mori, 1992). 
It was initially believed that the binding site within fbg for the gpllb/Illa complex, lay in the 
carboxyl terminal 12 residues of they chain and more specifically in the K-Q-A-G-D-V sequence 
within y401-y41 l (Kloczewiak et al., 1984). It was subsequently shown that the Arg-Gly-Asp or 
R-G-D sequence at the carboxyl terminus (Aa572-575, -R-G-D-S) and in the middle of the Aa 
chain of fbg (Aa95-98, -R-G-D-F) is also involved in the binding of fbg to stimulated platelets. 
This was indicated by the ability ofthis sequence, in a tetrapeptide R-G-D-X, to inhibit agonist 
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induced platelet aggregation by competitive inhibition of fbg binding (Gartner and Bennett, 1985;
 
Hantgan et al., 1992). The conformation of the tetrapeptide appears to correlate directly with its 
inhibitory activity (Peishoff et al., 1992). The K-Q-A-G-D-V peptide is also capable of inhibiting 
platelet aggregation but to a lesser degree than R-G-D-S (Hantgan et al., 1992; Xinjie et al., 1993) 
although Kloczewiack et al. (1984) claimed that K-Q-A-G-D-V was in fact the more potent 
inhibitor. The differences observed may have been due to variations in the conformations of the 
prepared peptides. Of interest is the fact that K-Q-A-G-D-V crosslinks with IIb (residues 256-306
) 
while R-G-D peptides crosslink to both Ilb and Illa (Illa, residues 109-171) (from Perutelli and 
Mori, 1992; Sheu et al., 1992). 
The binding described above is reversible, Ca2+ dependent and involves soluble fbg. Parise et al. 
(1993) have, however, documented an irreversible, non-covalent and Ca2+ independent binding o
f 
immobilised fbg to purified gpllb/Illa via novel binding sites on both the platelet receptor and the
 
fbg molecule. This may be explained by the exposure of novel binding sites on immobilised fbg or
 
fibrin due to altered conformation and these exposed sites could act co-operatively resulting in a 
high affinity interaction with distinct properties. In conflict with the above results, is the 
observation by Muller et al. (1993) that soluble fbg binds to the platelet in a biphasic manner with 
initial weak, reversible binding followed by a stronger, irreversible interaction. The method used t
o 
measure this binding involved incorporating the aIIbP3 integrin into planar lipid bilayers and thus
 
avoided possible artefactual results of previous methods with immobilised receptor on plastic 
surfaces or interference from other receptors when platelets were used. The results of this report 
may have implications for many previous studies where inhibition of fbg binding to platelets by 
various peptides was assessed. The period of preincubation of these peptides with platelets may 
have influenced the resultant inhibition observed. 
2.B.6.6. Interaction of fibrinogen with bacteria 
Fbg may clump certain strains of Staphylococcus aureus but the exact function of this interaction 
is not known and not all species have fbg binding receptors capable of this interaction. Fbg bindin
g 
to S. Aureus occurs via the same region on the y chain where fbg/platelet interactions are believed 
to occur (Doolittle, 1984). 
43 
2.B.7. FIBRINOGENOLYSIS 
2.B.7.1. Digestion of fibrinogen by plasmin 
Fbg is important for haemostasis and wound healing but it is necessary that it eventually be 
cleared from sites of injury and this is achieved primarily via the plasmin mediated pathway. Fibrin 
dissolution is also essential for the removal of clots which may be found in the general circulation 
(Castellino, 1981; Pizzo et al., 1972; Doolittle, 1981; Lau et al., 1993). Fibrinogenolysis does not 
appear to differ significantly from fibrinolysis indicating that the intermolecular associations of 
fibrin do not shield the molecule from proteolytic attack (Ferguson et al., 1975). 
A crucial step in the digestion of fbg is the activation of the inactive proenzyme, plg to active 
plasrnin by tissue-type plasrninogen activator (t-PA), which is released from vascular endothelium 
(Yonekawa et al., 1992). It has been shown that fibrin monomers, polymers as well as fibrin (not 
crosslinked) and to a lesser degree, fbg, may themselves enhance the rate of plasrnin formation 
(Gron et al., 1992). Yonekawa et al. (1992) have also shown that plasrnin derived fragments offbg 
may accelerate t-P A catalysed pig activation. This has been attributed to a peptide in the Aa chain 
described as FCB-2 (Aal48-160) (Voskuilen, 1987) and a peptide in they chain described as FCB-
5 (y3 l l-379) (Yonekawa et al., 1992). FCB-5 exerts its effect by interacting lysine independently 
with t-P A while FCB-2 interacts with plg, in a lysine dependent, as well as independent, fashion 
(Grailhe et al., 1994). FCB-2 and FCB-5 have a particular orientation with respect to each other in 
the fibrin molecule and may this may serve to concentrate both t-P A and plg on the fibrin surface 
(Yonekawa et al., 1992). These enhancing sequences appear to be exposed upon fbg fragmentation 
or fibrin formation. 
Plasrnin has a specificity for lysyl peptide bonds (Plow, 1980). Digestion of both fbg and fibrin by 
plasrnin gives rise to a set of core products, described as A-E, which have molecular masses of 
85kDa or less (Pizzo et al., 1972) and these very specific products have been used to assess and 
characterise fbg structure (Fig 2). The Aa chain of fbg is the first to be degraded by plasrnin and is 
cleaved from the carboxyl terminus. Concomitant with the degradation of the Aa chain is the 
formation of fragments A, B, C (±15 kDa) and X (240-265 kDa). The Bl3 chain is the next to be 
degraded, from the amino terminus (Ferguson et al., 1975). When approximately half of the Bl3 
chain has been cleaved to a species with a molecular mass of 52 kDa, described as Bl31, fragment X 
is present in maximum amounts (Doolittle, 1984). Fragment X appears to exist in a number of 
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variants, with differing molecular masses, relative to the extent of degradation of the Aa and the 
BJ3 chains. The two Aa chains of the dimer may also degrade at different rates (Azpiazu and 
Chapman, 1992). They chain is the most resistant to degradation and concomitant with its 
cleavage is the formation of fragments D (83-100 kDa), E (±41 kDa) and Y (±lSSkDa). Both 
fragments D and E are terminal digestion products while fragment Y is transient (Doolittle, 1984)
. 
Like fragment X, fragment Y may exist in several intermediate forms depending on the extent of 
degradation of they chain e.g. D1 (92 kDa), D2 (86 kDa) and D3 (82 kDa) which differ in the 
extent of the carboxyl terminal degradation of they chain from 38 kDa to 32 kDa and 28 kDa 
respectively (Ferguson et al., 1975). If they chain is crosslinked (184 kDa), then no further 
digestion of they chain occurs and a product described as DD is formed. The cleaved Bl3 chain in
 
fragment Y has a molecular mass of 44 kDa, is described as B !3
11
, and is resistant to further 
degradation along with the Aa
11 chain (12 kDa) (Azpiazu and Chapman, 1992). Fragment D 
contains partially degraded Bl3 and y chains and extensively degraded Aa chains. Fragment D also 
contains different species of cleaved y chain described as/(± 44kDa, D1), /
1 
(±37 kDa, D2) and 
Ill 
y (±25 kDa, D3) and may exist as distinct populations with differing amounts of these different 
constituent chains (Pizzo et al., 1972). Fragment E contains extensively degraded Aa, Bl3 and y 
chains with molecular masses of 10 kDa and less and these are linked by disulphide bonds. 
Degradation products with extensively degraded Aa chains still retain the ability to clot but as the 
Bl3 and y chains are degraded this ability is lost (Pizzo et al., 1972). Fragment X, for example, 
retains the ability to clot despite extensive degradation of the Aa chain and slight degradation of 
the Bl3 chain. As they chain begins to degrade with the advent of fragment Y formation, the 
products still have the ability to clot but clotting times become much extended. Properly formed 
fragment Y cannot clot at all (Pizzo et al., 1972). It is interesting to note that although fragment 
D1 (y86-41 l) cannot clot it still retains complementary sites for polymerisation (y363) and is able
 
to act as an inhibitor of fibrin formation. Fragments D2 (y86-356) and D3 (y86-301), on the other
 
hand, do not contain polymerisation sites and do not exhibit this anticoagulant activity (Y amazum
i 
and Doolittle, 1992). Fragment E has also lost these sites and can neither clot nor act as an 
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Figure 2. Schematic form of fibrinogen. Each half molecule of fibrinogen contains three non-identical chains 
which are covalently linked by disulphide bonds and are joined by symmetrical disulphide bonds between 
two Ao. and two y chains (Doolittle, 1984). Three globular domains exist: one central E domain, 
containing the N-termini of the six chains, and two peripheral D domains, containing the C-termini 
(Doolittle, 1984). Fragments X, D and E are plasrnic products. * denotes new termini generated through 
initial plasrnin cleavage and ** denotes new termini generated through further plasrnin cleavage. The 
arrows indicate the cleavage sites of thrombin on the Ao. and the BP chain, resulting in the generation of 
fibrinopeptides A and B. They chain C-terrninal dodecapeptide sequence (y400-411), which contains a 
crosslinking site, is indicated in the box. 
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2.B. 7.2. Digestion of fibrinogen by non-plasmin mediated pathways 
In addition to the plasmin mediated fibrinogenolytic systems in the plasma phase of the blood 
there exists a quantitatively important (70-80%) cellular-phase component to blood 
fibrinogenolysis (Langleben and Moroz, 1985; Hammouda and Moroz, 1987; Grau and Moroz, 
1989). Neutrophils are known to accumulate intra- and extravascularly at fbg deposits and are 
capable of penetrating thrombi and exerting anticoagulant effects, contributing significantly to the 
percentage of blood fibrinolysis (Moroz, 1984; Plow, 1982). Cellular (neutrophils and possibly 
monocytes) fibrinogenolytic activity may be stimulated by physiological stimuli such as venous 
occlusion, exercise, pathological processes such as surgical trauma and thromboembolism, and 
pharmacological agents such as urokinase and t-P A. This cellular activity may be reduced in certain 
surgical patients and patients with SLE (Langleben and Moroz, 1985; Grau and Moroz, 1989). 
Bilezikian and Nossel (1977) degraded fbg with a leukocyte extract and after a certain time the fbg 
was rendered unclottable. They showed, with the use of inhibitors, that the major enzyme 
responsible for this fibrinogenolytic activity was human neutrophil elastase (HNE). Gramse et al. 
( 1977) characterised the degradation products of fbg following the action of HNE and found them 
to be distinct from those generated by plasmin, although there were some antigenic similarities 
between D and E and products generated by elastase. A major difference lies in the observation 
that plasminolysis gives rise to specific end products whereas cleavage by HNE is progressive and 
the extent of degradation is directly related to HNE concentration. Another difference lies in the 
ability of elastase to readily cleave all three fbg chains whereas the y chain is only cleaved after 
prolonged incubation of fbg with plasmin. Elastase has a specificity for alanyl peptide bonds and its 
activity results in the release of fibrinopeptide A (FPA) and fibrinopeptide B (FPB) containing 
fragments whereas plasmin cleaves no FP A containing fragment until the end stages of digestion 
(Plow, 1980; Bilezikian and Nossel, 1977). 
Both plasma and interstitial spaces contain numerous elastase inhibitors (Travis and Salvesan, 
1983). Despite this, stimulated neutrophils are able to maintain HNE in an active form (Weiss and 
Regiani, 1984). The reason for this has been suggested .to be that elastase mediated fibrinogenolysis 
occurs in a 'pocket' on the neutrophil membrane surface where fbg is bound to the Mac- I receptor 
(see 2.C.7.4.1. Neutrophil integrins) (Weitz et al., 1987). The secreted elastase is thus protected 
from the high molecular mass protease inhibitors present in the surrounding medium e.g. a2-
macroglobulins and a1-proteinase inhibitors (a1PI's). This mechanism requires adherence of 
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neutrophils to a ligand or ligand coated surface which results in a protected zone that excludes 
inhibitors with a molecular mass of>SO kDa. Consequently, cell associated proteases are more 
resistant to inhibition than free enzyme. It was also suggested that HNE activity may be protected 
from anti protease activity by the antioxidants produced by the neutrophil ( oxidative inactivation
 of 
cx.1PI) (Weiss, 1989; Bangalore and Travis, 1994) but this was claimed not to be so under 
physiological conditions due to the presence of anti-oxidants and competitive antagonists 
(Campbell et al., 1982). Another suggestion was made by Bangalore and Travis (1994) who have 
demonstrated that upon secretion ofHNE from the activated neutrophil, there is a partial rebind
ing 
of the enzyme to the neutrophil surface. They found this 'rebound' form of elastase to be reistan
t to 
inhibition by the elastase-specific inhibitors. 
The initial high molecular mass products, formed through the action of elastase (270 kDa, larger
 
than fragment X), are no longer clottable by thrombin, indicating that degradation is not confine
d 
to the carboxyl termini of the Acx. and the B~ chains, as is that of plasmin (Plow, 1980). Recent 
work by Bach-Gansmo et al. (1994), however, showed that the initial cleavage by HNE occurs at 
the carboxyl terminus of fbg and this cleavage appears to cause the prolongation of clotting time
 
and loss of clottability. The low molecular mass fbg products of elastase activity differ in size to 
all 
other known fbg products and exhibit potent anticoagulant activity (Plow and Edgington, 1975).
 A 
specific low molecular mass, FP A containing peptide is produced by the early action of elastase 
on 
fbg and is formed by the cleavage of the Acx. chain between Acx.21-Val and Acx.22-Glu (Weitz et al., 
1986). This peptide (Aa 1-21) has since been used as a specific indicator for elastase activity and
 a 
detection assay was developed to demonstrate elevated levels of Aal-21 in patients with a 1AT 
deficiency and pulmonary emphysema (Weitz et al., 1992). 
An important observation by Weitz et al. (1987) showed that unstimulated neutrophils in contact 
with fbg coated filters still released small quantities of Aal-21. This would suggest that the 
interaction of the cells with the substrate was, in itself, enough of a stimulus for HNE release. Th
is 
may explain the presence of Aal-21 in the plasma of normal individuals where each day ±109 
neutrophils emigrate from the vascular compartment into extravascular tissues (Weitz et al., 1987) 
and in doing so must come into contact with the extracellular matrix comprised of, for example, 
fbg. A low level of fibrinogenolysis may thus be an inescapable consequence of neutrophil 
emigration from the vasculature. 
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Cathepsin G has also been indicated to play a major role in the leukocyte fibrinogenolytic pathway 
(Plow, 1980). Cathepsin G, within the neutrophil granules, initially cleaves the Aa chain in the 
presence ofCaCl2, followed by the BB and then they chain (Gramse et al., 1980). Cathepsin G has 
a specificity for leucyl bonds and aromatic amino acids and the products formed are not identical to 
those produced by the action ofplasmin but a fragment with similar antigenicity and molecular 
mass to fragment E is formed (Plow, 1980). ca2+ appears to have a significant effect on fbg 
degradation by cathepsin G, where the y chain shows a greater susceptibility to cathepsin G than 
the BB chain in the absence of Ca2+. Also, the main degradation products appear smaller in 
molecular mass than those formed in the presence of Ca2+. In the case of plasmin, only the 
susceptibility of fragment D is affected by the presence of Ca2 +. 
Platelets have been shown to contain proteolytic enzymes capable of digesting fbg but they appear 
to contribute a quantitatively minor role to fibrinogenolysis in the circulation (Moroz, 1984 ). 
Macrophages also contain enzymes with elastolytic activity, capable of cleaving fbg, but these 
enzymes are immunologically unrelated to neutrophil elastase (Plow, 1982). 
Monocytes have been shown to bind fbg via the CDl lb/CD18 (Mac-1) receptor (see 2.C.7.3. The 
integrins), followed by internalisation into the lysosomes and subsequent degradation (Simon et al., 
1993). 
2.B.7.3. Fibrinogen degradation products (FDP's) - Function 
Fragments D, DD and E are typically present in patients with disseminated intravascular 
coagulation (DIC), which is commonly associated with severe bacterial infection and neutropenia, 
as well as related conditions in which neutrophil defence against bacterial infection may be 
compromised (Kazura et al., 1989; Robson et al., 1994). Kazura et al. (1989) showed that FDP's 
inhibit neutrophil 02- release and chemotaxis stimulated by FMLP. Fragment E was primarily 
responsible for the inhibition ofFMLP induced neutrophil 02- release, possibly by inhibiting FMLP 
interaction with neutrophil receptors. Inhibition of chemotaxis by FD P's also involves cell 
receptor/FMLP modulation. PMA and zymosan activated neutrophil 02- release was also inhibited 
by FD P's, but inhibition was not due to interference of stimulator binding and was possibly due to 
impairment of activation and translocation of PKC from the cytosol to the membrane. D and DD 
were also shown to inhibit lymphocyte proliferation in response to T-cell mitogens, allogeneic 
mononuclear leukocytes and anti-CD3 in vitro (Robson et al., 1993). This inhibitory activity is 
derived from a sequence within the C-terminus of the 'Y chain ofD or DD namely K-Q-A-G-D-V 
which binds to the CD1 lb/CD18 monocyte receptor (see 2.C.7.3. The integrins) (Gresham et al., 
1992). Conflicting results to these were reported by Hatzfield et al. (1982) who showed 
stimulation of proliferation of human haemopoeitic cells ( monocytes, promyelocytes, pre-B cells, 
T-cells and erythroid cells) by FDP's in vitro. 
Other proposed functions of FD P's include the following: 
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a) Fragment D has been shown to induce cytoskeletal alterations and eventual retraction of venous 
endothelial cells in vitro. Ge et al. (1992) showed that this endothelial cell detachment occurred 
concurrently with an increase in cell associated urokinase plasminogen activator (u-PA) and, to a 
lesser extent, t-PA and a subsequent increase in sub-endothelial matrix (fbg and vitronectin) 
degradation by plasmin. Fragment E was also found to elicit endothelial cell detachment but to a 
much lesser extent. This function may have pathological relevance where elevated levels ofD are 
found in patients with adult respiratory distress syndrome (ARDS) associated with increased 
pulmonary vascular permeability and injury. These results were, however, in direct contrast with 
those of Tanaka and Sueishi (1993) who found that fibrin caused endothelial cell injury while 
fragments D and E did not. The exact reason for this discrepancy is not certain. b) Fragment E has 
been found to stimulate focal smooth-muscle cell proliferation during the formation of stenosing 
atherosclerotic lesions. The E fragment must, however, have been derived from fibrin and thus have 
lost the fibrinopeptides in order to exert these effects. Fbg derived fragment E or fbg did not 
stimulate muscle cell proliferation (Stirk et al., 1993). c) Fragment E competes with fbg for 
fibroblast binding and inhibits directed migration of these cells in a fbg concentration gradient (from 
Kazura et al., 1989). d) Fragments D and E appear to be chemotactic for monocytes (from 
Lorenzet et al., 1992). e) Fragments X and D have been shown to adhere to melanoma cells, in 
vitro, via the a.vJ33 integrin (see 2.C. 7.3. The integrins) (Felding-Habermann et al., 1992). Whereas 
the binding of whole fbg to melanoma cells results in significant cell spreading, the binding of 
fragment X and D does not. This differing biological response following the binding of fragment X 
and D to the J33 integrin, in comparison to binding of whole fbg, appears to relate to the different 
relative affinities of these ligands for the same receptor (Felding-Habermann et al., 1992). f) 
Various low molecular mass peptides (<20 kDa) have been found to induce chemotaxis of 
neutrophils as well as to inhibit lymphocyte blastogenesis (from Kazura et al., 1989; Robson et al., 
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1993). Low molecular mass FDP's are also able to stimulate the release of endothelial cell-derived 
growth factors (Lorenzet et al., 1992). FPB has been shown to have chemotactic activity for 
neutrophils with a potency equivalent to that of C5a, leukotrine B4 and FMLP (from Kazura et al., 
1989). g) BfH-42 mediates retraction of bovine artery endothelial cells and h) Bf343-47 induces 
vasodilation of bovine mesenteric arteries (from Lorenzet et al., 1992). i) Synthetic peptides 
containing the carboxyl terminus of the y chain, specifically y402-4 l l containing the K-Q-A-G-D-V 
sequence, were found to inhibit the binding of tbg to the platelet surface via the a1Ibf33 (gpllb/llla) 
integrin receptor (see 2.C.7.3. The integrins and 2.B.6.5. Interaction of tbg with platelets) 
(Kloczewiak et al., 1984). Synthetic peptides containing the R-G-D sequence, present in the Aa 
chain of fbg, and retaining an appropriate conformation, were, however, found to be more potent 
inhibitors of platelet aggregation than the K-Q-A-G-D-V sequence (Xinjie et al., 1993). j) 
Synthetic peptides beginning with, or containing only, the sequence Gly-Pro-Arg (G-P-R), which 
represents the amino terminal segment of the fbg Aa chain after the release of FP A, can prevent or 
delay the clotting of tbg by thrombin (Laudano and Doolittle, 1980; Kawasaki et al., 1993). This 
anticoagulant activity was observed to be due to the interaction of the peptide with tbg and not 
thrombin. The exact sequence of the peptide was also found to be critical e.g. G-P-R-P, was shown 
to be a far more efficient anticoagulant than G-P-R-V (Laudano and Doolittle, 1980). 
Anticoagulant activity has also been observed in a 24 kDa product of plasmic digestion of tbg 
which represents the middle two thirds of the Aa chain beginning at Met-240 from the N terminus 
(Lau, 1993). The exact mechanism of inhibition of fibrin polymerisation by this 24 kDa peptide is 
not yet certain but results point to an interaction with tbg, rather than with thrombin or Ca2+ ions. 
It was suggested that this peptide does not function as a complementary binding site for fibrin 
monomers per se, but may interfere with the maintenance of polymerisation (Lau, 1993). 
These observations suggest that increases in the plasma concentration of various fbg fragments 
modulate the inflammatory response by virtue of the effects these fbg fragments have on multiple 
cellular components of blood. 
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2.C. THE NEUTROPHIL 
2.C.1. INTRODUCTION - THE ROLE OF THE NEUTROPHIL IN INFLAMMATION 
Neutrophils represent over 90% of the circulating granulocytes. They typically contain numerous 
granules which can be observed at the ultrastructural level. These granules fuse with the 
phagosomes, following phagocytosis, to form phagolysosomes (Roitt et al., 1985). Initially 
believed to be a purely mechanical phagocytic cell for the removal of foreign substances from the 
body, the neutrophil has recently come to the fore as a highly sophisticated inflammatory cell that 
may interact with its environment and perform numerous inflammatory functions. 
Acute inflammation is a complex response of the body to local injury or infection. Neutrophils 
represent the first line of defence during inflammation and rapidly emigrate from the vasculature to 
the site of injury and infection. This is achieved in a five step process involving attachment to the 
blood vessel wall, transmigration into the tissues, chemotaxis, phagocytosis and killing (from 
Malech and Gallin, 1987) (Fig 3). Each of these cellular processes is initiated by the occupation of 
specific surface receptors. Once phagocytosed the foreign particle is treated to a lethal 'cocktail' of 
reactive oxygen species, acidic pH, cationic proteins and a number of antimicrobial proteases. 
Although this represents a very effective means of host defence aberrant neutrophil numbers or 
behaviour may potentiate severe pathophysiological disorders and it is, therefore, necessary that we 
understand the mechanism of neutrophil function (from Malech and Gatlin, 1987). 
In this review a general outline of neutrophil function will be provided while particular relevant 
aspects will be discussed in detail. 
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Figure 3. Migration of neutrophils out of the vasculature and into the underlying tissue, toward sites of 
infection or inflammation, occurs as a co-ordinated sequence of events. Initially the neutrophils, 
activated by various inflammatory mediators, 'roll' along and sample the endothelial surface. This 
rolling action is mediated by the selectins, on both the neutrophil and the endothelium, and their 
respective oligosaccharide ligands. Expression of IL-8 and release of P AF by the endothelial cells 
stimulates expression of the ~rintegrins on the neutrophil which may then interact with counter-
receptors of the irnmunoglobulin superfarnily on the endothelium. This leads to 'tight' adhesion of the 
neutrophil to the vessel wall and is accompanied by a change of shape of the neutrophil followed by 
extravasation of the cell into the underlying tissue. The neutrophil migrates toward the site of infection 
as its movement is directed along a chemotactic gradient. Opsonisation of the foreign particle by IgG and 
C3 allows phagocytosis to proceed by means of the IgG Fe and C3 receptors present on the neutrophil. 
The foreign particle becomes incorporated into the phagosome where it is treated to a lethal cocktail of 
reactive oxygen species, acidic pH, cationic proteins and a number of antimicrobial proteases (adapted 
from Gearing and Newman, 1993 and Cohen, 1994). 
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2.C.2. NEUTROPHIL CHEMOTAXIS 
When an acute inflammatory response develops at a local site, there is an increase in vascular 
permeability and subsequent migration of the neutrophils out of the vasculature toward the infected 
site. The mechanism of diapedesis is discussed in detail below (see 2.C.7.4. Endothelial-neutrophil 
interaction). 
Chemotaxis is a complicated and finely regulated process involving the interaction of chemotactic 
factors, their antagonists and their receptors and results in the orientated migration of neutrophils 
as they migrate along a chemotactic gradient (Van der Valk and Herman, 1987). Chemotactic 
substances are numerous and include various host plasma-derived factors as well as substances 
released from various host cell types and infective organisms (Table 1 ). The most important 
chemotactic agents are believed to be the complement components, C3 and C5a, as well as 
components and degradation products of the clotting system (Van der Valk and Herman, 1987; 
Wardle, 1986). 
Table 1. Factors that are chemotactic for neutrophils (Wardle, 1986). 
ENDOGENOUS 
•Immune complexes 
•C5a and C5a desArg complement components 
Plasma derived •Kallikrein (by activation of coagulation) 
•Leucegresin ( or protease treated immunoglobulin) 
•lgG 
•Oxidised lipids or platelet factor 4 
•Fibrinopeptides and FDP 
•Lymphokines (from lymphocytes) 
Cell-derived •Neutrophil chemotactic factor (P AF, HETE or 
LTB4) of other neutrophils, mast cells or monocytes 
•Collagen fragments in damaged tissues 
EXOGENOUS 
•Chemotactic peptides and lipids of bacteria 
•Calcium Ionophores 
chemotactic peptides FMLP, Con A: PM.A, opsonised 
zymosan (C3b ): combined C3b and IgG stimulation 
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Receptors on the neutrophil responsible for directional chemotaxis include those for N-formyl 
peptides of bacterial origin e.g. FMLP, C5a, IL-8 and bioactive lipid products e.g. P AF and 
leukotriene B4 (from Cohen, 1994). Occupancy of a critical number of receptors leads to rapid 
shape changes (polarisation) and directional movement of the cell. The most extensively studied of 
the chemotactic receptors are those for FMLP (from Cohen, 1994). The expression of the FMLP 
receptors has been shown to be increased by stimulation of the neutrophil with low doses of PMA 
which leads to the limited and preferential release of the specific granules (see 2.C.5. Neutrophil 
granules) (Fletcher et al., 1982). Following ligand binding to the FMLP receptor, the mechanisms 
for signal transduction are unclear but may generate multifunctional signals e.g. chemotaxis, 
degranulation and increased oxygen uptake, depending on the concentration of the stimulus (from 
Cohen, 1994). 
2.C.3. NEUTROPHIL PHAGOCYTOSIS 
Once the neutrophil has migrated to the source of the chemotactic stimulus e.g. an invading 
pathogen, it ingests the foreign particle in a process described as phagocytosis (Borregaard, 1988; 
Stossel, 1994). Phagocytosis is mediated by the IgG Fe and C3 surface receptors and, following 
receptor occupation, an invagination occurs on the neutrophil surface as actin/myosin 
polymerisation alters the organisation of the underlying microfilaments (Fig 3). The neutrophil 
changes shape and 'fingers' of organelle-free cytoplasm, described as pseudopods, extend out and 
surround the foreign particle (Stossel, 1994). The plasma membrane engulfs the foreign particle 
and as the pseudopods meet and fuse, the foreign object is encased in a phagocytic vacuole 
(Borregaard, 1988). The primary or azurophilic granules fuse with the newly formed phagocytic 
vacuole and release their toxic components resulting in the destruction of the foreign body by 
various means (see 2.C.4. Neutrophil killing). 
As mentioned briefly, the receptors involved in the phagocytic process are the C3 and Fe receptors. 
The Fe receptors include FcRII and FcRIII and both recognise the Fe portion of the 
immunoglobulin. Ingestion of bacteria mediated by the F cRII has been noted to effect the 
microbicidal response more efficiently than FcRIII (Kimberly et al., 1990; Huizinga et al., 1990). 
The complement receptor CRl is primarily responsible for the recognition of C3b but, in some 
cases, ingestion of C3b-coated particles requires concomitant occupancy of the Fe receptor (Joiner 
et al., 1984). CR3 mediates the binding of C3bi-coated particles but also requires the second Fe-
mediated signal for ingestion (Joiner et al., 1984). 
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2.C.4. NEUTROPHIL KILLING 
Following phagocytosis of a foreign pathogen a number of destructive substances or processes 
are released or activated in the phagocytic vacuole and in concert these ensure a highly effective 
means of 1killing' (Fig 3) (Wardle, 1986; Cohen, 1994). The toxic substances may, in some 
instances e.g. adhesion and spreading, also be secreted from the granules, into the extracellular 
milieu and may bring about the degradation of extracellular matrix components. This may be 
beneficial for the cell in the case of neutrophil migration from the vasculature toward inflammatory 
sites, but may also be contributory to the development of tissue destructive pathological disorders 
(from Suchard and Boxer, 1994). 
2.C.4.1. The respiratory burst 
Phagocytosis or adherence of neutrophils to extracellular matrix proteins may be accompanied by 
a sudden increase in Oz consumption (from Cohen, 1994; Sud'ina et al., 1991). This leads to the 
oxidation of increased amounts of glucose (via the hexose monophosphate shunt, HMP) and the 
generation of reactive oxygen intermediates e.g. superoxide (Oz-) (Clark, 1990; Rotrosen et al., 
1992). Oz- is generated by the activation of membrane NADPH oxidase by cytochrome b558 
which is released from the secondary granules (see 2.C.5. Neutrophil granules). Hydrogen peroxide 
(HzOz) is then generated either by the spontaneous dismutation of Oz- or via a superoxide 
dismutase (SOD) catalysed reaction. Secondary oxygen metabolites may also be formed (Wardle, 
1986; from Cohen, 1994). Hypochlorous acid (HOCl), which is primarily responsible for killing 
bacteria in the phagosomes, is formed by the action of myeloperoxidase (MPO) on Hz Oz. MPO, in 
the presence ofHzOz, may also lead to the deamination and decarboxylation of amino acids to 
generate chloramines which cause oxidative damage to proteins (Weiss et al., 1983). Hydroxyl 
radicals (Off) are formed by the interaction ofHOCl with Oz- as well as the reduction ofFe3+ to 
Fe2+ by Oz- resulting in reduction ofHzOz to Off (Ramos et al., 1992). An interesting 
observation is the ability of lactoferrin to bind Fe3+, preventing the formation of Off and possibly 
presenting a mechanism for the control of hydroxyl radical formation at inflammatory sites 
(Britigan et al., 1986). 
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The respiratory burst is localised at the membrane of the cell and consequently also of the 
phagocytic vacuole membrane resulting in the release of toxic oxygen metabolites into both the 
extracellular medium and the phagosome (from Van der Valk and Herman, 1987). Pre-treatment of 
neutrophils with endotoxin e.g. LPS as well as TNF, has been shown to 'prime' the neutrophil to 
release increased amounts of superoxide when stimulated and this appears to be mediated by an 
alteration in calcium flux (Bajaj et al., 1992; from Cohen, 1994). 
2.C.4.2. Acidification of the phagosome 
Some microbes are killed by low pH and some of the neutrophil antimicrobial systems require a 
low pH for optimal activity e.g. the MPO dependent formation ofHOCl and bacterial killing by 
HOCl are optimal at pH 5.0 (Hurst and Barrette, 1989). In resting cells acidification results from 
release of lactic acid formed during neutrophil aerobic glycolysis. In phagocytosing cells numerous 
factors result in acidification. These include release of lysosomal granule hydro lases into the 
phagosome, generation of protons by internalised micro-organisms and their degradation products, 
dissociation of carbonic acid formed through the HMP and the active transport of W ions through 
a Na+/H+ antiport and an anion/OH- ion antiport (from Cohen, 1994). 
2.C.4.3. Antimicrobial proteins and proteases 
The antimicrobial proteins and proteases work in concert with the free radicals (see above) and 
are all contained within the numerous cytoplasmic granules of the neutrophil (from Cohen, 1994). 
The neutrophil granules and their toxic contents are discussed in detail below. 
2.C.5. NEUTROPHIL GRANULES 
The neutrophil granules contain severely toxic products and it is crucial that they not be released 
by the unstimulated circulating neutrophil (Borregaard et al., 1993b). It seems that the neutrophil 
has a highly sophisticated means of communicating with the environment and is capable of 
separately mobilising four different types of intracellular granules and secretory vesicles, some of 
which are crucial for interaction with the endothelium and migration, others for phagocytosis and 
microbial killing (Borregaard et al., 1993b ). The process of degranulation is guanidine triphosphate 
(GTP)-dependent and the presence of small GTP-binding proteins (SGBP's) have been suggested 
to play a role in the differential exocytosis of the different granules. Two of these SGBP's have thus 
far been identified and specifically associate with the membrane of the secondary granules or the 
plasma membrane. They have been named rap 1 and rap2 and are notably not associated with the 
cytosol or the primary granules (Maridonneau-Parin and De Gunzburg, 1992). 
Upregulation of the neutrophil surface membrane proteins has been shown to be the result of the 
exocytosis of different granule subsets and may lead to the expression of, for example, adhesion 
proteins, receptors for complement factors and chemotactic peptides and components of the 
microbial NADPH-oxidase, necessary for respiratory burst activity (Borregaard et al., 1993b). 
Thus, upregulation of the surface membrane proteins may represent an important feature of the 
inflammatory response of the neutrophil. 
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The toxic components of the granules may be confined to the phagolysosomes following 
phagocytosis or may be released into the extracellular medium during adhesion and spreading of 
the neutrophil. In many instances this release of destructive substances from the cell may lead to a 
variety of pathologic processes (from Suchard and Boxer, 1994). The process of neutrophil 
mediated endothelial injury is thought to result in the loss of the selective permeability barrier 
giving rise to oedema and haemorrhage, as well as the loss of nonthrombogenic surface properties 
resulting in platelet adhesion and coagulation. Culminatively these effects appear to play a role in 
the pathophysiology of, for example, ARDS, vasculitides (Kawasaki syndrome, Wegeners 
granulomatosis) as well as the complications arising from clinical treatments such as thrombolytic 
therapy of myocardial infarction and haemodialysis (pulmonary leukostasis, rnicroembolism, 
disseminated intravascular coagulation) (Westlin and Gimbrone, 1993). 
Neutrophil granules are traditionally classified into the peroxidase-positive (azurophil or primary) 
and peroxidase negative (specific or secondary) granules and more recently the tertiary or 
gelatinase granules (Kjeldson et al., 1992) and the secretory vesicles (Borregaard et al., 1987, 
1990; Sengelov et al., 1993). These groups may be even further differentiated according to density 
and listed in order of decreasing density are, a) the dense peroxidase positive granules, rich in 
defensins, b) light peroxidase positive granules, low in defensins, c) dense peroxidase negative 
granules, containing lactoferrin but no gelatinase, d) intermediate peroxidase negative granules, 
containing lactoferrin and gelatinase and e) light peroxidase negative granules, containing 
gelatinase but no lactoferrin (Borregaard et al., 1993a). 
The primary or azurophilic granules are formed at the myeloblast stage, are characterised by the 
presence ofMPO and are the stores for most of the proteolytic and bactericidal proteinases 
including elastase, the cathepsins, lysozyme and the recently identified proteinase 3 (PRJ) 
(Borregaard et al., 1993a). MPO is important for the generation of reactive oxygen species as it 
acts on H202 and converts it to the toxic HOCl (see 2.C.4.1. The respiratory burst). The 
membrane of the azurophil granules does not contain any important inflammatory receptors and 
they are mobilised very slowly indicating their primary function to be digestion and killing of 
phagocytosed material. These granules also act late in the inflammatory response upon 
disintegration of the cell (Borregaard et al., 1993a). 
Specific granules are formed at the myelocyte stage, are unique to neutrophils and serve as a 
marker for tenninal myeloid maturation. They are characterised by lactoferrin and vitamin B12-
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binding protein (Borregaard et al., 1993a). The specific granule also contains numerous membrane 
proteins, namely cytochrome b55g, FMLP receptors, TNF receptors, G-proteins, Mac-I and many 
others. They also contain the proteases, collagenase, lysozyme and plasminogen activator. A recent 
study (Suchard and Boxer, 1994) demonstrated that the exocytosis of the specific granules is a pre-
requisite for the production of the toxic reactive oxygen derivative, H202 and they postulated that 
this was related to the delivery of cytochrome b to the plasma membrane leading to the activation 
of NADPH oxidase. The specific granules have also been described as the 'adhesomes' (Singer et 
al., 1989) as they were believed to be responsible for the initiation of the inflammatory response in 
the neutrophils, due to their content of membrane adhesion receptors. Subsequently, however, the 
secretory vesicles, which are more easily mobilisable and contain inflammatory receptors, are 
considered to be more important than the specific granules for the initiation of inflammatory 
processes (Sengelov et al., 1993). 
The tertiary granules are a sub-set of light peroxidase negative granules which contain gelatinase 
but no lactoferrin. Although most lactoferrin containing granules contain gelatinase they should not 
be confused with the tertiary granules which contain the majority of the total cell gelatinase despite 
their low number (approximately 25% of peroxidase negative granules) (Kjeldson et al., 1992; 
Kjeldson et al., 1993). It was suggested that the tertiary ganules may contribute to the upregulation 
of the neutrophil membrane proteins during inflammation as they contain the same membrane 
components as the specific granules and are more readily mobilised. Tertiary granule numbers are 
now thought to be insufficient to account for the total upregulation of the membrane proteins 
during the inflammatory response. Their mobilisation does, however, appear to account for the 
substantial release of gelatinase from the neutrophil (Borregaard et al., 1993a). A major difference 
between tertiary and specific granule gelatinase is the association of this protease with a 25 kDa 
neutrophil associated gelatinase lipocalin (NGAL) in the specific granules and the absence of this 
association in the tertiary granules (Borregaard et al., 1993a). 
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The secretory vesicles have been described as highly mobilisable light vesicular structures 
containing alkaline phosphotase on the luminal side of the vesical membrane (Borregaard et al., 
1993a~ Borregaard et al., 1993b). These vesicles contain plasma proteins not synthesised by the cell 
and therefore represent a specialised form of endocytic vesicle which, once formed, behave like 
granules. They are suggested to be responsible for the upregulation of surface membrane proteins, 
namely Mac-1 (see 2.C.7.3.1. Neutrophil Integrins), following their fusion with the plasma 
membrane during exocytosis, and may thus be responsible for regulating the interactions of 
neutrophils with the endothelium during the inflammatory response (see 2.C.7.4. Endothelial-
neutrophil interaction) (from Borregaard et al., 1993a; Borregaard et al., 1993b ). 
The secretory vesicles are the most easily mobilisable and secreted granules, followed by the 
tertiary, gelatinase-rich granules, then the specific and finally the azurophilic granules (Borregaard 
et al., 1993a). With a given stimulus the granules 'hook on' to the microtubule system and are 
subject to the mechanical force of the microtubules. The lighter and smaller the granule, the faster it 
will move (Borregaard et al., 1993a). Granule exocytosis also appears to involve the sequential 
release of granule components with some being specifically released before others (Csemok et al., 
1994). The mechanism for this specificity or the signal which allows incorporation of a particular 
granule constituent into the plasma membrane e.g. PR3, where the other constituents are released 
into the extracellular milieu, e.g. elastase and cathepsin G, is not known. 
2.C.6. NEUTROPHIL PROTEASES 
The predominant function of neutrophil proteases is to facilitate neutrophil migration through the 
basement membrane as it moves out of the vasculature to inflammatory sites (from Adams and 
Shaw, 1994) and to digest foreign organisms within the phagolysosome (from Suchard and Boxer, 
1994). The neutrophil contains primarily two groups of proteases, the metalloproteases and the 
serine proteases. 
2.C.6.1. Neutrophil matrix metalloproteinases (MMP) 
Iv1MP's mediate the degradation of the extracellular. matrix and basement membrane components, 
collagen, glycoproteins and proteoglycans (Hirose et al., 1993). The metalloprotease gene family 
consists of at least two distinct interstitial collagenases (MMP-1 or fibroblast collagenase and 
MMP-8 or neutrophil collagenase ), three types of stromelysins, putative metalloproteinase 1 and 
two gelatinases (72 kDa [MMP-2] and 92 kDa [MMP-9]). All of these enzymes contain an 
essential catalytic zinc-binding domain, an amino terminal domain containing a "cysteine switch", 
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which preserves the latent state of the enzyme, and a variable carboxyl tenninus (Hirose et al., 
1993). They are all secreted as zymogens which undergo extracellular activation by, for example, 
elastase and reactive oxygen species. Apart from zinc the MMP's also require Ca2+ for activity. 
Interstitial collagenase and gelatinase are the two MMP's produced by the neutrophil (Hirose et al., 
1993). 
2.C.6.1.1. Collagenase 
Human neutrophil collagenase (MMP-8) is stored as a glycosylated proenzyme within the 
specific granules and is secreted in response to various inflammatory mediators (from Knauper et 
al., 1993). Activation of the procollagenase occurs in the extracellular medium following the 
cleavage of at least 80 or 81 N-terminal amino acids following interaction with proteases, reactive 
oxygen species or mercurial compounds (from Knauper et al., 1993). MMP-8 has a specificity for 
the interstitial collagens. The most distinctive characteristic of interstitial collagenases is their ability 
to cleave the interstitial collagens at a single peptide bond. The substrate specificity of this enzyme 
appears to reside in a 62 amino acid carboxyl tenninal region and is influenced by a disulphide loop 
in this region. Another locus, preceding the 62 amino acid collagenase specific locus, also appears 
to be necessary for general catalytic activity. Asp-253 in this region was found to be critical for 
activity and may represent a possible divalent cation binding site (Hirose et al., 1993). 
2.C.6.1.2. Gelatinase 
Gelatinase exists as a 92 kDa protein (MMP-9) in the specific granules or a 72 kDa (MMP-2) 
form in the tertiary granules (see 2.C.5. Neutrophil granules; Borregaard et al., 1993). Unlike the 
neutrophil collagenases, the gelatinase gene appears to be identical in neutrophils, fibrosarcoma 
cells, macrophages, monocytes etc. despite the fact that it is stored in granules in the neutrophils 
and is constitutively secreted by all other granulocytes (Devarajan et al., 1992). Gelatinase is co-
ordinately expressed with lactoferrin (Graubert et al., 1993). It cleaves type IV basement 
membrane collagen into 1 of 4 amino terminal and 3 of 4 carboxyl tenninal fragments andf is also 
able to cleave fibronectin, types V and VII collagen and denatured collagen (gelatin) (Morel et al., 
1993). 
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2.C.6.2. Neutrophil serine proteases 
The serine proteases are a family of enzymes which utilise a uniquely activated serine residue in 
the substrate binding site to catalytically hydrolyse peptide bonds (Devlin, 1992). They are 
characteristically inhibited by diisopropyl fluorophosphate (DFP) and phenylmethylsulphonyl 
fluoride (PMSF) which interact with this serine residue within the active site of the enzyme (Stryer, 
1981 ). 
2.C.6.2.1. Human neutrophil elastase (HNE) 
HNE has sparked quite an interest due to its putative role in the pathogenesis of pulmonary 
emphysema. HNE activity has also been implicated in the pathology of ARDS and rheumatoid 
arthritis (Thomas et al., 1991). The specific substrate for elastase is elastin and it attacks the 
peptide bonds on the carboxyl side ofvaline and, to a lesser extent, alanine. HNE has a pl of 5.5-
5.9, a molecular mass of 30 kDa and is specifically inhibited by the serpin a.1 PI, which has recently 
been found to exist in the neutrophil cytosol (Thomas et al., 1991). The cytosolic inhibition of 
HNE may represent a means of protecting the intracellular environment from proteolytic injury 
during degranulation. HNE-a.1 PI complexes have been found to be chemotactic for neutrophils and 
an HNE-a.1 PI receptor has been identified on the neutrophil surface which mediates endocytosis 
and catabolism ofHNE-a.1PI complexes (Joslin et al., 1992). Reduced levels of a.1 PI in the 
plasma, which manifests as a disorder described as a.1 PI deficiency, leads to unopposed protease 
activity in the lungs and culminates in pulmonary emphysema (Thomas et al., 1991). HNE is 
susceptible to other inhibitors besides a.1 PI, namely, the general serine protease inhibitors, a.2-
macroglobulin, antileukoprotease (or secretory leukocyte protease inhibitor) as well as (Ala)2-Pro-
Val-chloromethyl ketone. Despite the definite specificity of HNE for elastin, HNE has been shown 
to have broad substrate specificity for many extracellular matrix proteins e.g. the endothelial 
proteoglycans (Key et al., 1992), collagens, fibronectin, fbg, basement membrane and 
immunoglobulins (Thomas et al., 1991). As mentioned above, a membrane form ofHNE, which is 
the result of rebinding of secreted HNE to the neutrophil surface, has been noted (Bangalore and 
Travis, 1994). This membrane form ofHNE demonstrates resistance to HNE inhibitors including 
a.1PI. 
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A study done by Woodman et al. (1993) demonstrated that aside from the destructive potential of 
HNE at inflammatory sites it also has the ability to upregulate the expression of the 13 subunit of the 
CD11/CD18 integrin complex and to a lesser extent CD1 lb on the neutrophil surface (see 
2. C. 7 .3 .1. Neutrophil integrins ). This upregulation was found to affect neutrophil migration, but 
not adhesion, at inflammatory sites, although the mechanism for this remains unclear. HNE has als
o 
been implicated in the priming of macrophage superoxide production, modification of platelet 
aggregation and stimulation of B cell proliferation (Kusner and King, 1989). 
2.C.6.2.2. Cathepsin G 
Cathepsin G is a 29 kDa chymotrypsin-like serine protease which is also capable of cleaving 
elastin but in a manner distinct to HNE as it attacks bonds on the carboxyl side of tyrosine and 
phenylalanine. Like HNE, cathepsin G has a pl of 5.5-5.9 and is specifically inhibited by the 
cytosolic a 1 PI (Kusner and King, 1989). It is released in significant quantities at sites of 
inflammation. The precise function of cathepsin G is ill defined but it has been suggested to 
function as an immune response modifier. Examples of this include its ability to a) prime 
macrophage superoxide response, b) enhance phagocytosis of immune complexes by neutrophils, 
c) 
cleave human IgG, IgM, fbg, fibronectin and Cl, C4, C3 and C5 and d) stimulate B cell 
proliferation (from Kusner and King, 1989). Like HNE, secreted cathepsin G has been shown to 
partially rebind to the neutrophil surface and consequently demonstrates anti-protease resistant 
behaviour (Bangalore and Travis, 1994, see 2.B.7.2. Digestion offbg by non-plasmin mediated 
pathways). 
2.C.6.2.3. Proteinase 3 (PR3) 
PR3 was first discovered in 1978 by Bagglioni et al. who showed its electrophoretic mobility to 
differ from that ofHNE and cathepsin G (from Kao et al., 1988). PR3 was initially found to be able 
to cause emphysema in hamsters with a severity equal to, if not greater, than that caused by HNE 
(Kao et al., 1988). PR3 is able to degrade elastin more efficiently than HNE at pH 6.5 but not at 
pH 7.4 or 8.9. Besides being able to degrade elastin, PR3 has been shown to have broad substrate
 
specificity, similar to that of HNE and cathepsin G, and may cleave fibronectin, laminin, vitronecti
n 
and collagen type IV but not interstitial collagens type I and III (Rao et al., 1991 ). The substrate 
specificity of PR3 indicates a possible role in the migration of neutrophils through the endothelium
. 
The pl of PR3 is less than HNE and cathepsin G and it is also immunologically distinct from HNE
 
(Kao et al., 1988). The exact sites of attack of PR3 on elastin were not determined but were 
suggested to be different from those ofHNE and cathepsin G (Kao et al., 1988) although Rao et 
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al. (1991) showed that PR3, like HNE, prefers small aliphatic amino ac
ids (alanine, serine and 
valine ). PR3 bears resemblance to myeloblastin and has been implica
ted in myeloblast 
differentiation. The cDNA of PR3 has been isolated and cloned and 
the predicted amino acid 
sequence was found to be highly homologous to the primary structur
e of elastase, cathepsin G and 
other serine proteases and it was suggested that the genes for these t
hree proteins share a common 
progenitor (Campanelli et al., l 990~ Sturrock et al., 1992). The PR3 ge
ne is on human 
chromosome 19 which was thought to be unique for the trypsin-like 
serine proteases (Sturrock et 
al., 1992) but work by Zimmer et al. (1992) showed PR3 to be a memb
er of a cluster of elastase-
related genes in the terminal region of the short arm of chromosome
 19. The other two members 
are elastase and azurocidin (an antimicrobial substance of the primar
y granules, see below) and all 
three are co-ordinately expressed. PR3 was shown to share both the 
catalytic triad and the 
substrate binding pocket of elastase. There are a few small difference
s in the substrate binding 
pockets of the two proteases with one or two amino acid substitution
s (Val-168 to Ile in PR3 and 
Ala-187 to Asp in PR3) and insertions in PR3 (between the Gly-22 a
nd Gly-23 and between the 
Gly-23 and His-24 ofHNE) which may explain the slight differences
 in reactivity of PR3 for the 
HNE substrates (Rao et al., 1991). PR3 is inhibitable with PMSF, DFP,
 a1PI and a2-
macroglobulin but not a 1-anti-chymotrypsin and secretory leukocyte
 protease inhibitor. PR3 is also 
inhibited by the elastase specific chloromethyl ketone inhibitor, MeO
-Suc-Ala2-Pro-Val-CH2Cl, 
but less effectively than HNE, and is not inhibited at all by MeO-Suc
-Ala2-Pro-Ala-CH2Cl (Rao et 
al., 1991). PR3 was found to exist in isoenzyme forms with the predom
inant form being 
approximately 26 kDa and, similarly to elastase, it is localised in the 
neutrophil primary granules 
(Kao et al., 1988). 
PR3 may also be expressed, following stimulation with TNF-a and I
L-8, in small amounts on the 
plasma membrane (Csernok et al., 1990; Csernok et al., 1994) and this 
correlates with release of 
the primary granule contents from the cell but is not associated with 
the translocation of MPO or 
elastase to the plasma membrane. This may suggest that PR3 has a d
ifferent accessibility to the 
membrane when compared with other azurophil granule components
, although the mechanism for 
this is not understood. Interestingly, PR3 is more abundant than HN
E and may be responsible for 
functions previously attributed to HNE (Campanelli et al., 1990). An im
portant pathological 
finding is the ability of PR3 to act as an autoantigen in the generation
 of anti-neutrophil 
cytoplasmic antibodies (ANCA) in Wegeners granulomatosis (WG), 
which is a systemic necrotising 
vasculitis associated with granuloma formation (Csernok et al., 1990; C
sernok et al., 1994). 
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2.C.6.2.4. Azurocidin and azurophil granule protein 7 (AGP7) 
Azurocidin and AGP7 are both found in the primary granules of the neutrophil and show 
considerable sequence homology to elastase (Wilde et al., 1990). Azurocidin has been shown to 
share 65% sequence homology with the active site of elastase. Despite this homology, the catalytic 
serine is replaced with a glycine in azurocidin and it is subsequently unable to bind DFP (Wilde et 
al., 1990). Despite the lack of proteolytic activity, azurocidin has been demonstrated to display 
antimicrobial activity in vitro. AGP7, on the other hand, shows 70% homology with elastase at the 
active site and is capable of binding DFP, thus demonstrating active serine proteolytic activity. 
Azurocidin comprises three predominant bands on SDS-P AGE with molecular mass values 28-30 
kDa and AGP7 comprises four distinct glycoforms of molecular mass values 28-34 kDa (Wilde et 
al., 1990). Both these proteins, and in particular AGP7, are extremely insoluble at neutral pH and it 
was suggested that they may be associated with the neutrophil membrane. A relationship between 
PR3 and AGP7 has also been suggested and is under investigation (Wilde et al., 1990). 
2.C.6.3. Neutrophil membrane-associated proteases 
A serine protease which differs in its catalytic and molecular properties to the well known 
proteases of the primary granules (see above) was isolated from the neutrophil membrane 
(Pontremoli et al., 1986). This protease is released into the extracellular medium with stimulation 
oflow concentrations of PMA ( optimally at IO ng/ml) and this release is concomitant with the 
production of oxygen radicals. Contribution of the secondary granules was excluded due to the 
observation of only limited release of the secondary granule constituents with low concentrations of 
PMA (Pontremoli et al., 1986). The release of this protease from the membrane was found by 
Melloni et al. (1986) to be dependent on ATP and PKC activation. It was proposed to have a role 
in the cytolytic effects of the neutrophil, in co-operation with the oxygen radicals. The protease 
was characterised as a high molecular mass (approximately 300 kDa), ca2+ independent enzyme 
with a pH optimum between 7.4-7. 8 (Pontremoli et al., 1986). Subsequent to the identification of 
this membrane associated neutral serine protease Pontremoli et al. (1990) noted that it is in fact 
localised at sites of interaction of the neutrophil cytoskeletal proteins with the cell membrane. They 
also noted an activity of this serine protease for the modification and down-regulation of the PKC 
isoforms following PMA or FMLP stimulation. 
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The existence of a chymotrypsin-like protease in the neutrophil membrane has been no
ted by King 
et al. (1986). This membrane protease was initially described with an approximate molec
ular mass 
of 150-180 kDa (King et al., 1986) but was later shown to be approximately 65-70 kDa 
with an 
isoelectric point of 6.3 and displaying Ca2+ dependent serine protease activity (King et a
l., 1991 ). 
The murine anti-human neutrophil IgG1 monoclonal antibody, Ab 1-15, is specific for
 this enzyme 
and inhibits activity related to cell activation or more specifically 02- generation and c
AMP 
production, following FMLP or PMA stimulation (King et al., 1987). The mechanism of
 cellular 
activity modulation by this serine protease was not ascertained but was suggested to b
e due to the 
proteolytic alteration and activation of secondary messenger pathways situated in the 
neutrophil 
membrane. The protease was found in association with the FMLP receptor, which is k
nown to 
mediate neutrophil activation by the stimulation of NADPH oxidase as well as a neutr
ophil-specific, 
guanosine-dependent regulatory G protein which activates phospholipase C. It was initia
lly 
suggested that the membrane associated serine protease forms part of the FMLP rece
ptor complex 
on the neutrophil. It was later proposed, however, that this membrane enzyme represent
s a low 
affinity FMLP binding protein distinct from the cell activating FMLP receptor which m
ay also be 
involved in degradation of the FMLP receptor/ligand (King et al., 1991 ). The exact role 
of this 
membrane bound protease was not identified. 
Having demonstrated a membrane enzyme in the neutrophil which is associated with t
he initiation 
of the superoxide response in the presence of inflammatory stimuli (King et al., 1987), a 
subsequent study by Kusner and King ( 1989) was of interest. They showed that local 
release of the 
neutrophil primary granule neutral proteases, cathepsin G and elastase, into the extrac
ellular 
medium can also augment neutrophil effector function by upregulating oxidative respo
nses to 
inflammatory stimuli. 
A 100 kDa neutral endopeptidase (NEP) has also been found in the neutrophil plasma
 membrane 
which is capable of cleaving FMLP at the Met-Leu bond with subsequent inhibition o
fFMLP 
mediated chemotax.is (Connelly et al., 1985; Painter et al., 1988). This protease was iden
tified as a 
metalloprotease which is constitutively expressed in the membrane and does not requi
re neutrophil 
activation for expression. The neutrophil NEP was found to be identical to the kidney
-brush border 
neutral proteinase and the brain enkephalinase. NEP was found to modulate the chem
otactic 
response of neutrophils by reducing FMLP concentration suggesting a mechanism of c
ontrolling 
the amount of chemotactic stimuli interacting with the neutrophil in the face of overwh
elming 
concentrations of the chemoattractant. Patients presenting with ARDS and especially 
when 
complicated with septic pneumonia, show abnormally high levels of this enzyme (Conn
elly et al., 
1985). 
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2.C. 7. NEUTROPHIL ADHESION 
The migration of neutrophils from the vasculature, through the endothelium and into the tissue, 
toward sites of inflammation, involves a complex series of events and a number of adhesion 
receptors on both the neutrophil and the endothelium (Zimmerman et"al., 1992; Bevilacqua, 1993; 
Adams and Shaw, 1994) (Fig 3). The sequence of events ofneutrophil adhesion and migration has 
been documented as follows: initially the neutrophils appear to 'slow down' and 'roll' along the 
endothelial surface. This so-called 'rolling' of the neutrophils is mediated by the interaction of the 
selectins on both the neutrophil and endothelial surface and is the initiating process for subsequent 
'tighter' binding and movement of the neutrophils through the endothelium, mediated by neutrophil 
integrins and receptors of the immunoglobulin superfamily on the endothelium (Fig 3). Neutrophil 
migration utilises a combination of regulated and reversible adherence processes to the matrix 
components which is a necessary requirement for the production of reactive oxygen species and 
release of degradative proteases (from Adams and Shaw, 1994). 
In order to achieve a complete understanding of the adhesive process and functions of the 
neutrophil a brief outline of the selectins, the immunoglobulin superfamily and the integrins, which 
play a role in this process, will be provided. 
2.C. 7.1. The selectins 
The selectins consist of a group of three glycoproteins which are expressed on the endothelium, 
platelets and leukocytes and interact with specific carbohydrates (Bevilacqua and Nelson, 1993 ). 
The nomenclature of the three selectins has been confusing in the past but are now named 
according to the cell type from which they were originally identified, namely, E-selectin 
(endothelium), P-selectin (platelets) and L-selectin (lymphocytes). The 'old' names of the selectins 
include endothelial-leukocyte adhesion molecule 1 (ELAM-I) (now E-selectin), platelet activation 
dependent granule-external membrane protein (P ADGEM) or granule membrane protein 140 
(GMP-140) or CD62 (now P-selectin) and murine lymph node homing receptor (mLHR) or MEL-
14 antigen or leukocyte-endothelial cell adhesion molecule 1 (LECAM-1) (now L-selectin) 
(Bevilacqua and Nelson, 1993). 
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E-selectin expression is largely restricted to activated endothelial cells and supports the adhesion of 
neutrophils, monocytes and a subpopulation of memory T-lymphocytes. Endotoxin, IL-I or TNF 
may stimulate synthesis and expression ofE-selectin within 4-6 hr (Bevilacqua and Nelson, 1993). 
P-selectin has a molecular mass of approximately 140 kDa and is associated with the a.- and dense-
granules in resting platelets and the Weibel-Palade bodies ofinactive endothelium. Thrombin, 
histamine, terminal complement compounds and H202 stimulate the immediate redistribution of P-
selectin to the platelet or endothelial surface where, in the endothelial cells, it is then reinternalised 
and its expression declines within minutes (Zimmerman et al., 1992). P-selectin contains a 
sequence within its cytoplasmic domain which routes it for degradation in the lysosomes following 
internalisation. This constitutive mechanism for the down-regulation of P-selectin is unusual in that 
it does not require an extracellular signal (Green et al., 1994). P-selectin expression on platelets 
and endothelium may support initial leukocyte adhesion (Bevilacqua and Nelson, 1993). 
L-selectin is constitutively expressed on most circulating human lymphocytes, neutrophils and 
monocytes and supports their adhesion to endothelium (Bevilacqua and Nelson, 1993 ). Activation 
of the cells results in a change in avidity ofL-selectin rather than its expression and downregulation 
of the receptor is achieved by the 'shedding' ofL-selectin from the cell surface (Bevilacqua and 
Nelson, 1993). Pizcueta and Luskinskas (1994) have recently noted a role for L-selectin in the 
recruitment of neutrophils during chronic inflammation (up to 48 hr) in contrast with previous 
studies which have all looked at initial adhesive interactions (2-4 hr). 
The selectins are typically Type I transmembrane proteins with a well conserved N-terminal lectin-
like domain, an EGF repeat and a variable number of modules (approximately 60 amino acids each) 
similar to those found in certain complement binding proteins (Bevilacqua and Nelson, 1993). The 
lectin and EGF domains have been found to be crucial for selectin mediated adhesion. The function 
of the complement binding-like region is not known but is proposed to 'hold' the other two regions 
away from the cell surface thereby enhancing adhesive function. Selectins require Ca2+ for activity 
(Bevilacqua and Nelson, 1993). 
The specific ligands for the selectins are carbohydrate containing compounds (Bevilacqua and 
Nelson, 1993). L-selectin binds to phosphorylated monosaccharides such as mannose-6-phosphate 
as well as certain sulphated polysaccharides such as fucoidan and sulphatides, namely, 3-0-
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sulphate-galactosyl ceramide. P-selectin may also bind to fucoidin, heparin and 3-0-sulphate-
galactosyl ceramide. More recently oligosaccharide structures related to the fucosylated 
lactosamines, namely, sialylated Lewis x (sLeX, Neu5Aca.2-3Galf31-4(Fuca.l-3)GlcNAc) and 
sialylated Lewis a (sLea, Neu5Aca.2-3Galf31-3(Fuca.l-4)GlcNAc) have been identified as 
important selectin ligands. sLeX and other fucosylated lactosamines are found in abundance on 
circulating neutrophils and monocytes which would support their adhesion to the endothelium via 
E-selectin. sLea is not typically expressed on leukocytes but has been found on cancer cells and it is 
suggested to play a role in metastasis (Bevilacqua and Nelson, 1993). Of interest is the theory that 
L-selectin may represent a ligand for E-selectin on the endothelium (Bevilacqua and Nelson, 1993). 
P-selectin also appears to recognise its ligand when presented in a glycoprotein form but the nature 
of participation of protein and carbohydrate in these selectin ligands is not known (Bevilacqua and 
Nelson 1993). 
An interesting feature of the selectins is the fact they have soluble isoforms which can be found in 
the circulation (Gearing and Newman, 1993). P-selectin was shown to have an alternately spliced 
mRNA lacking a transmembrane domain which shows only transient expression on the cell surface. 
L-selectin is cleaved from the cell surface in a proteolytic fashion and E-selectin appears to be lost 
from the cell surface within 24 hr of expression. These soluble isoforms are bioactive, can inhibit 
cellular adhesion and have been found to be raised in association with disease activity, for example, 
in patients with sepsis, HIV, haemolytic uremic syndrome, SLE, acute Plasmodium falciparum 
malaria and diabetes (Gearing and Newman, 1993). It is tenable that these circulating adhesion 
molecules may be useful monitors of disease activity. 
2.C. 7.2. The immunoglobulin superfamily-intercellular adhesion molecules (!CAM'S) 
This family of adhesion molecules is characterised structurally by repeated imrnunoglobulin-like 
domains in the extracellular domain. The numerous members of the imrnunoglobulin superfamily 
(lg SF) are believed to have evolved from a single ancestral unit, the lg fold ( Garrod, 1993; Pigott 
and Power, 1993) which is typically 70-110 amino acids organised into two parallel f3 sheets and 
stabilised with disulphide bonds (Pigott and Power, 1993). 
The IgSF is vast and this review covers, only briefly, one group of receptors within this family, 
namely the intercellular cell adhesion molecules (ICAM's). The ICAM's consist of three members, 
ICAM-1, ICAM-2 and ICAM-3 which have varying numbers oflg-like domains. ICAM-1 and 
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ICAM-2 contain five and two lg-like domains, respectively, (Fougerolles and Springer, 1993) and 
ICAM-3 consists of five immunoglobulin domains with 15 N-linked glocosylation sites (Vives, 
1994). As their name suggests the ICAM's are found as cell surface molecules although, as in the 
case of the selectins, soluble isoforms are known to exist (Fougerolles and Springer, 1993). A 
specific feature of the ICAM's is their ability to recognise the 132 integrin LFA-1 (see below) and 
they are believed to function, not only as adhesive receptors, but, in the case ofICAM-3, as signal 
transducers (Vives, 1994). 
ICAM-1 (CD54) is basally expressed in significant amounts on monocytes and is inducible on 
thymocytes, dendritic cells, endothelial cells, fibroblasts, keratinocytes, chondrocytes and epithelial 
cells (Pigott and Power, 1993). Induction ofICAM-1 expression may occur with the action of IFN-
Y, IL1f3, TNF-a and LPS. ICAM-2 (CD102) is constitutively expressed on endothelial cells, 
subpopulations of lymphocytes, monocytes, splenic sinusoids and dendritic cells. The functions of 
these receptors are numerous but of interest here is their ability to mediate the attachment of 
neutrophils to the endothelium. ICAM-3 (CD50) is constitutively and strongly expressed on resting 
lymphocytes and neutrophils (Vives, 1994; Fougerolles and Springer, 1993). Modulation ofICAM-
3 expression on human neutrophils appears to involve a PMA-activated proteolytic shedding 
mechanism with the release of soluble ICAM-3 into the circulation (del Pozo et al., 1994). The role 
ofICAM-3 interaction with LFA-1 on neutophil homotypic aggregation has not been investigated. 
2.C.7.3. The integrins 
The integrins are a family of membrane glycoproteins which exist as heterodimers with an a and 
f3 subunit (Fig 4). The a subunits vary in size between 120 and 180 kDa and are non-covalently 
associated with a f3 subunit which ranges from 90-110 kDa. Most cells express integrins and so far 
there are 8 known P subunits and 15 known a subunits (Smyth et al., 1993). The integrin family is 
subdivided into classes based on the P subunit. The most widely distributed integrins belong to the 
P1 class, also known as the very late antigens (VLA). The second class constitutes the leukocyte 
specific receptors or P2 integrins and the third class are the p3 integrins, otherwise described as the 
cytoadhesins. Less is known of the f34 through to f3g integrins (Smyth et al., 1993). The integrins 
expressed by different cell types varies greatly although some integrins are definitely cell-type 
specific. For example, megakaryocytes and platelets exclusively express gpllb/Illa (P3) while the 





CD11a/CD18 = LFAl 
CD11b/CD18 = Mac 1 
CD11c/CD18 = p150.95 
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Figure 4. Schematic representation of a typical integrin. Integrins are a family of heterodimeric, transmembrane 
glycoproteins. The leukocyte specific or P2 integrins possess a common P subunit (CD18) which may 
associate with one of three ex. subunits (CDlla, CD11b or CDllc) to give rise to CDlla/CD18 (LFA-1), 
CD1lb/CD18 (Mac-1) and CD1lc/CD18 (pl50,95) (adapted from Pigott and Power, 1993). 
A wide variety of proteins serve as ligands for integrin receptors and in general may be classified 
into three groups, namely, extracellular matrix proteins ( collagen, fibronectin, fbg, laminin, 
thrombospondin and vitronectin), plasma proteins (fbg and factor X) and cell surface molecules 
(C3bi, ICAM-1,2,3 and VCAM-1) (Smyth et al., 1993). Individual integrins can often bind to more 
than one ligand and similarly individual ligands may be recognised by more than one integrin. The 
tripeptide sequence R-G-D which is present in a number of ligands, e.g. fbg, fibronectin, 
thrombospondin, type 1 collagen and vitronectin, has been found to be a common recognition 
sequence for a number ofintegrins, particularly a.5~1, a.1Ib~3 and a.v~4 (Smyth et al., 1993). The 
conformation of the R-G-D sequence appears to be critical for optimal binding as well as 
determining to which integrin it will bind (Ruoslahti, 1991; Gurrath et al., 1992). Other ligand 
sequences include K-Q-A-G-D-V in fbg which is recognised by a.Ilb~3 as well as the novel LRI on 
neutrophils (see below) (Gresham et al., 1992). Asp-Gly-Glu-Ala (D-G-E-A) in collagen is 
recognised by a.2~1, Glu-Ile-Leu-Asp-Val (E-I-L-D-V) in fibronectin is recognised by a.4~1 and 
G-P-R-P in fbg is recognised by a.x~2- Synthetic peptides of these recognition sequences may 
mimic the activity of the intact protein but do not always bind with the same affinity as the native 
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protein indicating that conformation, or additional contact sites, may be important for optimal 
binding (Hynes, 1992; Smyth et al., 1993). Another interesting feature of integrins is the expression 
of different ligand specificities by the same integrin on different cell types which is related to either 
cell-type specific structural modifications of the integrins or association with cell-type specific 
protein or lipid factors (Smyth et al., 1993). 
Both the a and the f3 subunit contain a single hydrophobic transmembrane segment with a short 
cytoplasmic carboxyl domain (with the exception of f34) and a large extracellular amino terminal 
domain (Fig 4). The extracellular domains of the a and the f3 subunit associate with each other 
toward the globular, amino terminus to form the ligand binding pocket of the af3 subunit (Smyth et 
al., 1993). It has been suggested that high affinity ligand recognition requires both a and f3 subunit 
participation (from Loftus et al., 1994). The integrin cytoplasmic domains are believed to interact 
indirectly with the cytoskeletal filaments by associating with intermediary linker proteins e.g. talin 
and a-actinin (Pavalko and Otey, 1994). This association may result in the translation of the 
extracellular signal, following ligand binding, into an intracellular event by reorganisation of the 
cytoskeleton. The amino terminus is tightly folded with disulphide loops and contributes to the 
ligand binding domain (Hynes, 1992). Some a subunits contain an extra segment of about 180 
amino acids called the I domain which is inserted directly before the cation binding domain. The 
exact function of the I domain is not really known but appears to contribute to ligand binding and 
recognition. (Diamond et al., 1993; Hynes, 1992). 
An interesting feature of integrins is that individual cells can vary their adhesive properties by 
selective expression of integrins as well as the ability to modulate the binding properties of the 
integrins. For example, the f32 integrins on leukocytes are inactive and will not bind their respective 
ligands until the receptor is activated and a conformational change has taken place (Andrew et al., 
1993). This activation may be achieved with phorbol esters and various inflammatory mediators 
such as TNF, C5a, PAF or FMLP and may be crucial for localising the adhesion of leukocytes to 
inflammatory sites. The adherence of the leukocyte to the extracellular matrix via the f32 integrins 
may itself lead to activation of the cell manifested in the induction of the respiratory burst, cell 
motility and Ca2+ transients in the cytoplasm (Hynes, 1992). It has been suggested that the 
interaction of the integrin with ligand may result in the exposure of novel binding sites described as 
'ligand-induced binding sites' and subsequent increased binding affinity (Hogg et al., 1993). 
Upregulation of the expression ofintegrins on various cells may also be influenced by various 
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growth and differentiation factors, namely, TNF- f3, IFN-y and retinoic acid (Smyth et al., 1993). 
The avidity state of the integrin is transient and the ligand may 'de-adhere' following a period of 
time (Hogg et al., 1993). The exact mechanism for this is not understood but clearly represents an 
important means for controlling integrin/ligand induced activity at inflammatory sites. 
2.C.7.3.1. Neutrophil integrins 
The P2 integrins have been described as leukocyte specific and consist of a.Lf32 (LFA-1), a.Mf32 
(Mac-I) and a,xf32 (plS0,95) (Fig 4). These are more commonly referred to using the CD 
nomenclature where the f3 subunit (CDI8) is common and may associate with one of three a. 
subunits resulting in CDI la/CDI8 (LFA-1), CD1 lb/CDI8 (Mac-I) and CD1 lc/CD18 (plS0,95) 
(Hynes, 1992). P2 integrins exist in both resting and active conformations and activation occurs 
rapidly and reversibly in response to soluble stimuli (see above). These stimuli increase intracellular 
ca2+ concentrations, through kinase stimulation, resulting in phosphorylation of the f3 subunit. The 
cytoplasmic domain of CD 18 also appears to associate with a.-actinin in the cytoskeletal actin 
filaments, following cellular activation (Pavalko and LaRoche, 1993) ( see above). Although these 
two processes of kinase activation and cytoskeletal rearrangement are known to occur in 
association with cellular activation following integrin/ligand interactions, the exact mechanism 
remains unknown. Strong evidence has been provided that phospholipase A2 (PLA2) activity may 
play a direct role in the regulation of expression and function of the Mac- I integrin (Jacobson and 
Schrier, 1993). Of interest is the presence, in activated neutrophils only, of a lipid factor whose 
function appears to be the enhancement of ligand binding to the f32 integrins CR3 and LF A-1 and 
has been described as integrin modulating factor-I (IMF-1). It was suggested that neutrophils 
control adhesivity by controlling synthesis ofIMF-1, which acts as an allosteric activator of 
neutrophil integrins. Degradation ofIMF-1 may then lead to a relaxation of the f32 integrin to a low 
avidity state. IMF-I does not appear to affect the function of the f31 or the f33 integrins 
(Hermanowski-Vosatka et al., 1992). 
A unique leukocyte integrin was identified by Gresham et al. (1989) and isolated by Carreno et al. 
(1993). It was found to be distinct from, but most immunologically closely related to, the f33 
integrins of the cytoadhesin family and was described as leukocyte response integrin (LRI). It 
typically binds to the basement membrane protein entactin but may also bind a number of other 
ligands including fbg. This receptor, when not activated, was shown to have ligand specificity for 
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the R-G-D sequence but following FMLP stimulation was shown to have a greater affinity for the 
. K-Q-A-G-D-V sequence present in the carboxyl terminus of they chain of fbg and surprisingly 
showed the greatest affinity for a K-G-A-D-G-V peptide (Gresham et al., 1992). The ability ofLRI 
to interact with its ligand (via R-G-D) without prior activation, as well as the ability to bind the 
synthetic K-G-A-G-D-V peptide, distinguishes it from all other integrins. Another interesting 
feature ofLRI is its physical and functional association with a separate 50 kDa protein described as 
integrin-associated protein (IAP), forming a signal transduction unit for the activation of 
phagocytosis (Brown et al., 1990; Zhou and Brown, 1993). Binding of monoclonal antibody to 
LRI results in stimulation oflgG mediated phagocytosis and the K-Q-A-G-D-V peptide as well as 
monoclonal antibody to IAP are able to inhibit fbg stimulated phagocytosis by leukocytes ( Gresham 
et al., 1989; Gresham et al., 1992). The binding of the R-G-D sequence in entactin to LRI has also 
been shown to elicit neutrophil adhesion and chemotaxis (Senior et al., 1992) indicating an 
important role for this novel receptor in neutrophil modulation at inflammatory sites. LRI appears 
to exert its function early in the inflammatory response as it does not require activation for R-G-D-
dependent ligand binding and it is inactivated by the products of the respiratory burst. It is, 
therefore, interesting to note that the LRI-IAP signal transduction unit itself is able to activate the 
phagocytic respiratory burst in a CD 18-independent cell adhesion manner (Zhou and Brown, 
1993). 
2.C. 7.4. Endothelial-Neutrophil interaction 
Neutrophils act as the first line of defence against invading pathogens and acute tissue injury and 
it is thus imperative that they are able to rapidly migrate toward the site of inflammation. Of equal 
importance is that the number of neutrophils, the intensity and the duration of their action be 
controlled so as to prevent leukocyte mediated tissue damage. The neutrophils are able to exhibit 
adhesion and de-adhesion in a finely regulated manner and the inflammatory mediators which 
control this process are differentially expressed and regulated for this purpose (Zimmerman et al., 
1992). 
Migration of neutrophils from the vasculature toward .sites of inflammation takes place as a three 
step process. Neutrophils initially interact via the selectins which cause the cells to 'roll' along the 
endothelial surface (Fig 3). It is generally believed that E-selectin and P-selectin, on the 
endothelium, interact with L-selectin and surface glycoproteins containing fucosylated lactosamines 
on the neutrophil to allow for neutrophil 'rolling' along the endothelium (Bevilaqua, 1993). Ley et 
al. (1993) have, however, indicated that L-selectin alone can mediate leukocyte rolling under 
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conditions of shear stress. They also showed that L-selectin does not bind to E- or P-selectin but 
they could not identify the relevant endothelial ligand. Thrombin and histamine stimulate the 
redistribution of P-selectin from the endothelial storage granules within minutes whereas endotoxin, 
IL-1 or TNF may stimulate biosynthesis ofE-selectin over a period of hours to days (Bevilacqua, 
1993). 'Rolling' of the neutrophils or tethering of the neutrophil to endothelial P-selectin appears to 
be necessary for the neutrophil to 'sample' the endothelium for trigger factors (P AF and IL-8) 
necessary for optimal upregulation of integrin function and subsequent 'firm' attachment of the 
neutrophil to the endothelium (Zimmerman et al., 1992; Adams and Shaw, 1994) (Fig 3). PAF and 
IL-8 are released from the endothelium in response to inflammatory stimuli (Zimmerman et al., 
1992; Adams and Shaw, 1994). Action of the selectins in 'slowing-down' of the neutrophils may 
also be important for optimal avidity to be achieved by the integrins, which are believed not to 
function under conditions of shear stress (Lawrence et al., 1990; Zimmerman et al., 1992). 
The 132 integrin, on the neutrophil, interacts with the immunoglobulin-related cell adhesion 
molecules (IgCAMs) on the endothelium, namely, ICAM-1 and ICAM-2 (Bevilacqua, 1993) (Fig 
3). CDI lb/CD18 adheres to ICAM-1 only whereas CDI la/CDI8 recognises ICAM-1 and ICAM-
2 (Zimmerman et al., 1992). ICAM-1 is found in low levels on unstimulated endothelial cells and 
synthesis is induced by IL-1 and TNF over several hours. ICAM-2, on the other hand, is 
constitutively expressed and provides a ready surface for ~2 integrin adhesion. Activation of the 
neutrophil by activated endothelial associated P AF and IL-8, results in increased avidity of 
CDI la/CD18 and increases in number ofCDl lb/CD18 and CDI lc/CD18 (Bevilacqua, 1993). 
Rochon and Frojmovic (1992) believe that activation of the endothelial cells alone is sufficient to 
allow adhesion of unactivated neutrophils. Once adhered, neutrophils are activated and serve to 
'capture' other neutrophils, by means of their ability to aggregate and adhere to each other, thus 
overcoming shear stresses. 
Following adherence neutrophils undergo a change of shape where they 'flatten' onto the 
endothelial surface and migrate into the underlying tissue toward the inflammatory site (Fig 3). This 
process of transendothelial migration is less understood but Vaporciyan et al. ( 1993) demonstrated 
that PECAM-1 (platelet-endothelial cell adhesion molecule 1 or CD3 l of the Immunoglobulin 
Superfamily), expressed on both the neutrophils and endothelium, may play a role. 
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The importance of these interactions between endothelium and leukocyte is indicated in patients 
with leukocyte adhesion deficiency (LAD) who have reduced numbers of the {32 integrins and 
present with recurrent infections and an absence of neutrophils at sites of infection. This deficiency 
may often be fatal (from Adams and Shaw, 1994). However, besides host defence, 
leukocyte/endothelial interactions may also lead to the generation of unwanted pathological 
inflammation and consequently a thorough knowledge of these interactions could have clinical 
implications. Examples may include asthma, where antibodies to E-selectin may prevent antigen 
induced airway hyperresponsiveness by inhibiting neutrophil infiltration. Also, antibodies to !CAM-
I have shown promise in the prevention of graft rejection and treatment of rheumatoid arthritis 
(from Adams and Shaw, 1994). 
2.C.7.5. Neutrophil-Extracellular Matrix interaction 
The interaction of the neutrophil with components of the extracellular matrix (ECM), via the 
integrin receptors, may have important consequences for both ligand and cell in the inflammatory 
process (Juliano and Haskill, 1993). The translation of receptor occupancy into intracellular events 
(chemotaxis, phagocytosis, respiratory burst) is not fully understood and there are two, not 
necessarily mutually exclusive, views in this regard. Integrins have firstly been suggested to 
transmit signals by conformational changes associated with reorganisation of cytoskeletal 
components, thus regulating internal cellular organisation (Heidemann, 1993) and secondly, as a 
result of tyrosine phosphorylation and Ca2+ channel flux (Smyth et al., 1993; Juliano and Haskill, 
1993). Heidemann (1993) has demonstrated that integrins colocalise with the actin bundles and 
actin binding proteins in the cytoskeleton and can bind, in vitro, to talin and a-actinin. The different 
integrin a subunits may trigger different intracellular functions and different ligands for the same 
integrin may also elicit different intracellular responses (Juliano and Haskill, 1993 ). 
Neutrophils are able to interact with a number ofECM components, namely fbg, laminin, 
fibronectin, gelatin, collagen IV and vitronectin (Singer et al., 1989; Brown and Goodwin, 1988; 
Bohnsack et al., 1990). The adherence of activated neutrophils to fibronectin has been shown to 
result in complement receptor mediated phagocytosis {Brown and Goodwin, 1988). An interesting 
feature of the adherence of neutrophils to laminin is the fact that, although it is predominantly P2 
integrin mediated, adherence also appears to occur via a P1 VLA-like integrin (Bohnsack et al., 
1990). 
76 
In the case of fbg interaction with neutrophils the specific stimulator or agonist determines the 
specific neutrophil receptor which interacts with fbg. Phorbol esters stimulate adhesion of 
neutrophils to fbg via CD 11 b/CD 18 while TNF stimulated neutrophils adhere via the CD 11 c/CD 18 
receptor (Wright et al., 1988; Loike et al., 1991). Neutrophils stimulated with TNF adhere to fbg 
coated surfaces via the CDl lc/CD18 (pl50,95) integrin (Loike et al., 1991). Fbg is also able to 
bind to the neutrophil via the LRI (see above). Most integrins, including the f32 integrin, recognise 
their ligands via the specific tri-peptide sequence, R-G-D (Smyth et al., 1993). Fbg, on the other 
hand, interacts with the CD 11/CD 18 integrin via a unique structural motif. CD 11 c/CD 18 interacts 
with fbg via the G-P-R sequence at positions 17-19 of the amino terminus of the Aa. chain {Loike 
et al., 1991) and CD1 lb/CD18 and LRI interact with the K-Q-A-G-D-V sequence at the carboxyl 
terminus of they chain (Wright et al., 1988; Gresham et al., 1992). Altieri et al. (1993) showed 
that Mac-I, on chemoattractant (FMLP) stimulated neutrophils and monocytes, interacts with a 30 
kDa plasmic fragment D offbg which lacks the R-G-D sequence as well as the carboxyl terminus 
of they chain. The binding of this fragment was found to occur via the Gly-190 to Val-202 
sequence of they chain, shown by the ability of this sequence to block adhesion of these 
neutrophils and monocytes to immobilised fbg as well as to block adhesion of fbg to isolated 
CD 11 b/CD 18. This sequence was also able to support adhesion of monocytes in a CD 11 b/CD 18 
dependent manner. Diamond and Springer (1993) demonstrated that binding of neutrophils to fbg 
occurs via a small subpopulation ( 10%) of the total CD 11 b/CD 18 present on the neutrophil. 
Studies have shown that the I-domain on the a chain of Mac-I represents the recognition site for 
fbg. The amino terminus of the a chain and a divalent cation binding region also co-operatively 
contribute to ligand binding specificity despite being separated by the 200 amino acids of the I 
domain (Diamond et al., 1993). 
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REAGENTS 
Monoclonal antibodies (all IgGl) to CD16 (FcRIII, low avidity Fe receptor), CD1 la (LFA-1 a 
chain), CD1 lb (Mac-1 a chain), CD1 le (plS0,95 a chain), CD18 (CR3 P chain), and CD4la 
(intact gpllb/Illa, p3 integrin family) were obtained from Sanbio, Uden, Netherlands. The 
monoclonal antibodies OKMl (lgG2b) and OKMI O (IgG2a) (both directed against CD 11 b) were 
obtained from Ortho Pharmaceuticals, Raritan, NJ. Monoclonal antibodies to CDI la (IgG2a), 
CD 11 c (IgG I) and CD 18 (IgG 1) were also purchased from Serotec, Oxford, England. 4-(2-
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aminoethyl)-benzenesulphonyl fluoride (AEBSF, Pefabloc® SC) (serine protease inhibitor) and 
bisindolylmaleimide (protein kinase C [PKC] inhibitor) were obtained from Boehringer Mannheim
, 
Germany. [ 1251]-Na and Na2[S l Cr ]03 was from Amersham International, England. A kit 
containing prestained molecular weight markers for use in sodium dodecyl sulphate polyacrylamid
e 
electrophoresis (SDS-PAGE) was obtained from Amersham International, Amersham, UK. The ki
t 
includes myosin (200 kDa), phosphorylase b (97 kDa), bovine serum albumin (69 kDa), ovalbumin
 
(46 kDa), carbonic anhydrase (30 kDa), trypsin inhibitor (21 kDa) and lysozyme (14 kDa). 
Autoradiography was performed using Kodak XAR-5 film (Eastman Kodak, Rochester, NY). A 
Sephacryl S-300 and S-200 gel filtration matrix as well as a Sephadex G25 matrix were obtained 
from Pharmacia, Uppsala, Sweden. All other chemicals and reagents were obtained from the Sigm
a 
Chemical Co. (St. Louis, MO) unless indicated otherwise. 
3.1. PREPARATION AND IODINATION OF CRP 
A pool of acute phase sera was prepared from patients 48 hrs post-surgery. Informed consent 
and ethical committee approval was obtained. CRP was isolated from the acute phase sera using 
calcium-dependent phosphorylethanolamine affinity chromatography and Sephacryl S-200 gel 
filtration (De Beer and Pepys, 1982). The pure CRP migrated as a single homogenous band with a
n 
apparent molecular mass of24 kDa when subjected to 12% SDS-PAGE (reduced) (Laemmli, 
1970). The CRP was iodinated using 0.5 µCi [1251]-Na/µg CRP and Iodogen (Pierce Warriner, 
Cheshire, England) as an oxidising agent (Fraker and Speck, 1978). Iodine, not incorporated into 
the protein, was separated from the protein-bound iodine on a Sephadex G25 column. [1251]-CRP
 
maintained its binding capacity to CPS and >98% of the radioactivity associated with the CRP wa
s 
precipitable by trichloracetic acid (TCA, 10% w/v). The specific activity of the [1251]-labelled CR
P 
was found to be 0.4 µCi/µg protein. The purity of the iodinated CRP was confirmed by 12% SDS
-
PAGE (reduced) (Laemmli, 1970) and autoradiography (400 000 cpm/track). 
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3.2. PREPARATION AND IODINATION OF FIBRINOGEN 
Fbg was isolated by ammonium sulphate precipitation of plasma obtained from hepara
nised blood 
donated from healthy laboratory workers (Kalvaria et al., 1986). The pure tbg migrated on
 5-20% 
SDS-P AGE (non-reduced) (Laemmli, 1970) as a single band corresponding to the ap
parent 
molecular mass of 340 kDa. This preparation contained a trace amount of factor XIII
 which was 
used to catalyse crosslinking during fibrin formation. The clottability of the purified tb
g was 97%. 
Fbg was iodinated using Io do gen (Pierce and Warner, Cheshire, England) as an oxidising
 agent and 
0.5 µCi [125I]-Na/µg tbg (Amersham International, England) (Fraker and Speck, 1978). The 
specific activity of the [125I]-labelled fbg was 0.5 µCi/µg protein. SDS-PAGE (5-20%
 non-
reduced) (Laemmli, 1970) and autoradiograph analysis ofthis [125I]-labelled fbg (400
 
OOOcpm/track) revealed no evidence of degradation. 
3.3. PREPARATION OF NEUTROPHILS, NEUTROPHIL MEMBRANES, 
CYTOSKELETON, CONDITIONED MEDIUM AND NEUTROPHIL LYSOSOMA
L 
ENZYMES 
Neutrophils were isolated from heparinised blood (SU preservative-free heparin/ml bl
ood), 
donated by healthy laboratory workers, by hypaque/ficoll gradient centrifugation follo
wed by 
hypotonic lysis of the red blood cells (Boyum, 1968). The neutrophils were 97-99% v
iable as 
determined by the exclusion oftrypan blue and were found to be 98-100% polymorph
onuclear 
using differential counts made on Wright-Giemsa stained smears. Neutrophils were re
suspended 
either in phosphate-buffered saline (PBS) or in hanks balanced salt solution (HBSS) (
Highveld 
Biological, Ilffi). The neutrophils were used immediately following purification. 
Neutrophil conditioned medium was prepared by incubating neutrophils in the absenc
e or presence 
of phorbol 12-myristate 13-acetate (PMA, Sng/rnl for fbg degradation and 10 ng/ml fo
r CRP 
degradation) at 370c for 20 min (Shephard et al., 1989). These doses of PMA and period
 of 
incubation released insignificant amounts of f3-glucuronidase and a maximum of 12% 
of the total 
vitamin B12-binding protein of the intact cells (Shephard et al., 1989; Pontremoli et al., 19
86). 
Centrifugation at 400 g for 5 min at 40c removed the cells and the cell-free neutrophi
l conditioned 
medium was used within 5 min of collection. When the conditioned medium was to be
 loaded on a 




Neutrophil cytoskeletons were isolated by lysing neutrophils (40x106/ml) for 10 min on ice in lysi
s 
buffer (50rnM Tris-HCl, pH 7.5, containing 160 mM KCl, 10 mM EDTA and 1% (v/v) Triton X-
100) (Yassim et al., 1985). The triton insoluble cytoskeletons were pelleted by centrifuging at 12 
000 g for 10 min at 40c, then washed in the lysis buffer without Triton X-100. 
Neutrophil membranes were prepared by lysing the cells (25x106/ml) in a hypotonic lysis buffer (2
0 
mM Tris [pH 9.6], 10 rnM NaCl, 5 rnM MgCl2 and lmM ATP) for 20 min at 4°C (Shephard et 
al., 1989). The nuclei were removed by centrifugation at 400 g for 5 min followed by 
centrifugation of the supernatant at 10 000 g for 1 hr, to yield a membrane-rich pellet. The pellet 
was resuspended in 7% (w/w) sucrose in 10 mM Tris (pH 7.5) and 5 mM EDTA (Tris-EDTA) and 
layered onto a stepwise sucrose gradient in this buffer (50% [w/w, 5 ml], 35% [w/w, 10 ml], 20%
 
[w/w, 10 ml]) and centrifuged at 80 000 g for 3 hr (Beckman, SW 27 rotor). The membrane 
fraction was collected at the 20%/35% interface, washed three times with Tris-EDTA and finally 
resuspended in 10 mM Tris (pH 7.4) and 140 mM NaCL (Tris-NaCl). 
The neutrophil cytoskeleton and membrane proteins were solubilised in 10 mM Tris-HCI (pH 7.4) 
containing lM NaCl, for 1 hr on ice. Insoluble protein was removed by microfuging at 12 000 g fo
r 
5 min at 40c. The solubilised proteins were dialysed through a Spectrapor membrane, molecular 
mass cut off3.5 kDa (Spectrum Medical Industries Inc.,California), against PBS (pH 7.4, 40c) an
d 
protein content was determined by the method of Lowry et al. (1951) using BSA as a standard. 
The membrane fraction was identified by the plasma membrane marker alkaline phosphatase and 
was found to be devoid of lysozyme, ~-glucuronidase and vitamin B 12-binding protein (Shephard
 
et al., 1989). 
Neutrophil lysosomal enzymes were obtained by degranulating neutrophils (5xl06) with the 
synthetic chemotactic tripeptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP, 1 µM) 
for 15 min at 37°C in the presence of cytochalasin B (5 µg/ml) (Bentwood and Henson, 1980). 
Centrifugation at 300 g for 5 min at 4°C removed the cells and the lysosomal-rich supernatant was
 
used immediately after preparation. 
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3.4. INTERACTION OF CRP WITH NEUTROPHILS 
3.4.1. Association of [1251]-labelled CRP with neutrophils and concomitant degradation 
[1251]-labelled CRP (0-100 µg) and PMA (10 ng/ml) were incubated with neutrophils (10x106) 
prewarmed to 37 oc (15 min), in a final volume of 1 ml PBS and in the absence or presence of 
AEBSF (1 mM). When the effect of CaCh on the association of CRP with neutrophils was 
investigated the incubation buffer was a O. 5 mM N a2HPO 4 buffer ( containing 1. 2 mM Ca Ch, 140 
mM NaCl, 4 mM KCl, 5 mM D-glucose, 20 mM HEPES and 1 mM MgCh, pH 7.4). In 
monoclonal antibody inhibition experiments PMA-stimulated neutrophils (10x106) were also 
preincubated (370C, 15 min) without or with AEBSF (1 mM) with saturating concentrations (as 
determined by flow cytometry) of monoclonal antibodies directed against CDI le (Serotec), 
CD1 la (Sanbio 1020), CD1 lb (Sanbio 1019), CD18 (Sanbio 1110), CD16 (Sanbio 1041c) and 
CD4la (Sanbio 1144 and Sanbio 1145 directed against Fe dependent reactions and fbg binding 
sites on platelets respectively) followed by the addition of the [1251]-labelled CRP. All reactions 
looking at association of CRP with neutrophils were set up in duplicate and were terminated at 
specified time points ( see results) by washing the cells three times with the incubation buffer at 
40c followed by transfer of the cells to clean tubes. The total radioactivity associated with the 
cells was quantified by gamma counting. The duplicates did not differ by more than 10% from 
each other and the mean of the duplicates was calculated. Non-specific binding was determined in 
the presence of both a 250 fold and 50 fold molar excess of unlabelled CRP. The nature of the 
neutrophil associated [1251]-labelled CRP, in the presence of AEBSF, with and without a 250 fold 
or 50 fold molar excess of unlabelled CRP, was assessed by solubilising the final pellet of washed 
neutrophils with 100 µ1 of20 mM Tris (pH 8.3), 1% (w/v) sodium decyl sulphate, and 7 M Urea 
followed by the addition of 50 µ1 SOS-sample buffer (0.012 M Tris [pH 6.8] with 4% SDS and 
24% glycerol) and analysing on SDS-PAGE (5-20%) (Laemmli, 1970). The gels were dried 
immediately and autoradiographed. Degradation of the [1251]-labelled CRP, during the course of 
the association of [ 1251]-labelled CRP with neutrophils was monitored by 10% ( w/v) TCA-soluble 
peptide formation (Shephard et al., 1989). 
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3.4.2. Degradation of [1251]-labelled CRP by neutrophil conditioned medium, neutrophil 
membranes, neutrophil cytoskeleton and neutrophil lysosomal enzymes 
CRP degradation reactions contained 100 µg [1251]-labelled CRP and the enzyme source in 1 ml 
PBS without CaCl2 and MgCl2. The enzyme source was either neutrophil conditioned medium 
from lOx106 non-stimulated or PMA (10 ng/ml)-stimulated neutrophils (I0x106), neutrophil 
membranes (I 00 µg), neutrophil cytoskeleton (I 00 µg) or lysosomal enzymes from 5x 10
6 
neutrophils. When required, inhibitors, as stated in the results, were preincubated (370C, 15 min) 
with the enzyme source before the addition of [ 1251]-labelled CRP. [ 1251]-labelled CRP 
degradation was monitored qualitatively at specific times by mixing aliquots of the reaction with a
n 
equal volume of SDS-sample buffer (0.012 M Tris [pH 6.8] with 4% (w/v) SDS, 24% (v/v) 
glycerol and 10% (v/v) 2-mercaptoethanol) and analysing by SDS-PAGE (12%) (Laemmli, 1970)
 
followed by autoradiography (Shephard et al., 1989). Degradation was measured quantitatively by 
10% TCA-soluble peptide formation. A 50 µl aliquot of the reaction mixture was precipitated wit
h 
50% TCA (w/v) (40C) to give a final concentration of 10% (w/v) (Shephard et al., 1989). 
3.4.3. Influence of CRP on the release of CRP-degrading activity from neutrophils 
Several studies were conducted to confirm whether CRP caused the release of proteolytic 
activity from neutrophils. 
3.4.3.1. CRP-mediated release of proteolytic activity from neutrophils 
To investigate the possibility that during an incubation of CRP with neutrophils, proteolytic 
activity is released from the cells into the extracellular medium, [1251]-labelled CRP (100 µg) was
 
incubated with non-stimulated and PMA-(10 ng/ml) stimulated neutrophils (10x106) for specific 
time periods (see results). The cells were then removed by centrifugation ( 400 g for 3 min at 4°C)
 
and the extracellular medium returned to 3 70c. Further degradation of [ 1251]-labelled CRP in the
 
cell-free extracellular medium was monitored as described above and compared with that had the 
cells not been removed from the reaction and that by neutrophil conditioned medium. 
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3.4.3.2. Quantification of the proteolytic activity released from neutrophils
 during an 
incubation with CRP 
The proteolytic activity released by the neutrophil, in the presence of CRP,
 was quantified at the 
end point of CRP degradation. In order to do this a CRP-released conditio
ned medium was 
prepared by incubating unlabelled CRP (100 µg) with PMA-stimulated neu
trophils (10xl06) for 40 
min, after which the cells were removed by centrifugation (400 g for 3 min
) and the extracellular 
medium returned to 370c for 20 hr. At this time point more than 90% of th
e unlabelled CRP in the 
extracellular medium had been degraded to TCA (10%, w/v)-soluble produ
cts and [1251]-labelled 
CRP ( 100 µg) was then added. The conditions required for the generation 
of greater than 90% 
TCA-soluble peptides were determined in a duplicate reaction containing [
1251]-labelled CRP. 
Degradation of the [1251]-labelled CRP by proteolytic activity released fro
m neutrophils by 
unlabelled CRP, was quantified at various times as TCA soluble (10%, w/v
) [1251]-labelled peptide 
formation. This degradation was compared to that by PMA-stimulated neu
trophils as well as a 
control conditioned medium which was subject to all the preparation steps 
described above, but in 
the absence of unlabelled CRP. 
3.4.3.3. Quantification of CRP-degrading activity of the membrane and cy
toskeleton of 
neutrophils following an incubation with CRP 
Non-stimulated and PMA (10 ng/ml)-stimulated neutrophils (10xI06) were
 incubated (370C) 
with unlabelled CRP (2 µg or 500 µg) for 40 min whereupon the membran
e and cytoskeleton 
fractions of the neutrophils were isolated (see above). These neutrophil fra
ctions were incubated 
with [1251]-labelled CRP (100 µg) and the generation of TCA (10%, w/v)-
soluble peptides was 
compared to that of neutrophil cytoskeleton and membrane fractions isolat
ed from control cells 
which had not been preincubated with unlabelled CRP. 
3.4.4. Determination of the molecular size of the neutrophil CRP-degrading
 protease 
3.4.4.1. SDS-PAGE analysis 
Neutrophil membranes (200 µg), cytoskeletons (200 _µg) and lyophilised co
nditioned medium 
from 100xl06 PMA stimulated neutrophils (prepared as described above) w
ere analysed by 3-13% 
SDS-P AGE under non-reducing conditions (Laemmli, 1970). In order to re
cover enzyme activity 
the gels were washed for 45 min at 40c in PBS/H20, 1: 1 (v/v) containing 0
.2% (v/v) Triton X-100 
followed by an additional 45 min wash in PBS/H20, I: 1 (v/v) to remove th
e Triton X-100. The gels 
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were cut into 2 mm slices and each slice was assayed for activity by incubating it a
t 3 7°C with 
[1251]-labelled CRP (100 µg) in a final volume of 1 ml PBS. TCA (10%, w/v)-soluble [1251]-
labelled CRP degradation products were measured (see 3.4.2.) at 18 hr. In order to visu
alise the 
protein within these three neutrophil fractions they were analysed on 3-13% SDS-P
AGE (reduced 
and non-reduced) (Laemmli, 1970) followed by staining of the protein with 0.12%
 (w/v) coomassie 
blue. The three neutrophil fractions were also labelled with [1251]-Na {150 µCi) (a
s described for 
the iodination of CRP in 3 .1) and analysed by 3-13% SDS-PAGE (Laemmli, 1970
) followed by 
autoradiography. A kit containing pre-stained protein molecular weight markers fo
r molecular 
weights 14-200 kDa, ferritin (subunit size 220 kDa), purified human fbg (340 kDa
) and fibronectin 
( 440 kDa) were used as calibration standards. 
3.4.4.2. Size Exclusion Chromatography 
A Sephacryl S-300 column (lx45 cm) equilibrated with PBS, was loaded with eith
er neutrophil 
membranes (500 µg), cytoskeletons (500 µg) or conditioned medium from 100xlo
6 PMA-
stimulated neutrophils. Fractions of 0.6 ml, at a flow rate of 3 ml/hr, were collected and assayed
 for 
CRP-degrading activity (see 3.4.2.). The peak fractions possessing proteolytic acti
vity were 
iodinated and analysed by 3-13% SDS-P AGE (Laemmli, 1970) and autoradiograph
y. 
3.5. CHARACTERISATION OF FIBRINOGEN PROTEOLYSIS BY NEUTROPH
ILS 
3.5.1 Degradation of [125I]-labelled fibrinogen 
All degradation reactions were conducted in duplicate. [ 1251]-labelled fbg ( 1 or 2 m
g, as 
indicated) was incubated (3 7°C) for various time points from 5 min to 20 hr with e
ither 
conditioned medium (from Sx 106 non-stimulated or PMA-stimulated neutrophils ), 
neutrophil 
membranes (25 µg), neutrophil cytoskeleton (25 µg), lysosomal enzymes (from 5x
l06 neutrophils) 
or pure human neutrophil elastase (HNE) (2 µg) in a final volume of 1 ml HBSS, in the abs
ence or 
presence of ethylene glycol tetra acetic acid (EGT A, 10 mM). [ 1251]-labelled fbg (
2 mg) was also 
incubated (37°C) for various time points from 2 min to· 60 min with non-stimulated
 or PMA-
stimulated neutrophils (5x106) in a final volume of 1 ml HBSS, in the presence or absence 
of 
EGTA (10 mM). When required, the concentration of the enzyme source was varie
d (see results). 
[1251]-labelled fbg (I mg) was degraded (37°C) with plasmin generated by the add
ition of porcine 
plasminogen (0.5 µg) and urokinase (4 iu, human kidney cells) in a final volume of
 1 ml Tris (10 
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mM, pH 8.1) containing NaCl (140 mM) and either CaCl2 (2 mM) or EGTA (10 mM). Fbg 
degradation products, generated by neutrophil conditioned medium were also degraded further 
with plasmin. The neutrophil conditioned medium from 5xl0
6 PMA-stimulated neutrophils was 
incubated (37°C, 18 hr) with [1251]-labelled fbg (2 mg) whereafter porcine plasminogen (0.5 µg) 
and urokinase (4iu, human kidney cells) in a final volume of 1 ml Tris (10 mM, pH 8.1) containing 
CaCh, was added (37°C, 30 min). Degradation reactions containing the enzyme source were also 
preincubated for 15 min at 370c with inhibitors prior to the addition of substrate (see results). At 
specific times (see results) 10% (w/v) TCA-soluble [1251]-labelled fbg peptide formation was 
monitored (as for CRP degradation, see 3.4.2.). For visual analysis of [1251]-labelled fbg 
degradation, aliquots of degradation reaction mixtures, at various time points, were mixed with an 
equal volume of SDS-sample buffer (0.012 M Tris [ph 6.8] with 4% [w/v] SDS and 24% [v/v] 
glycerol with or without 10% [ v/v] 2-mercaptoethanol) and analysed by 5-20% SDS-P AGE (non-
reduced) and 10% SDS-P AGE (reduced) (Laemmli, 1970). The gels were dried immediately and 
the products visualised by autoradiography. A kit containing pre-stained molecular weight markers 
of 14-200 kDa were used as calibration standards. When necessary the reduced 10% gels were 
stained for carbohydrate using a Periodic acid-Schiff base reagent (PAS) kit (Mantle and Allen, 
1978) prior to autoradiography. 
3.5.1.1. Two-dimensional iso-electric focusing of fibrinogen degradation products 
[
1251]-labelled fbg degradation products generated by neutrophil conditioned medium at 20 hr as 
well as plasmin at 20 hr (as described above) were dialysed against water overnight (4°C), freeze 
dried and resuspended at 4 mg/ml in 20 mM Tris (pH 8.3), 1% (w/v) sodium decyl sulphate, and 7 
M Urea (Shephard et al., 1989). Aliquots of 80 µg of both the neutrophil conditioned medium and 
the plasmin generated fbg degradation products were loaded onto a prefocused Ampholine P AG 
plate (5% polyacrylamide with 3% crosslinkage and 2.2% [w/v] ampholine), (Pharmacia, Uppsala, 
Sweden) with a broad pH range between 3.5 and 9.5. An isoelectric calibration kit (Pharmacia, 
Uppsala, Sweden) containing standards with a pH range of 3.5-9.3 was included. This kit contains 
amyloglucosidase (pH 3.5), soybean trypsin inhibitor (pH 4.55), ~-lactoglobin A (pH 5.2), bovine 
carbonic anhydrase B (pH 5.85), human carbonic anhydrase B (pH 6.55), horse myoglobin (pH 
6.85), horse myoglobin (pH 7.35) lentil lectin (pH 8.15), lentil lectin (pH 8.45), lentil lectin (pH 
8.65) and trypsinogen (pH 9.3). The proteins were focused on the PAG plate with a constant 
power of 15 watts, 1 500 volts and 25 milliAmps at 10°C. The iso-electro focused plates were 
either stained with Coomassie (0.12%), left to dry between two sheets of polyester film and 
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autoradiographed or they were subjected to second dimension SDS-PAGE (5-20% non-reduced) 
(Laemmli, 1970). In order to load the iso-electro focused protein onto the SDS-P AGE the PAG 
plate was inserted above the polyacrylamide gel and sealed with 1 % low melting agarose in SDS-
sample buffer (0.004 M Tris [pH 6.8] with 4% [w/v] SDS and 24% [v/v] glycerol). Fbg and fbg 
degradation product standards were loaded onto filter paper wicks which were similarly inserted 
above the polyacrylamide gel and sealed as described above. The gels were dried immediately and 
autoradiographed. 
3.5.2. Determination of the molecular size of the neutrophil fibrinogen-degrading protease 
by SDS-PAGE analysis 
Neutrophil membranes (200 µg), cytoskeleton (200 µg) and lyophilised conditioned medium 
from 50xI06 PMA-stimulated neutrophils were analysed separately by 3-13% SDS-PAGE (non-
reduced) (Laemmli, 1970). The SDS was removed from the gel (as described above in section 
3. 4. 4. 1.) and enzyme activity was determined by incubating (3 7°C, 24 hr) 2 mm gel slices with 
[1251]-labelled fbg (1 mg) in HBSS (1 ml) and measuring the generation of 10% (w/v) TCA-
soluble [1251]-labelled fbg peptides (as described in section 3.4.2. for CRP degradation). 
3.5.3. Functional assessment of the fibrinogen degradation products 
3.5.3.1. Thrombin-induced clotting time 
Fbg degradation products were generated by incubating (370C) [1251]-labelled fbg (1 mg) with, 
either the conditioned medium from PMA-stimulated neutrophils ( 5x 106), neutrophil cytoskeleton 
(25 µg), neutrophil membrane (25 µg) or plasmin, over a period of 5 min to 20 hr (see 3.5.1.). The 
thrombin induced clotting time of these [1251]-labelled fbg degradation products was determined 
by the addition of 10 µl thrombin (bovine plasma, 2 iu/10 µl), to 100 µl aliquots of the fbg 
degradation products or intact [ 1251]-labelled fbg to which 5 µg a 1 AT and 100 iu/ml aprotinin had 
been added (5 min, 37°C) to stop degradation. From a dose response study using intact [125I]-
labelled fbg, a 50% reduction in functional [1251]-labelled fbg extended the thrombin induced 
clotting time to 3 5 sec. The sample was considered uncoagulable if clotting had not occurred in 3 
mm. 
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3.5.3.2. Generation of anticoagulants 
In order to determine anticoagulant activity of the fbg degradation products, 100 µl aliquots of 
the fbg digests, generated as described in 3. 5. 3 .1. and to which 5 µg a 1 AT and 100 iu/ml aprotinin 
had been added ( 5 min, 3 70c) to stop degradation, were mixed with 100 µl intact fbg (3 mg/ml 
HBSS) and thrombin (1 iu/10 µl). The thrombin induced clotting time was measured, as described 
in 3.5.3.1., and anticoagulant activity was assessed by the prolongation of the clotting time. 
3.5.3.3. Crosslinked fibrin formation by degraded fibrinogen 
Intact [125I]-labelled fbg and fbg degradation products, as generated in 3.5.3.1. from [125I]-
labelled fbg, were treated with 5 µg solid a 1 AT followed by thrombin (1 iu/10 µl), incubated at 
370c for 3 min and then solubilised in an equal volume of20 mM Tris (pH 8.3), 1 % (w/v) sodium 
decyl sulphate, 7 M urea and 5% (v/v) 2-mercaptoethanol (Shephard et al., 1989). The nature of 
the [125I]-labelled fibrin and the formation ofy-y dimers was then analysed on 10% SDS-PAGE 
(Laemmli, 1970) followed by autoradiography after the addition of an equal volume of SDS sample 
buffer (0.012 M Tris [pH 6.8] with 4% [w/v] SDS and 24% [v/v] glycerol with 5% (v/v) 2-
mercaptoethanol. 
3.5.4. Production of fibrinogen peptides and separation by h.p.l.c. 
Unlabelled fbg (2 mg) was digested with neutrophil conditioned medium (from 5xl06 PMA-
stimulated neutrophils), neutrophil cytoskeleton (25 µg) and neutrophil membrane (25 µg) for 
various time periods (see above), in a final volume of 1 ml HBSS. When required the degradation 
was allowed to proceed to 20 hr and either stopped at this point or thrombin (2 iu/ml) was added 
to the mixture and the incubation was continued for a further 1 hr at 370c. Unlabelled fbg (2 mg) 
was also digested with 2 µg pure HNE in a final volume of 1 ml HBSS. All reactions were stopped 
at the appropriate times by the addition of 50% (w/v) TCA to a final concentration of 10% (w/v) 
and the precipitated protein was removed by centrifugation (400 g for 10 min at 40C). The TCA 
was extracted from the soluble peptide mix four times with four volumes of diethyl ether. The 
supernatant fraction was then freeze dried and resuspended in pyrogen free distilled H20 (10% of 
the original volume). As required, aliquots of the peptide mix were adjusted to pH 7.4 with O. lM 
NaOH, then incubated (37°C) with thrombin (2 iu/ml) or pure HNE (2 µg/ml) for 2 hr. Remaining 
high molecular mass protein was removed from this digest using a Sep-Pak C18 cartridge (Waters 
Associates, Milford, MA) equilibrated with 0.1 % trifluoroacetic acid. The adsorbed peptides were 
eluted with 75% acetonitrile in 0.1 % trifluoroacetic acid (3 ml). After evaporation of the solvent, 
the peptides were redissolved in 0.1 % trifluoroacetic acid and subjected to h.p.l.c. analysis. 
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The peptides were separated using a Merck Hibar Column (250x4 mm) prepacked with LiChrosorb 
RP-18 (5 µM, E. Merck, Darmstadt, Germany). H.p.l.c. was performed using a Waters Associates 
liquid chromatograph equipped with a model 600E controller, solvent delivery system (model 
6000), automatic injector (model 710B), variable wave length absorbance detector (model 484 set 
at 220 nm), and a data module (model M730). The column was loaded with 100 µl peptide aliquots 
and eluted using a binary gradient formed from 0.1 % trifluoroacteic acid (solution A) and 0.1 % 
trifluoroacetic acid in acetonitrile/water (75:25, solution B). The initial condition of 95% solution 
A and 5% solution B run isocratically for 7 min was followed by a linear gradient for a further 53 
min to 30% solution A and 70% solution B at a flow rate of 1 ml/min. 
3.5.5. Amino acid analysis 
Peptides for amino acid analysis were collected and further purified, then subjected to 6N HCL 
hydrolysis, in vacuo, for 24 hr. Amino acids were separated using the Waters h.p.l.c. amino acid 
analysis protocol employing a CXpak strong cation exchange column and detected by o-
phthaldialdehyde (OP A) derivatisation. When proline was determined, the OP A-hypochlorite 
detection system was used. 
3.5.6. Association of [1251]-labelled fibrinogen with neutrophils and concomitant 
degradation 
[125]I-labelled fbg (1mg) was incubated (370C) for various time points from 2 to 60 min with 
5x106 non-stimulated and PMA (5 ng/ml)-stimulated neutrophils in a final volume of 1 ml HBSS. 
In order to assess the effect of Ca
2
+ on the association offbg with PMA-stimulated neutrophils, 
PBS was used as a Ca
2
+ depleted incubation buffer. A concentration curve of [ 1251]-labelled fbg 
(from 0-1 mg) with non-stimulated and PMA ( 5 ng/rnl)-stimulated neutrophils ( 5x 106) in the 
absence and presence of AEBSF (lmM) was also set up. Prior to the addition of[125I]-labelled 
fbg (1mg), PMA stimulated neutrophils (5x106) were also preincubated (37°C) for 15 min with 
saturating concentrations (as determined by flow cytometry) of monoclonal antibodies to CD16 
(Sanbio 1041C), CD1 la (Sanbio 1020, Serotec), CD1 lb (Sanbio 1019, OKMl and OKMIO), 
CD1 lc (Sanbio 1011, Serotec), CD18 (Sanbio 1110, Serotec), and CD4la (Sanbio 1144 and 
Sanbio 1145 directed against Fe dependent reactions and fbg binding sites on platelets 
respectively). When the effect of monoclonal antibody and AEBSF was investigated, AEBSF (1 
mM) was preincubated (15 min at 37°C) with 5xl06 neutrophils prior to the addition of the 
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antibody, whereafter a further incubation period (15 min at 37°C) was allowed prior t
o the addition 
of[125I]-labelled tbg (1mg). In order to assess the effect oftbg peptides on neutrophil a
ssociation 
offbg, the peptides were prepared, as described in 3.5.4., by the action of neutrophil c
onditioned 
medium and adjusted to pH 7.4. These neutrophil-derived fbg peptides as well as the 
synthetic fbg 
peptides RGDS (50 µg), HlO (50 µg), Hl2 (50 µg) and HIS (50 µg), were preincuba
ted {37°C for 
20 min) with 5x106 PMA stimulated neutrophils, prior to the addition of [1251]-labell
ed tbg (1mg). 
Degradation reactions containing non-stimulated or PMA-stimulated neutrophils were
 also 
preincubated (37°C, 15 min) with inhibitors, prior to the addition of substrate (see res
ults). All 
reactions were carried out in duplicate. At specific time points (see results) the associa
tion of 
[ 1251]-labelled tbg with the cells was assessed by washing the neutrophils three times 
with 
incubation buffer (HBSS) at 4°C, then transferring the cells to clean tubes and monito
ring the 
[1251]-labelled fbg bound to the neutrophils in a gamma counter. Non-specific binding
 was 
determined in the presence of a 100 fold molar excess of unlabelled tbg. Specific bind
ing was 
calculated by subtracting the non-specific binding. The nature of neutrophil associated
 [ 1251]-
labelled tbg, in the absence of AEBSF, was investigated by mixing aliquots of the was
hed 
neutrophil suspension with an equal volume of SDS-sample buffer (0.012 M Tris [pH
 6.8], 4% 
(w/v) SDS and 24% (v/v) glycerol) and analysing by 5-20% SDS-PAGE (Laemrnli, 1
970). Gels 
were dried immediately and subjected to autoradiography. Degradation of the [1251]-
labelled fbg, 
during the course of these binding studies, was monitored by TCA (10%, w/v)-soluble
 peptide 
formation (see 3.5.1). The duplicates did not differ by more than 10% from each othe
r and the 
mean of the duplicates was calculated. 
3.5. 7. Influence of fibrinogen on the release of fibrinogen degrading activity from th
e 
neutrophil 
[125I]-labelled fbg (1mg) was incubated (370C) with PMA (5 ng/rnl)-stimulated neutr
ophils 
( Sx I 06). At specific time points ( see results) the cells were removed by centrifugation
 ( 400 g for 3 
min) and the extracellular medium returned to 3 70c. Degradation of [ 1251]-labelled f
bg in the 
extracellular medium was assessed and compared, at specific matching time points, w
ith that of 
degradation of [125I]-labelled fbg (1mg) by PMA stimulated neutrophils (5xl06) or b
y neutrophil 
conditioned medium, prepared in the absence of fibrinogen, from SxI06 cells. Degrad
ation was 
monitored by 10% (w/v) TCA-soluble peptide formation (see 3.5.1.). 
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3.5.8. The influence oflow molecular weight fibrinogen peptides on the association of 
cstcr]-labelled neutrophils to solid phase fibrinogen 
Falcon 3911 Microtest ID (Falcon Labware, Becton-Dickinson, Oxnard, CA) 96-well plates were 
coated with 250 µl aliquots offbg (1 mg/ml PBS) at 40c overnight. The wells were washed three 
times with PBS, blocked with PBS containing I% BSA for 2 hr at room temperature and finally 
washed three times with HBSS and used immediately. Neutrophils (50x106) were incubated 
(370C) with Na2[S lcr]03 (100 µCi) for 1 hr and subsequently washed three times with HBSS to 
remove unincorporated [Slcr]. Prior to the addition ofPMA (5 ng/ml) TCA (10%, w/v)-soluble 
fbg peptides (prepared by degrading fbg with neutrophil conditioned medium for 9 hr, as described 
above in 3.5.4.), at a concentration range of 0-100 µg, were preincubated (30 min at 370C) with 
2x106 [5 lcr]-labelled neutrophils in a final volume of 1 ml HBSS. Immediately following 
stimulation with PMA, quadruplicate 100 µl aliquots were transferred to the fbg coated wells and 
incubated (370C) with the solid phase fbg for 30 min. The non-adherent cells were removed by 
washing the wells three times with HBSS. Individual wells were cut from the plate and counted in a 
gamma counter in order to quantify the adherent cells. Quadruplicates did not differ by more than 
10% and the mean of the quadruplicates was calculated. The number of adherent cells in the 
presence of the fbg degradation products was expressed as a percentage of the total number of 
adherent cells in the absence of these products. 
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CHAPTER4 
INTERACTION OF CRP WITH NEUTROPHILS 
RESULTS AND DISCUSSION 
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4.A. C-REACTIVE PROTEIN ASSOCIATION WITH NEUTROPHILS AND 
CONCOMITANT DEGRADATION 
4.A.1. INTRODUCTION 
There are numerous reports indicating the interaction of [
1251]-labelled CRP with neutrophils via 
a receptor-mediated process (Muller and Fehr, 1986; Buchta et al., 1987a; Shephard et al., 1986). 
However, a study investigating the integrity of CRP following association with neutrophils revealed 
considerable neutrophil-mediated degradation of CRP which generated both high molecular weight 
CRP intermediates and low molecular weight TCA-soluble CRP peptides. The study also showed, 
with the use of SDS-PAGE, that the neutrophil-associated CRP was comprised of both intact CRP 
and the CRP degradation products (Shephard et al., 1989). There was a positive correlation 
between the extent of degradation and the association of CRP and CRP intermediates with the 
neutrophil. This association of CRP degradation products with the cell was suggested by Shephard 
et al. ( 1989) to account for the high, non-specific binding of CRP to neutrophils, observed in 
previous studies (Muller and Fehr, 1986; Buchta et al., 1987a). Neutrophil association of both CRP 
and CRP degradation products was enhanced two fold when the cells were stimulated with PMA at 
10 ng/ml., a concentration of PMA that did not cause significant release from the azurophil 
granules (Shephard et al., 1989; Pontremoli et al., 1986). Inclusion of calcium in the incubation of 
CRP with PMA-stimulated neutrophils caused a 25% to 40% decrease in the total neutrophil 
associated CRP, although the ratio of associated CRP to CRP degradation products remained the 
same as that in the absence of calcium. This modulation of CRP association with neutrophils by 
calcium was suggested to be due to a calcium dependent conformational change in the CRP 
molecule (Shephard et al., 1989). 
The generation of CRP degradation products was concluded to occur as a result of the action of a 
PMA-upregulatable neutrophil membrane-associated neutral protease during the association of 
CRP with the cells (Shephard et al., 1989). 
The aim of this study was to investigate the interaction of CRP with neutrophils in the presence of 
inhibitors of neutrophil-mediated degradation of CRP iri the hope of identifying the process of CRP 




4.A.2.1. Influence of AEBSF, in the presence and absence of ca2+, on neutrophil association 
and degradation of CRP 
PMA-stimulated neutrophil association and degradation of [ 1251]-labelled CRP was investigated 
in the presence and absence of the serine protease inhibitor AEBSF. AEBSF (1 mM) was shown to 
inhibit the degradation of20 µg [1251]-labelled CRP by PMA-stimulated neutrophils (10xl06), by 
98% at 30 min. In the absence of AEBSF 706 ng [1251]-labelled TCA-soluble CRP peptides were 
generated and in the presence of AEBSF 14 ng [1251]-labelled TCA soluble peptides were formed. 
In the absence of AEBSF the association of CRP with PMA stimulated neutrophils was shown to 
occur as early as 2 min and reached a steady state between 30 and 40 min (not shown). This 
confirmed previous results of Shephard et al. ( 1989). Concentration dependence curves, in the 
absence of AEBSF (Fig 5) also confirmed previous results that saturation could not be reached. 
With 100 µg [ 1251]-labelled CRP offered and in the absence of Ca2+, 860 ng [ 1251]-labelled CRP 
associated with PMA-stimulated neutrophils (10xI06) in a final volume of I ml at 30 min (Fig 5). 
With the addition of Ca2+ to this reaction a decrease in the total neutrophil associated [ 1251]-
labelled CRP by approximately 50%, was observed (Fig 5). 
In the presence of AEBSF (1 mM) the association of [1251]-labelled CRP with PMA-stimulated 
neutrophils was inhibited by 55-58% when compared with that in the absence of AEBSF (Fig 5), 
but the association appeared to be saturable (Fig 5). With 100 µg [1251]-labelled CRP offered to 
I0xl06 neutrophils in the absence of Ca2+, 360 ng [I25J]-labelled CRP was associated with the 
cells after 30 min (Fig 5). Half maximal saturation occurred at 20 µg [1251]-labelled CRP/ml (Fig 
5). In the presence of Ca2+, 208 ng [1251]-labelled CRP (100 µg offered) was found to associate 
with 10xI06 PMA-stimulated neutrophils within 30 min. Half maximal saturation was found to 
occur at 40 µg [I25J]-labelled CRP/ml (Fig 5). Ten different experiments gave results within 10% 
of these. 
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The association of [ 1251]-labelled CRP (20 µg offered) with I0xl06 PMA-stimulated neutrophils at 
30 min, in the presence of AEBSF, (I mM) (Fig 5) could not be inhibited by an excess of 
unlabelled CRP, either in the absence or presence of Ca2+ (Table 2). The association of [1251]-
labelled CRP (20 µg offered) with I0xl06 neutrophils at 30 min, in the absence ofCa2+ (140 
ng/I0x106 cells, Fig 5) was increased to 220 ng/10xl06 cells/ 30 min (in the presence of 5 mg 
unlabelled CRP), while that in the presence of Ca2+ (60 ng/I0xl06 cells, Fig 5), was increased to 90 
ng/10xl06 cells/ 30 min (Table 2). Neutrophil associated [1251]-labelled CRP (20 µg offered) in the 
absence of Ca2+ (140 ng/I0xl06 cells/30 min, Fig 5) was increased to 164 ng in the presence of 1 
mg of unlabelled CRP and to 75 ng from 60 ng/I0xl06 cells/30 min (Fig 5), in the presence of Ca2+ 
(Table 2). 
Table 2. Infuence of unlabelled CRP on the association of [125I]-labelled CRP with neutrophils, in the presence 
of AEBSF with or without Ca2+. PMA-stimulated neutrophils (10xl06) were incubated (37°C, 30 min) 
with [125I]-labelled CRP (20 µg) in the presence of AEBSF (lmM), with or without Ca2+. Unlabelled CRP 
of either 5 mg or 1 mg was included in the incubation. Association of [1 25I]-labelled CRP is expressed as 
ng/l0x106 neutrophils at 30 min. 
ng [1251]-labelled bound CRP/10xl06 cells 
unlabelled CRP +Ca2+ C 2+ - a 
none 60 140 
5 mg 90 220 
1 mg 75 164 
SDS-PAGE (5-20% non-reduced) (Fig 6) of the cell-associated [1251]-labelled CRP in the presence 
of AEBSF and in both the absence and presence of Ca2+ at 30 min, clearly showed there to be more 
[1251]-labelled CRP associated with the cell in the presence of the unlabelled CRP than in its 
absence. The extent of [ 1251]-labelled CRP binding to neutrophils in the presence of unlabelled CRP 
appeared to be related to the concentration of unlabelled CRP in the incubation (Table 2, Fig 6). A 
21 kDa degradation product, in addition to the CRP subunit (24 kDa) could be detected in 
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Figure 5. Association of (1251]-labelled CRP with PMA stimulated neutrophils as a function of concentration. 
[1 251]-labelled CRP (0-100 µg) was incubated (37°C, 30 min) with PMA-stimulated neutrophils (10xl0
6
) 
in the presence of the inhibitor AEBSF (1 mM), with (0) or without calcium(•), and in the absence of 
AEBSF, with (D) or without calcium(•). Association of [
1251]-labelled CRP was measured and expressed 
as ng [1251]-labelled CRP/10xl0
6 cells. Each value is a mean of duplicates which did not differ by more 
than 10%. Ten experiments gave results within 10% of these. 
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Figure 6. SDS-PAGE of neutrophil associated [1251]-labelled CRP. [125I]-labelled CRP (20 µg) was incubated 
(37°C, 30 min) with 10xl06 PMA-stimulated neutrophils in the absence and presence of Ca2+ and in the 
presence of a 250 fold or 50 fold excess of unlabelled CRP. The neutrophils were washed at the end of 
the incubation period and analysed on 5-20% SDS PAGE (non-reduced) as described in the Materials 
and Methods. Track 1 represents an undigested CRP standard. Neutrophil associated [125I]-labelled CRP 
in the absence of unlabelled CRP is indicated in tracks 2 and 5 (without and with Ca2+, respectively), 
while tracks 3 and 6 represent neutrophil associated [1251]-labelled CRP in the presence of a 250 fold 
excess of unlabelled CRP and in the absence and presence of Ca2+, respectively. Tracks 4 and 7 show the 
association of [125I]-labelled CRP to PMA-stimulated neutrophils in the presence of a 50 fold excess of 
unlabelled CRP and in the absence and presence of Ca2+, respectively. 
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4.A.1.2.4. Influence of monoclonal antibodies to neutrophil integrins on neutrophil 
association and degradation of [1251]-labelled CRP 
The influence of monoclonal antibodies to neutrophil integrin receptors, on the neutrophil 
association and degradation of [ 1251]-labelled CRP was pursued. Saturating concentrations of the 
monoclonal antibodies directed against CD 11 a, CD 11 b, CD 11 c, CD 18, CD 16 and the gpllb/Illa 
complex (CD41a) were determined by flow cytometry. These studies were conducted in the 
presence and absence of the inhibitor AEBSF, which, at a concentration of 1 mM was shown to 
inhibit [1251]-labelled CRP degradation by 98%. 
None of the monoclonal antibodies preincubated with PMA-stimulated neutrophils, in the absence 
or presence of AEBSF and the absence of ca2+, modulated the association of 360 ng [1251]-
labelled CRP with I0x106 PMA-stimulated neutrophils at 30 min (20 µg [1251]-labelled CRP 
offered) ( data not shown). 
A 90% inhibition of degradation of 20 µg [ 1251]-labelled CRP by 1Ox106 PMA-stimulated 
neutrophils at 30 min was observed in the presence of anti-CDl lc (Serotec). The generation of 
706 ng [1251]-labelled TCA-soluble CRP peptides by 10xl06 cells at 30 min was thus reduced by 
635 ng [1251]-labelled TCA-soluble peptides when anti-CDl lc was included in the incubation, in 
the absence of AEBSF. The inclusion of AEBSF (1 mM) in the reaction increased the inhibition of 
degradation to 100%. In addition, saturating concentrations of the monoclonal antibodies directed 
against CD 11 b (Sanbio ), CD 11 a (Serotec) and CD 18 (Sanbio) reduced the neutrophil-mediated 
degradation of [1251]-labelled CRP (20 µg offered) at 30 min, in the absence of AEBSF, by 45%, 
75% and 65%, respectively. However, in the presence of AEBSF, no further inhibition of [1251]-
labelled CRP degradation was observed with any of these monoclonal antibodies. No inhibition of 
[
1251]-labelled CRP degradation was observed with the monoclonal antibodies directed against 
CD16 (Sanbio) and CD41a (Sanbio), in the absence or presence of AEBSF. Two different 
monoclonal antibodies directed against two different epitopes of CD41 a gave the same result. Due 
to the complete absence of inhibition of [1251]-labelled CRP degradation by the antibodies directed 
against CD 16 and CD41 a, these antibodies were treated as negative controls. 
Due to the expense of monoclonal antibodies, experiments showing saturation curves of neutrophil 
association of [1 251]-labelled CRP, in the presence of both AEBSF and anti-CDl lc where 100% 
inhibition of degradation was shown, were not possible. However, SDS-PAGE analysis of the 
neutrophil associated [1251]-labelled CRP at 30 min, in the presence of AEBSF and anti-CDl lc, 
showed it to be of subunit size (24 kDa) (not shown). This binding was not inhibitable in the 
presence of unlabelled CRP, but rather facilitation of [1251]-labelled CRP binding to neutrophils, as 




Previous studies, which have attempted to identify the putative CRP receptor on the neutrophil, 
have reported high (50%) non-specific association ofCRP with the neutrophil (Muller and Fehr, 
1986; Buchta et al., 1987a; Shephard et al., 1989). In addition, degradation of CRP, during its 
association with neutrophils, has been shown to occur by a PMA-activatable membrane-associated 
protease and the CRP degradation products have been demonstrated to associate with the 
neutrophil surface (Shephard et al., 1989). The demonstration of concomitant degradation of CRP 
during association with PMA-stimulated neutrophils thus precludes identification of a CRP 
receptor on the neutrophil membrane by Scatchard analysis of binding data. 
This study re-examines the interaction of CRP with PMA-stimulated neutrophils in the presence of 
the inhibitor AEBSF, which inhibits neutrophil-mediated degradation of CRP by 98%. In 
accordance with previous results (Shephard et al., 1989), saturation of CRP binding to neutrophils 
could not be reached in the absence of AEBSF. When neutrophil-mediated degradation of CRP 
was inhibited by AEBSF, the total association of CRP with the cell was saturable, but the total 
amount of CRP associated with the cell was less than that in the absence of this inhibitor. The 
presence of Ca2+ in the incubation medium, in both the absence and the presence of AEBSF, also 
influenced the total amount of CRP associated with the neutrophil. Thus, the conformation of CRP, 
which is calcium dependent Swanson et al., 1991; Mullenix and Mortensen, 1994), governs the 
extent of interaction ofCRP with neutrophils, as previously described (Buchta et al., 1987a; 
Shephard et al., 1989). SDS-PAGE analysis of the neutrophil associated material, in the presence 
of AEBSF with or without Ca
2
+, revealed the association of CRP corresponding to the molecular 
mass of the CRP subunit (24 kDa) in addition to a CRP degradation product of21 kDa. The 
generation of the 21 kDa product could reflect the inability of AEBSF to completely inhibit CRP 
degradation. From the autoradiographic analysis it appears that this 21 kDa product was less than 
10% of the total CRP associated with the cell. The specificity of the interaction of CRP with the 
neutrophil, in the presence of AEBSF, could not, however, be deduced as no inhibition of the 
interaction of radiolabelled CRP with neutrophils could be achieved with unlabelled CRP, but 
rather facilitative binding was observed. The total association of [
125I]-labelled CRP with 
neutrophils appeared to be positively related to the concentration of unlabelled CRP in the 
incubation reaction. 
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The facilitation of radiolabelled CRP binding to neutrophils, in the presence of unlabelled CRP, 
could be due to CRP subunit binding to neutrophils rather than intact pentameric CRP binding to 
the neutrophil as SDS-P AGE analysis does not distinguish between pentameric and subunit CRP. 
The CRP subunit has, however, been found to be very hydrophobic and consequently if it is 
associated with the neutrophil membrane could facilitate further CRP binding. In addition, the 21 
kDa degradation product could also facilitate CRP binding. A decrease in solubility of CRP has 
been noted upon its degradation or reduction into subunits with a resultant propensity for the 
products to aggregate (Bray et al., 1987; Potempa et al., 1987). 
Thus, even though neutrophil-mediated degradation of CRP is inhibited by 98% by AEBSF and the 
association of CRP with neutrophils is saturable in the presence of this inhibitor, the inability of the 
association of radio labelled CRP to be inhibited by unlabelled CRP, precludes Scatchard analysis of 
the binding data. However, the ability of the antibodies to the CDl le, CDI la, CDI lb and CD18 
neutrophil integrin receptors to inhibit neutrophil-mediated degradation of CRP suggests that the 
putative CRP receptor may be in close proximity to these receptors. Since this inhibition was 
greatest (90%) in the presence of anti-CD 11 c, the CRP receptor may be postulated to be closest to 
CDI lc/CD18 as opposed to CD1 lb/CD18 or CDI la/CD 18. The observed inhibition ofCRP 
degradation by anti-CDl la, anti-CDl lb and anti-CD18 may be due to obstruction of ligand 
interaction with the putative CRP receptor in the vicinity of CD 11 c, by these antibodies. We have 
shown that during the incubation of fibrinogen with neutrophils there is degradation of this ligand 
by the membrane-associated protease described here (see Chapter 5). We also showed that 
neutrophil-mediated degradation of fibrinogen could be inhibited with the antibody directed against 
CD 11 c. This supports the hypothesis that the interaction of CRP with the neutrophil membrane, 
which is a necessary requirement for neutrophil-mediated CRP degradation, occurs at a position in 
close proximity to the CD 11 c integrin receptor. Of significance, was the inability of the antibody 
directed against the IgG Fe receptor (CD16) to modulate neutrophil degradation or association of 
CRP, in the presence and absence of AEBSF. Previous reports have suggested the CRP receptor 
on the neutrophil to either be, or be in close proximity to, the IgG receptor (Buchta et al., 1987a; 
Zeller and Sullivan, 1992; Zeller and Sullivan, 1993) .. 
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4.B. IDENTIFICATION OF THE CRP-DEGRADING PROTEASE AND THE 
MECHANISM OF CRP PROTEOLYSIS 
4.B.1. INTRODUCTION 
Previous studies looking at the interaction of CRP with neutrophils have established concomitant 
degradation of the ligand giving rise to large molecular weight products which become cell 
associated and small peptides which remain in the extracellular medium (Shephard et al., 1989). An 
important consequence of this neutrophil-mediated degradation of CRP is the observation that the 
low molecular weight peptides are potent non-specific inhibitors of neutrophil migration and 
oxidative metabolism (Shephard et al., 1989; Shephard et al., 1990; Shephard et al., 1992). The 
inhibitory activity of these peptides was shown to be related to the inhibition of the glycolytic 
enzyme, enolase, with subsequent inhibition of glycolysis followed by depletion in intracellular ATP 
levels (Shephard et al., 1992). 
Although non-stimulated neutrophils were able to degrade CRP, the rate of degradation was only 
minimally greater than that of neutrophil conditioned medium. When neutrophils were stimulated 
with PMA, a neutrophil-associated enzyme considerably enhanced the rate of CRP-degradation 
when compared with CRP degradation by PMA-stimulated neutrophil conditioned medium. 
Detection of CRP degradation products within 2 min of incubating CRP with PMA-stimulated 
neutrophils, led to the suggestion that neutrophil-mediated degradation of CRP is due to a 
neutrophil membrane-associated protease which is maximally activated by PMA. Further 
confirmation for this was obtained when it was shown that isolated neutrophil membranes 
produced CRP peptides with identical amino acid sequences as those generated by intact 
neutrophils (Shephard et al., 1991 ). In addition, the inhibitor profile and nature of CRP products 
generated by isolated neutrophil membranes was the same as that of PMA-stimulated neutrophils 
(Shephard et al., 1989). 
This study attempts to further identify the neutrophil membrane-associated protease with respect to 
cellular distribution and molecular size. The mechanism of CRP degradation, with particular 
reference to the interaction of CRP with the neutrophil surface resulting in degradation, will be 
examined. 
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4.B.2. RES UL TS 
4.B.2.1. Identification of the CRP-degrading protease 
4.B.2.1.1. Association of the CRP degrading enzyme with the neutrophil cytoskeleton 
Proteins involved in the attachment of the cytoskeleton with the plasma membrane are found to 
co-isolate in both membrane and cytoskeleton fractions (Luna and Hitt, 1992). When a neutrophil 
Triton X-100 insoluble fraction, containing cytoskeleton proteins, was incubated with [125I]-
labelled CRP (100 µg), TCA-soluble [1251]-labelled CRP peptides were produced in both a time 
and enzyme concentration dependent manner (Table 3). [125I]-labelled CRP degradation products 
were observed on 12% SOS-PAGE (reduced) at apparent molecular mass values of21 kDa and 18 
kDa (Fig 7). These CRP degradation products, formed through the action of the neutrophil 
cytoskeleton fraction, were found to be identical in molecular mass to those generated by the action 
of the neutrophil membrane and the conditioned medium from PMA-stimulated neutrophils but 
different from those generated by the action of neutrophil lysosomal enzymes (Fig 7). 
Approximately 98% of the total CRP-degrading enzyme associated with the insoluble cytoskeleton 
was solubilised with IM NaCl and the proteolytic activity remained in solution following removal 
of the I M NaCl by dialysis against PBS. Similar solubility of the membrane associated protease 
has been described by Shephard et al.(1989). 
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Table 3. Generation of (usl]-labelled TCA-soluble CRP peptides by neutrophil cytoskeleton. (
1251]-labelled CRP 
(100 µg) was incubated with varying concentrations of neutrophil cytoskeleton and at various time points 
(2 hr-6 hr) the generation of 10% (w/v) TCA-soluble [1251]-labelled CRP petides was measured and 
expressed in µg/ml. 
(
1251]-labelled TCA-soluble CRP peptides (µg/ml) 
Time (hr) 
Cytoskeleton 2 4 6 
(µg) 
10 10 18 20 
50 14 25 35 
100 22 40 55 
The ability of the neutrophil cytoskeleton fraction to degrade CRP was inhibited by the serine 
protease inhibitor PMSF ( 1 mM), the elastase inhibitor a 1 AT ( 1. 5 mg/ml) (Fig 7), the chymotrypsin 
inhibitor L-1-tosylamido-2-phenyl-ethyl-chloromethyl-ketone (TPCK, 5 µM) and the trypsin 
inhibitor a 1-p-tosyl-L-lysine-chloromethyl-ketone (TLCK, 10 µM). These inhibitors were shown 
previously to be equally capable of inhibiting the CRP-degrading activity associated with the 
neutrophil membrane (Shephard et al., 1989). Inhibition of the cytoskeleton associated enzyme by 
these inhibitors was such that less than 3 µg ofTCA-soluble CRP peptides were formed when they 
were present during the incubation of CRP with neutrophils. 
CRP 
subunit 
1 2 3 4 5 
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Figure 7. SDS-PAGE (12% reduced) of [u51]-labelled CRP degradation products. [1 25I]-labelled CRP (100 µg) 
was degraded (37°C, 1 hr) by either, 100 µg neutrophil cytoskeleton (Track 1), 100 µg neutrophil 
membranes (Track 2), conditioned medium from 10xl06 PMA-stimulated neutrophils (Track 3) or the 
lysosomal enzymes from 5xI06 neutrophils (Track 6). Preincubation (37°C, 15 min) of the inhibitors 
PMSF and a.1AT with the neutrophil cytoskeleton, resulted in inhibition of [1
251]-labelled CRP 
degradation (Tracks 4 and 5, respectively). 
4.B.2.1.2. Molecular size of the CRP-degrading protease 
This was ascertained by SDS-PAGE using non-reducing conditions and by gel filtration. 
SDS-PAGE 
The proteins in the neutrophil cytoskeleton fraction (200 µg), membrane fraction (200 µg) and 
PMA-stimulated neutrophil conditioned medium (from I00xl06 neutrophils) were separated by 3-
13% SDS-PAGE (non-reduced). To determine which proteins possessed proteolytic activity the 
gel was cut into 2 mm slices which were then incubated with [125r]-labelled CRP and assayed for 
CRP-degrading activity. Each enzyme preparation was identified to contain four distinct protein 
bands which were capable of degrading [125I]-labelled CRP. For all three neutrophil fractions 
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about 1%, 5%, 70% and 20% of the total loaded CRP-degrading activity was detected in the gel slices 
containing molecules migrating to apparent molecular mass values of 501 kDa, 398 kDa, 316 kDa and 
209 kDa respectively. These four proteolytic components of the neutrophil cytoskeleton, membrane 
and conditioned medium could not, however, be visualised on 3-13% SDS-PAGE (reduced and non-
reduced) with coomassie staining (not shown). The three neutrophil fractions (150 µg) were 
subsequently labelled with [125J]-Na (150 µCi) and the proteins separated by 3-13% SDS-PAGE 
followed by autoradiographic analysis whereupon the proteolytically active bands could be visualised 
at the corresponding molecular mass values of 501 kDa, 398 kDa, 316 kDa and 209 kDa (Fig 8). 
None of the other bands visualised with autoradiographic analysis were shown to possess proteolytic 
activity (Fig 8). 
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Figure 8. Molecular size of the CRP-degrading protease. SDS-PAGE (3-13% non-reduced) followed by 
autoradiography of [1 25I]-labelled neutrophil membranes (200 µg) (Track 1), [125I]-labelled neutrophil 
cytoskeleton (200 µg) (Track 2) and [125I]-labelled conditioned medium from PMA-stimulated neutrophils 
(I00xl0
6
) (Track 3) revealed four bands possessing CRP-degrading activity (Materials and methods). 




The neutrophil cytoskeleton ( 500 µg) and membrane ( 500 µg) proteins and the conditioned 
medium from 100x106 PMA-stimulated neutrophils were individually subjected to gel filtration 
using Sephacryl S-300 equilibrated in PBS. Greater than 95% of the proteolytic activity of each of 
these three fractions eluted in a single peak with an apparent molecular mass of 600 kDa (Table 4). 
Table 4. Determination of the molecular mass of the CRP-degrading protease in isolated neutrophil 
membrane and cytoskeleton fractions and the conditioned medium from PMA-stimulated 
neutrophils by Sephacryl S-300 chromatography. The neutrophil membrane and cytoskeleton fractions 
(from 100x106 cells) and the PMA-stimulated neutrophil conditioned medium (from 100x10
6 cells) were 
loaded onto the Sephacryl S-300 column (lx45 cm) in PBS and eluted at 3ml/hr in 0.6 ml fractions. 
CRP-degrading protease activity was ascertained by incubating (37°C, 18 hr) 0.5 ml aliquots of each 
fraction with 100 µg [1251]-labelled CRP. Degraded CRP is measured as the generation of 10% (w/v) 
TCA-soluble peptides and is expressed as µg [1251]-labelled CRP/0.5 ml. The molecular mass of the 
protease in the peak fraction was calculated from the standards (used to calibrate the column) as 
indicated. They-intercept was calculated as 1.874, the slope as -0.3122 and r as -0.978. An average of 
the molecular mass of the protease within the three eluted peak fractions was calculated. 
Degraded CRP (µg/0.5 ml) 
Column Membrane Cytoskeleton Conditioned Kav kDa 
fraction Medium 
1-28 0 0 0 
29 2 1 1 0.053 691 
30 16 25 22 0.080 588 593 
31 24 30 25 0.107 501 
32 2 1 1 
33 0 0 0 
34 0 0 0 
35 0 0 0 
36 0 1 0 
37-60 0 0 0 
Protein Thyroglobulin 0.052 669 
Standards Catalase 0.190 210 
Aldolase 0.300 158 
Bovine serum albumin 0.342 67 
Ovalbumin 0.434 43 
When this eluted peak, from all three fractions, was labelled with [12511-Na, subjected to analysis 
by 3-13% SDS-PAGE (non-reduced) followed by autol.'adiography, four bands could be seen at the 
apparent molecular masses 501 kDa, 398 kDa, 316 kDa and 209 kDa (as in Fig 8). When the 
technique described above to recover proteolytic activity after SDS-P AGE was used, 
approximately 7%, 15%, 60% and 18% of the total loaded CRP-degrading activity could be 
recovered from the gel slices containing proteins which migrate to apparent molecular mass values 
501 kDa, 398 kDa, 316 kDa and 209 kDa respectively. 
4.B.2.2. Mechanism of CRP Proteolysis 
4.B.2.2.1. Influence of [1251]-labelled CRP on the proteolytic activity of the extracellular 
medium during cellular degradation 
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Degradation of [1251]-labelled CRP by PMA-stimulated neutrophils was markedly faster than 
that by PMA-stimulated neutrophil-conditioned medium (Table 5). Experiments were conducted to 
ascertain whether the presence of CRP itself may effect the release of proteolytic activity from the 
neutrophil and subsequently its own degradation in the extracellular medium. To accomplish this, 
[1251]-labelled CRP was incubated with PMA-stimulated neutrophils for various time periods 
whereupon the cells were removed and the cell-free medium restored to 3 7°C to allow the 
degradation of extracellular CRP to continue. Upon removal of the cells from the reaction the 
[1251]-labelled CRP in the cell-free medium continued to degrade. When the incubation period of 
[ 1251]-labelled CRP with the cells was less than 40 min the rate of [ 1251]-labelled CRP degradation 
in the extracellular medium was slower than the rate of [ 1251]-labelled CRP degradation in the 
presence of PMA-stimulated cells but faster than that by PMA-stimulated neutrophil-conditioned 
medium (Table 5). When the incubation period of [1251]-labelled CRP with the PMA-stimulated 
cells was greater than 40 min, the rate of [1251]-labelled CRP degradation in the extracellular 
medium was similar to that in the presence of PMA-stimulated cells (Table 5). This CRP mediated 
release of proteolytic activity from the neutrophil was found to be concentration dependent and 
optimal at a concentration of 500 µg CRP/10xl06 cells. 
CRP was also shown to mediate the release of CRP-degrading activity from non-stimulated 
neutrophils. As for stimulated cells, a 40 min incubation period of [ 1251]-labelled CRP with non-
stimulated neutrophils resulted in the degradation rate of [ 1251]-labelled CRP in the cell free 
medium to equal that of non-stimulated neutrophils and to be greater than that of the conditioned 
medium from non-stimulated neutrophils (Table 5). 
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Table 5. Degradation of [1251)-labelled CRP by PMA-stimulated neutrophils: Influence of [1251)-labelled CRP 
on the proteolytic activity of the extracellular medium during cellular degradation. Reactions (1 ml) 
contained 100 µg [1251]-labelled CRP and either PMA-stimulated neutrophils (10xl06) or the conditioned 
medium from these cells. Degradation was measured as 10% (w/v) TCA-soluble peptides and expressed as 
µg [1~-labelled CRP/rnl. Neutrophil-mediated or conditioned medium degradation was measured at 
specific times r·). Degradation in the extracellular medium. obtained by removing the cells from the 
neutrophil-mediated reactions at various times r·) and returning the cell-free medium to 37°C, was 
measured at the indicated times (*). 
Degraded [1251]-Iabelled CRP (µg/ml) 
+PMA 
Conditioned Neutrophil- Extracellular medium 
medium mediated 
Time (min) 60* 120 180 
10 .. 3 5 8 18 25 
20 4 8 16 28 39 
40 7 17 27 47 56 
60 10 27 - 47 56 
120 12 47 - - 56 
180 16 56 - - -
-PMA 
10 2 3 4 5 7 
20 3 4 6 8 11 
40 4 6 10 13 18 
60 6 10 - 13 19 
120 9 13 - - 19 
180 13 18 - - -
4.B.2.2.1.1. Quantification of the extracellular proteolytic activity 
The proteolytic activity released from neutrophils during an incubation with CRP was further 
demonstrated by directly assaying the enzymatic activity of the cell-free medium, following 
dissociation of extracellular CRP and enzyme. Dissociation of extracellular proteolytic activity and 
CRP could not be attained either by phosphorylethanolamine agarose affinity chromatography, 
known to bind CRP (Shephard et al., 1988), or by gel filtration of the extracellular medium in IM 
NaCl (data not shown). The extracellular proteolytic activity could, however, be fully dissociated 
from the ligand when more than 90% of the CRP was degraded to TCA-soluble peptides. For this a 
CRP-released conditioned medium was prepared by incubating unlabelled CRP (100 µg) with 
PMA-stimulated neutrophils (10xI06) for 40 min, after which the cells were removed and the cell-
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free medium returned to 3 70c to continue degradation. At a time when more than 90% of the 
unlabelled CRP remaining in the extracellular medium was degraded ( estimated to be at 20 hr from 
an identical reaction containing [1251]-labelled CRP), [1251]-labelled CRP (100 µg) was added. 
Degradation of this added [1251]-labelled CRP by the CRP-released conditioned medium equalled 
that of the [1251]-labelled CRP-degrading activity of PMA-stimulated neutrophils and was faster 
than that of control conditioned medium prepared from PMA-stimulated cells in the absence of 
CRP (Table 6). 
Table 6. Quantification of the proteolytic activity released from PMA-stimulatcd neutrophils by CRP. 
Degradation reactions (37°C) contained 100 µg [
125I]-labelled CRP/ml and either 10x10
6 PMA-
stimulated neutrophils or the conditioned medium from these cells prepared in both the presence and 
the absence (control) of CRP (as described in the Materials and methods). Degradation, at the 
indicated time points, was measured as 10% (w/v) TCA-soluble peptides and expressed as µg [
125I]-
labelled CRP/ml. 
Degraded [1251]-labelledCRP (µg/ml) 
Time (hr) Neutrophil- CRP-released Control conditioned 
mediated conditioned medium 
medium 
1 25 26 9 
2 42 42 14 
3 53 52 19 
4.B.2.2.1.2. [1251]-labelled CRP-degrading activity of cytoskeleton and membranes from 
neutrophils that have been incubated with CRP 
Since a CRP-mediated egress of enzymatic activity from neutrophils was observed, the possibility 
that this occurs from both the membrane and the cytoskeleton was investigated. Non-stimulated 
and PMA-stimulated neutrophils were incubated with unlabelled CRP for a period of 40 min 
whereupon the cytoskeleton and membranes were isolated and assayed for CRP-degrading activity. 
The [1251]-labelled CRP degrading activity of these fractions was then compared with that of the 
[1251]-labelled CRP-degrading activity of membrane and cytoskeleton fractions isolated from 
control cells not pre-incubated with unlabelled CRP. A minimal change in the [1251]-labelled CRP-
degrading activity of neutrophil membrane and cytoskeleton fractions occurred as a result of 
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stimulating neutrophils with PMA in the absence of CRP (Table 7). However, when these fractions 
were isolated from non-stimulated and PMA-stimulated neutrophils, which had been preincubated 
with unlabelled CRP, a substantial decrease in the CRP-degrading activity of these fractions was 
observed (Table 7). This phenomenon was dependent on the concentration of CRP and the time of 
incubation of CRP with neutrophils. A minimum of 2 µg CRP induced this loss of proteolytic 
activity from the neutrophil cytoskeleton and membrane. The maximum loss of proteolytic activity 
occurred when 500 µg CRP was incubated for 40 min with 10x106 PMA-stimulated neutrophils 
(Table 7). 
Table 7. (u51]-labelled CRP-degrading activity of cytoskeleton and membranes isolated from ncutrophils 
that have been incubated with CRP. Reactions contained 100 µg [
1251]-labelled CRP/ml and either 
the membrane or cytoskeleton from 10x106 neutrophils which had been incubated for 40 min (37°C) 
without or with CRP (2 µg or 500 µg) and in the absence (-) or presence (+) of PMA (10 ng/ml). 
Degradation, at the indicated time points, was measured as 10% (w/v) TCA-soluble peptides and 
expressed as µg [1251]-labelled CRP/ml. 
Degraded [1251]-labelled CRP (µg/ml) 
PMA ( 10 ng/ml) - + - + - + 
CRP (µg/ml) 0 0 2 2 500 500 
Time (hr) 
Membrane 1 19 14 13 6 11 2 
3 45 43 41 11 39 7 
Cytoskeleton 1 16 15 10 5 8 I 
3 38 37 32 11 27 6 
4.B.2.2.2. The effect of kinase inhibitors on the rate of degradation of CRP by PMA-
stimulated neutrophils 
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The degradation of [ 125I]-labelled CRP by PMA-stimulated neutrophils was concentration 
dependently inhibited by H7 and TFP to a rate similar to that by non-stimulated neutrophils (Table 
8). A minimum concentration of 20 µM and 10 µM, respectively, and a preincubation period of 5 
min was required for inhibition of degradation. Increasing the concentration ofH7 and TFP 
beyond 50 µMand 20 µM respectively and extending the preincubation period of the cells with 
these inhibitors to 30 min did not give rise to further inhibition (Table 8). At all concentrations of 
TFP and H7 used and with the use of dimethyl sulfoxide to solubilise the inhibitors, cell death was 
not observed. Neither leupeptin nor E-64 altered or inhibited the rate of [125I]-labelled CRP 
degradation by PMA-stimulated neutrophils (Table 8). None of the inhibitors tested affected the 
rate of [125I]-labelled CRP degradation by non-stimulated neutrophils (Table 8). 
Table 8. Influence of inhibitors on [1251]-labelled CRP degradation by neutrophils. Reactions (37°C) 
contained 100 µg [1 251]-labelled CRP/ml and 10xl06 non-stimulated or PMA-stimulated (10 ng/ml) 
neutrophils that had been pre-incubated (37°C, 15 min) with or without the indicated inhibitor. 
Degradation, at the indicated time points, was measured as 10% (w/v) TCA-soluble peptides and 
expressed as µg [1 251]-labelled CRP/ml. H7: 1-(5-isoquinolinesulphonyl)-2-methylpiperazine. TFP: 
Trifluoperazine. 
Degraded [1251]-labelled CRP/ml 
Inhibitor Time (min) 
30 60 
None 15 23 
H7 (10 µM) 13 18 
Neutrophil- H7 (20 µM) 11 16 
mediated H7 (50 µM) 6 10 
(+PMA) TFP (10 µM) 12 17 
TFP (20 µM) 6 10 
Leupeptin (100 µM) 16 24 
E-64 (10 µM) 15 24 
None 6 10 
Neutrophil- H7 (50 µM) 7 11 
mediated TFP (20 µM) 7 11 
(-PMA) Leupeptin ( 100 µM) 8 12 
E-64 (10 µM) 7 11 
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4.B.3. DISCUSSION 
4.B.3.1. Identification of the CRP-degrading protease 
The degradation of CRP observed during incubation with neutrophils, has been previously shown 
to be due to a neutrophil membrane-associated protease which is maximally activated by 
stimulation with PMA (Shephard et al., 1989; Shephard et al., 1990). In this study, it was shown 
that the neutrophil cytoskeleton fraction, prepared by non-ionic detergent extraction of the cell 
surface membrane proteins, also contains a neutral protease capable of degrading CRP. CRP 
degradation products with identical apparent molecular mass values were generated by the 
proteolytic activity of neutrophil cytoskeleton and membrane fractions and PMA-stimulated 
neutrophil conditioned medium. These products differ in molecular mass from those produced by 
the action ofneutrophil lysosomal enzymes on CRP. Thus, the CRP-degrading protease within the 
neutrophil cytoskeleton fraction, the neutrophil membrane fraction and PMA-stimulated 
conditioned medium could be the same but distinct from the CRP-degrading proteases within the 
neutrophil granules. This is supported by the observation that the enzyme within each of these three 
neutrophil fractions could be dissociated by SDS-PAGE into four discrete bands which migrated to 
positions with identical electrophoretic mobility at the apparent molecular mass values of 209 kDa, 
316 kDa, 398 kDa and 501 kDa. The association of this high molecular mass neutral protease with 
both the neutrophil membrane and cytoskeleton fraction suggests that it may be a sub-membrane 
protein localised at sites of interaction of the cytoskeleton with the membrane. Since actin is a 
component of the cytoskeleton fraction (Yassim et al., 1985) it is possible that the CRP-degrading 
protease is a sub-membrane protease which interacts with actin and lipids at the cytoplasmic 
surface of the plasma membrane and may, therefore, be localised at the interface of the 
cytoskeleton with the membrane. 
The CRP-degrading neutrophil protease described here appears to be different from a previously 
described serine protease, also associated with the neutrophil cytoskeleton and membrane and 
reported to have an apparent molecular mass of300 kDa (Pontremoli et al., 1986). This 300 kDa 
protease was not demonstrated to display any subunit.or aggregation characteristics and was 
shown to be almost completely released into the extracellular medium when the cells were 
stimulated with PMA, via the activation of PKC. 
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4.B.3.2. Mechanism of CRP proteolysis 
The results indicate that the mechanism for neutrophil-mediated CRP degradation resides in the 
ability of CRP to mediate a PMA-upregulatable egress of proteolytic activity from both the 
membrane and the cytoskeleton, which promotes its degradation in the extracellular milieu. 
Although some cleavage of CRP could occur at the neutrophil membrane during interaction of 
CRP with the cell, extracellular degradation of CRP also occurs through the released protease 
interacting with CRP in the extracellular medium where they form a tight complex that is not easily 
dissociated. Extracellular degradation of CRP would allow the generation of CRP degradation 
products which may then associate with the neutrophil surface as suggested by Shephard et al. 
(1989). 
The CRP-mediated egress of proteolytic activity was complete within 40 min which may relate to 
the time required to saturate the neutrophil surface with CRP. Perturbation of the neutrophil 
membrane, in the region of attachment of the membrane to the cytoskeleton, as a result of CRP 
binding to the putative CRP receptor (Shephard et al., 1989; Buchta et al., 1987a; Kilpatrick and 
Volanakis, 1985) could account for the observed egress of proteolytic activity from the neutrophil. 
Results from the previous section suggest the putative CRP receptor to be close to the 
CD 11 c/CD 18 receptor on neutrophils. 
The PMA-upregulatable, CRP-mediated release of CRP-degrading activity from the neutrophil, 
appears to involve the action of cellular kinases. Since no change in the rate of CRP degradation 
was achieved by sustaining PKC in the membrane, by inhibiting calpain with the thiol protease 
inhibitors leupeptin and E-64, the action of PKC may not be responsible for enhancing the CRP-
mediated egress of proteolytic activity from the neutrophil. On the other hand H7 and TFP, which 
are known to inhibit not only effector dependent PKC, but also the cyclic nucleotide-dependent 
kinases and calmodulin dependent processes activated by PMA (Hidaka et al., 1984; Seifert and 
Schachtele, 1988), were shown to be inhibitory for the rate of degradation of CRP by neutrophils. 
Thus, neutrophil kinase dependent processes other than PKC may be involved in the enhancement 
of the PMA-upregulatable, CRP-mediated egress of CRP-degrading activity from neutrophil 
membranes and cytoskeleton. The kinase(s) responsible may be suggested to achieve this 
enhancement of proteolytic egress from PMA-stimulated neutrophils by the phosphorylation of a 
specific intracellular substrate. 
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5.A. PROTEOLYSIS OF FIBRINOGEN BY A NEUTROPHIL MEMBRANE-
ASSOCIA TED PROTEASE 
5.A.1. INTRODUCTION 
Human fbg can be degraded by thrombin (Bailey et al., 1951), plasmin (Pizzo et al., 1972), 
neutrophil lysates (Bilezekian and Nossel, 1977; Gramse et al., 1977) and the human neutrophil 
proteases, elastase (HNE, Weitz et al., 1986) and cathepsin G (Gramse et al., 1980), to yield 
distinct products. Thrombin cleaves the Aa and Bf3 chains at positions 16 and 17 and positions 14 
and 15 from their N-termini respectively (Fig 2), resulting in the generation of fibrinopeptides A 
and B (FPA and FPB) and, following a subsequent series of reactions, fibrin is generated (Bailey et 
al., 1951). Plasmin cleaves fbg initially from the C-terminus of the Aa chain followed by the N-
terminus of the Bf3 chain and finally they chain, which is fairly resistant to degradation and is only 
cleaved once large parts of the Aa and the Bf3 chain have been split off (Pizzo et al., 1972; 
Ferguson et al., 1975; Azpiazu and Chapman, 1992). A consequence of this cleavage oftbg by 
plasmin is the generation of specific products (fragments A-E, Fig 2) of which fragments D and E 
possess anticoagulant activity (Doolittle, 1984; Olexa et al., 1981; Larrieu et al., 1972). Neutrophil 
fibrinogenolysis is characterised by N-terminal cleavage of all three constituent tbg chains to yield 
FPA- and FPB-containing peptides which display antigenic characteristics of D and E and also 
demonstrate anticoagulant activity (Gramse et al., 1977; Gramse et al., 1980; Plow and Edgington, 
1975). In addition, neutrophil generated fragments that are larger than the plasmin derived 
fragment X (Fig 2) are found to be non-clottable by thrombin (Plow and Edgington, 1975). A 
characteristic of fbg degradation by neutrophil lysates (Bilezekian and Nessel, 1977) and HNE 
(Weitz et al., 1986; Wright et al., 1988; Weitz et al., 1987) is the generation of an Aal-21 peptide 
through the cleavage of the bond between the amino acids Val and Glu at positions 21 and 22, 
respectively, from the N-terminus of the Aa chain. Plasma levels of this peptide have been used as 
a marker ofHNE activity in vivo and are proposed to be useful for monitoring HNE activity in 
conditions where a 1AT inhibitor activity is compromised and in subjects with homozygous and 
heterogeneous deficiency of this enzyme inhibitor (Weitz et al., 1986; Weitz et al., 1992). This 
study endeavours to characterise the degradation of tbg by the neutrophil membrane-associated 
protease, previously shown to degrade CRP (Shephard et al., 1989; Shephard et al., 1990), and 
evaluates the capacity of this protease to act as an alternative pathway to fibrinogenolysis by 
plasmin and neutrophil lysosomal enzymes. The nature and function of the resultant tbg 
degradation products will also be assessed. 
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5.A.2. RES UL TS 
5.A.2.1. Comparison of fibrinogen degradation by neutrophil conditioned medium, 
neutrophil cytoskeleton, neutrophil membranes, neutrophil lysosomal enzymes and 
plasmin 
When PMA-stimulated neutrophil conditioned medium was incubated with [1251]-labelled fbg 
and analysed by SDS-PAGE (5-20% non-reduced) at various time intervals, a progressive decrease 
in the size of the intact fbg molecule (apparent molecular mass 340 kDa) and the generation of 
[1251]-labelled fbg derivatives with apparent molecular mass values less than 340 kDa was 
observed (Fig 9A). The size of the degradation products, formed at a particular time point, was 
dependent on the concentration of enzyme, related to the number of neutrophils from which the 
conditioned medium was prepared (Fig 9A and lOB). The neutrophil cytoskeleton and membrane 
fractions generated [125r]-labelled degradation products of identical molecular size to those 
produced by the neutrophil conditioned medium (Fig 9A and Fig 10) and degradation was similarly 
shown to be dependent on time and the concentration of the enzyme source (data not shown). Each 
of the three neutrophil fractions generated terminal [125r]-labelled fbg degradation products which 
migrated on SDS-PAGE (5-20% non-reduced) to positions corresponding to apparent molecular 
mass values of270 kDa, 200 kDa, 100 kDa and less than 40 kDa (Fig 9A and 10). The terminal 
fbg products generated by these neutrophil enzyme sources differed in molecular mass to those 
generated at 20 hr by plasmin, in the presence and absence of CaCl2, neutrophil lysosomal enzymes 
and pure HNE (Fig 10). The terminal fbg degradation products generated by neutrophil 
conditioned medium, did not alter in apparent molecular mass when the Ca2+ was chelated with 
EGTA (Fig 11 ). The 100 kDa product, generated by the neutrophil conditioned medium, was 
found by two-dimensional iso-electrophoresis to have a pl of 6.25-6.3 which was similar to the pl 
of 6.15-6.35 found for the plasmin generated 90 kDa product thought to be fragment D (Fig 12). 
The high molecular mass fbg terminal products (270 kDa, 200 kDa and 100 kDa) generated in the 
presence of PMA-stimulated neutrophil conditioned medium were shown to be plasmin sensitive 
(Fig 13). 
In addition to the generation of high molecular mass fbg products, the three neutrophil fractions 
also generated TCA-soluble peptides. The generation of these peptides was dependent upon the 
time of incubation of the [125r]-labelled fbg with the specific enzyme source as well as the 
concentration of enzyme (Table 9). 
Figure 9. 
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The nature of the (125~-labelled fibrinogen degradation products generated by neutrophil 
conditioned medium. [ 12 !]-labelled fbg (2 mg) was incubated with the conditioned medium from 
PMA-stimulated neutrophils and, at the indicated times, aliquots of the reaction mixture were subjected 
to SOS-PAGE (5-20% non-reduced) and autoradiographic analysis, as descibed in the Materials and 
methods. A: Nature of the [ 1251]-labelled fbg degradation products generated by the conditioned 
medium from 5xI06 PMA-stimulated neutrophils occurring over time. B: Nature of the [ 1251]-labelled 
fbg degradation products generated when the conditioned medium was prepared from I0x106 PMA-
stimulated neutrophils (track 1), 5xI06 PMA-stimulated neutrophils (track 2), 2.5xI06 PMA-stimulated 
neutrophils (track 3) and lxI06 PMA-stimulated neutrophils (track 4). Undigested [1251]-labelled fbg is 
shown in the track marked Std. 
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Figure 10. Degradation of [1251]-Iabelled fibrinogen. Degradation reactions (37°C) containing [1251]-labelled 
fbg (2 mg) and the enzyme source, in a final volume of 1 ml, were prepared and the nature of the 
products, generated at 20 hr, was assessed by SDS-PAGE (5-20% non-reduced}, as described in the 
Materials and Methods section. Products were generated by HNE (2 µg, track l); conditioned medium 
from 5xl06 PMA-stimulated neutrophils (track 2), neutrophil cytoskeletons (25 µg, track 3), neutrophil 
membranes (25 µg, track 4), urokinase-activated porcine plasminogen in the presence of CaCl2 (2 mM, 
track 5) or EGTA (10 mM, track 6) and lysosomal enzymes released from neutrophils by FMLP (1 µM) 
in the presence of cytochalasin B (5 µg/ml, track 7). Track 8 shows undigested [ 1251]-labelled fbg. 
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Figure 11. Influence of ca2+ on the degradation of [USI]-labelled fibrinogen by neutrophil conditioned 
medium. [1251]-labelled fbg (2 mg) was incubated (37°C) with the conditioned medium from 5xl06 
PMA-stimulated neutrophils in the presence or absence of EGT A ( 10 mM) in a final volume of 1 ml. At 
the indicated times aliquots of the reactions were subject to analysis by SOS-PAGE (5-20% non-
reduced) as described in the Materials and methods section. Undigested [
1251]-labelled fbg is indicated 
in the track marked Std. 
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Figure 12. Iso-electric focusing of plasmin and neutropbil conditioned medium generated ['
251]-labelled 
fibrinogen degradation products, followed by two dimensional SDS-PAGE. A. Terminal [1
251]-
labelled fbg degradation products of a plasmin as well as a neutrophil conditioned medium degradation 
reaction (as indicated) were analysed on an isoelectric PAG plate with a broad pH range between 3.5 
and 9.5 (as described in the Materials and methods). Broad range pH markers (3.5-9.3) are indicated. 
B. The terminal degradation products separated on the isoelectric PAG plates (A) were then subjected 
to two dimensional SDS-PAGE (5-20% non-reduced) followed by autoradiography. The terminal 
degradation products of apparent molecular mass 90 kDa (generated by plasmin degradation) and I 00 
kDa (generated by the neutrophil conditioned medium) and their corresponding isoelectric points are 
indicated with arrows. Tracks 1 and 3 represent undigested [1251]-labelled fbg. Track 2 represents the 
terminal [125I]-labelled fbg degradation products generated by neutrophil conditioned medium in the 
first dimension and track 4 shows the terminal [
125I]-Iabelled fbg degradation products generated by 
plasmin. 









Figure 13. D~radation of (1251)-labelled fibrinogen by neutrophil conditioned medium, followed by plasmin. 
(1 51]-labelled fbg (2 mg) was incubated (37°C, 18 hr) with the conditioned medium from 5xto6 
neutrophils and the fbg products generated were analysed by SOS-PAGE (5-20% non reduced) followed 
by autoradiography as described in the Materials and methods section (track 1). The reaction mix was 
subjected to a further 30 min incubation (37°C) without (track 2) or with (track 3) urokinase-activated 
plasminogen in the presence ofCaCl2 (2 mM). Undigested [1251]-labelled fbg is indicated in track 4. 
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Table 9. Degradation of ( 1251]-labelled fibrinogen. Degradation reactions (37°C) contained [ 
1251]-labelled fbg (2 
mg) and either conditioned medium (from 2.5xl06, 5xl06 or lxl07 PMA-stimulated neutrophils), isolated 
neutrophil cytoskeletons (12.5, 25 or 50 µg of protein) or isolated neutrophil membranes (12.5, 25 or 50 
µg of protein) in a final volume of 1 ml (as described in Materials and methods). Degraded fbg, measured 
as 10%, (w/v) TCA-soluble peptide formation, at the indicated time, is expressed as µg [ 1251]-labelled fbg 
products/ml. 
Degraded [1261]-labelled fibrinogen (µg/ml) 
Time Conditioned medium Cytoskeleton protein Membrane Protein 
(neutrophils/ml) (µg/ml) (µg/ml) 
2.5x106 5x106 10x106 12.5 25 50 12.5 25 50 
5min 20 40 80 40 120 200 60 100 160 
20 min 60 140 200 120 260 420 140 240 420 
1 hr 160 240 440 200 440 640 220 400 660 
3 hr 380 560 640 280 660 820 360 660 800 
9 hr 660 820 880 560 920 960 640 810 940 
20 hr 810 920 940 720 960 980 770 860 1000 
No inhibition of [1251]-labelled fbg (1 mg) degradation by neutrophil conditioned medium (from 
5xJ06 cells) was achieved with E-aminocaproic acid (200 mM), aprotinin (100 µM), ethylene 
diamine tetra acetic acid (EDT A, 10 mM, metalloprotease inhibitor), leupeptin ( 100 µM, thiol 
protease inhibitor), phosphoramidon (10 µM, metalloprotease inhibitor), TLCK (5 mM, trypsin 
inhibitor), ATEE (50 mM, trypsin inhibitor), the elastase inhibitors Suc-(Ala))CHzCl (lmM), Suc-
(Ala)z-ValCH2Cl (lmM), or the cathepsin G inhibitor Suc-(Ala)z-Pro-PheCH2Cl (lmM) (Table 
10). Increasing the concentrations of these inhibitors 100 fold did not change the results. On the 
other hand, MeO-Suc-(Ala)z-Pro-ValCHzCl (1 mM), an inhibitor of proteases with specificities 
related to alanine or valine bonds, and a 1 AT ( 1. 5 mg/ml, elastase inhibitor) reduced the production 
of TCA-soluble [ 1251]-labelled fbg peptide formation, by neutrophil conditioned medium, by 50% 
and 80% respectively, at 20 hr (Table 10). The formation of [
1251]-labelled TCA-soluble fbg 
peptides at 20 hr was inhibited by greater than 95% by the serine protease inhibitor PMSF (lmM) 
and by 98% by the serine protease inhibitor analogue, AEBSF ( lmM) (Table 10). Identical results 
were obtained when the [ 1251]-labelled fbg was degraded with either neutrophil cytoskeleton or 
neutrophil membrane fractions ( data not shown). 
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Table 10. Influence of inhibitors on the degradation of [1251)-l_abelled fibrinogen by ne~trophil co~ditioned 
medium. PMA-stimulated neutrophil conditioned medium from 5x 10 neutrophils was premcubated 
(37oc, 15 min) with various enzyme inhibitors whereafter the conditioned medium was incubated 
(37oc, 20 hr) with cl25I]-labelled fbg (2 mg). Degradation was measured as 10% (w/v) TCA-soluble 
peptides and was expressed as µg degraded ( 125I]-labelled fbg generated per ml. 
Degraded (1261]-labelled fibrinogen (µg/ml) 
Inhibitor Concentration Time 20 hr 
None 460 
MeOSuc(Ala)2ProValCH2CI 1 mM 230 
PMSF 1 mM 23 
a 1-antitrypsin 1.5 mg/ml 92 
AEBSF 1 mM 9 
5.A.2.2. Molecular size of the fibrinogen degrading protease 
Neutrophil membranes (200 µg), neutrophil cytoskeleton (200 µg) and PMA-stimulated 
neutrophil conditioned medium (from 50xI06 cells) were subjected to SDS-PAGE (3-13% non-
reduced). Gel slices of 2 mm thickness were then incubated with [ 1251]-labelled fbg ( I mg) and 
TCA-soluble peptide formation was monitored. Fibrinogenolytic activity of all three neutrophil 
fractions was recovered from gel slices corresponding to apparent molecular mass values of 50 I 
kDa, 398 kDa, 316 kDa and 209 kDa. Of the total proteolytic activity loaded, 13%, 40%, 30% and 
17% was recovered from these respective bands, following a 24 hr incubation of each gel slice with 
[ 1251]-labelled fbg. The bands at apparent molecular mass values 50 I kDa, 398 kDa, 316 kDa and 
209 kDa thus generated approximately 180 µg, 500 µg, 300 µg and 230 µg TCA-soluble [ 1251]-
labelled fbg peptides/ml, respectively, irrespective of the enzyme source. 
5.A.2.3. Functional assessment of the fibrinogen degradation products 
When thrombin is added to fbg, clotting is induced. The time taken for a clot to form is referred 
to as the thrombin clotting time and is dependent on the specific integrity of the fbg molecule 
(Gramse et al., 1977; Plow and Edgington, 1975). Clot formation of the intact [1251]-labelled fbg 
molecule (340 kDa), following the addition ofthrombin, was observed within 15 seconds while a 
notable, progressive increase in the thrombin clotting time was observed when the [ 1251]-labelled 
fbg was degraded by neutrophil conditioned medium (Table 11). A fbg product with an apparent 
molecular mass of330 kDa (30 min, Fig 9A), prolonged the thrombin induced clotting time to 25 
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sec (Table 11). Further reduction of the fbg molecule to an apparent molecular mass of310 kDa 
(1.5 hr, Fig 9A) caused the clotting time to be greater than 3 min (Table 11). When the fbg 
molecule was reduced to an apparent molecular mass of290 kDa (3hr, Fig 9A) no clot formation 
was observed following treatment with thrombin (Table 11 ). A similar prolongation of the 
thrombin clotting time was achieved when [ 125I]-labelled fbg was degraded by either neutrophil 
cytoskeleton or membrane fractions. Generation of fragment X (±240 kDa) by plasmin (Fig 14) 
prolonged the thrombin induced clotting time beyond 25 sec (Table 11 ). 
None of the [125I]-labelled fbg products, generated by either neutrophil conditioned medium, 
isolated cytokeletons or membranes, exhibited any anticoagulant activity. In contrast, the [ 1251]-
labelled fbg degradation products generated by plasmin, namely fragments Y, D and E, all exhibited 
anticoagulant activity and prolonged the thrombin-induced clotting activity of intact fbg beyond 3 
min (Table 11 ). 
Table 11. The thrombin clotting time of fibrinogen and fibrinogen degradation products of varying 
molecular mass. Fbg degradation products were generated by either PMA-stimulated neutrophil 
conditioned medium or plasmin, as described in the Materials and methods. Thrombin (2 i.u./10 
µI) was added to intact fbg and the fbg products and the thrombin clotting time was measured 
visually and expressed in seconds. 
-
Molecular mass of fibrinogen/fibrinogen products 
(kDa) 
Intact fibrinogen Conditioned Plasmin Thrombin clotting 
medium degradation time (sec) 
degradation 
-
340 - - 15 -
- 330 - 25 
- 310 - >180 
- 290 - NO CLOT 
- - ±240 (X) >25 
- - 155M >180 
- - 90 (D) >180 
- - 41 (E) >180 
-----Mr x 10-3 









Figure 14. The nature of the [1251)-labelled fibrinogen degradation products generated by plasmin. [ 1251]-
labelled fbg (1 mg) was incubated (37°C, 30 min) with urokinase-activated plasminogen (0.5 µg) in the 
presence of CaC12 (2 mM, track 1) or EGTA (10 mM, track 2), in a final volume of 1 ml. The nature of 
the [1251]-labelled fbg products were assessed by SOS-PAGE (5-20% non reduced) followed by 
autoradiography as described in the Materials and methods section. Fragments X, Y and D are 
indicated. Due to the transient nature of fragment X, two bands are indicated to be possible 
representatives of this product. Undigested [ 1251]-labelled fbg is indicated in track 3. 
Clot formation, following thrombin treatment, occurs through covalent crosslinks between the y 
chains to generate y-y dimers (from Mosesson, 1992). These y-y dimers migrate on SOS-PAGE 
(10% reduced) to a position corresponding to the apparent molecular mass of90 kDa (Fig 15). 
Degradation of the [1251]-labelled fbg molecule, by PMA-stimulated neutrophil conditioned 
medium, caused a progressive decrease in the generation of these y-y dimers, subsequent to the 
addition of thrombin, as observed by the gradual decrease in the radiolabelled band migrating to an 
apparent molecular mass of90 kDa (10% reduced SOS-PAGE) as degradation proceeded (Fig 
15). [1251]-labelled fbg products of apparent molecular mass 310 kDa, and larger (1.5 hr, Fig 9A) 
clearly formed y-y dimers (Fig 15). However, y-y dimer formation did not occur when fbg products 
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Figure 15. The ability of (1251]-labelled fibrinogen degradation products to form y-y crosslinks. [1251]-labelled 
fbg (I mg) was incubated (J7°C) with the conditioned medium from 5xl06 PMA-stimulated 
neutrophils, in a final volume of I ml. At the indicated time points, the cells were removed and 
thrombin (I i.u./10 µl) was added for 3 min at J7°C. y-y crosslink formation was assessed by SDS-
PAGE (10% reduced) followed by autoradiography, as described in the Materials and methods section. 
The formation of the y-y dimer at apparent molecular mass 90 kDa is indicated and y-y crosslink 
formation of undigested [1251]-labelled fbg is shown in the track marked Std. 
A similar inability to form y-y dimers was found following the degradation of [ 1251]-labelled fbg to 
a product of apparent molecular mass 290 kDa by neutrophil cytoskeleton and neutrophil 
membrane fractions (not shown). When [ 1251]-labelled fbg was digested with plasmin for 30 min, 
fragment X ( ±240 kDa) (Fig 14) was generated and visible fibrin clots with y-y dimer formation 
were produced on treatment with thrombin (not show~.). 
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5.A.2.4. Structure of the neutrophil-derived [1251)-labelled fibrinogen degradation products 
In order to determine the kinetics of degradation of the constituent chains of [ I25J]-labelled fbg 
by neutrophil conditioned medium as well as the size of these chains at various stages during 
degradation, the products were subjected to SDS-PAGE (10% reduced) followed by PAS staining 
and autoradiography (Fig I6A, Band C). Clarification of the kinetics was achieved by performing 
the autoradiography over both a 30 min and a 2.5 hr period (Fig 16A and B). Following a 5 min 
digestion period the intensity of the radio label associated with the Aa chain, migrating to an 
apparent molecular mass of72 kDa, was already markedly decreased (Fig 16A and B). This 
degradation period coincided with the generation of radio labelled bands migrating to positions at 
apparent molecular mass values of 45 kDa, 38 kDa, 28 kDa, 25 kDa and small, unresolved peptides 
at the front of the gel (Fig 16A and B). By 20 min no intact Aa chain (72 kDa) was detected. At I 
hr an additional band migrating to an apparent molecular mass of 42 kDa was noted and at 3 hr 
bands at apparent molecular mass values of 40 kDa and 32 kDa were also generated (Fig 16A and 
B ). The radio label associated with these three bands was then noted to decrease as degradation 
proceeded to 9 hr (Fig 16A and B). As the degradation period proceeded to 9 hr there was also a 
gradual decrease in intensity of the bands at apparent molecular mass values 72 kDa (Aa chain, 
completely degraded by 20 min), 58 kDa (B0 chain), 45 kDa, 28 kDa and 25 kDa. At the same 
time an initial (see 10 min time point) increase in the intensity of the radiolabel associated with the 
band at apparent molecular mass 58 kDa (B0 chain) was observed followed by the gradual 
decrease in intensity observed as degradation proceeded to 9 hr (Fig 16A and B ). A gradual 
increase in the intensity of the radiolabel associated with the band at apparent molecular mass of 48 
kDa (y chain) was noted as degradation proceeded to 9 hr and the intensity of the radiolabel ofthis 
band was only noted to decrease as degradation continued beyond 9 hr to 20 hr (Fig 16A and B ). 
At the end point of digestion (20 hr) the radiolabelled bands which were still visible were those 
migrating to apparent molecular mass values 48 kDa, 45 kDa, 42 kDa, 40 kDa, 38 kDa, 32 kDa 
and less than 25 kDa (Fig 16A and B). No intact B0 chain was detected at 20 hr. The intensity of 
the radiolabel associated with the band migrating to an apparent molecular mass of 48 kDa, at 20 
hr, was greater than that of they chain of undigested tbg (Fig 16A and B). This would seem to 
indicate the migration of a product from either the Aa or B0 chain, or both, to an apparent 

























Figure 16. Structure of the [ 1251)-labelled fibrinogen degradation products. The [ 1251]-labelled fbg degradation 
products, generated at various times (5 min to 20 hr) from [ 1251]-labelled fbg (2 mg) by the conditioned 
medium from 5xl06 PMA-stimulated neutrophils, as described in the Materials and methods, were 
subjected to SOS-PAGE (10% reduced) analysis. A: 2.5 hr autoradiographic exposure; B: 30 min 
autoradiographic exposure; C: products stained for carbohydrate using PAS. 
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Prior to digestion only the B J3 ( 5 8 kDa) and the y chains ( 48 kDa) stained with PAS (Fig l 6C ). 
During the digestion period from 5 min to 9 hr those bands with apparent molecular mass values of 
58 k:Da, 48 k:Da and 38 k:Da appeared to contain carbohydrate as they were also stained with PAS 
(Fig 16C). The intensity of the PAS staining, associated with the band migrating to the apparent 
molecular mass 48 k:Da (y chain), appeared to increase as degradation proceeded to 9 hr (Fig 16C). 
The 42 k:Da product generated at 20 hr also contained carbohydrate (Fig 16C). 
The presence of the inhibitors a1AT (1.5 mg/ml) or MeO-Suc-(Ala)i-Pro-ValCH2Cl (1 mM) in 
these reactions inhibited degradation of the [125I]-labelled fbg BJ3 and they chains by the 
neutrophil conditioned medium. Degradation of the Aa chain still occurred in the presence of 
MeO-Suc-(Ala)i-Pro-ValCH2Cl and occurred more slowly in the presence of a 1AT (Fig 17). 
Identical results, to those described above, were found if the enzyme source was from either the 
neutrophil cytoskeleton or membrane fractions (not shown). 
-~ 
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Figure 17. Effect of inhibitors on cU51]-labelled fibrinogen degradation by neutrophil conditioned medium. 
(1251]-labelled fbg (2 mg) was incubated (37°C) with conditioned medium from 5xI06 PMA-stimulated 
neutrophils, in the presence or absence of either MeO-Suc-(Ala)i-Pro-ValCH2Cl (1 mM) or a1 AT (1.5 
mg/ml). At 30 min and 20 hr the nature of the fbg degradation products was analysed by SOS-PAGE 
(10% reduced). A: nature of the products at 30 min, B: nature of the products at 20 hr. Track l : 
products generated in the absence of inhibitor, Track 2: products generated in the presence of MeO-Suc-
(Ala)i-Pro-ValCH2Cl (1 mM), Track 3: products generated in the presence of a 1AT (l.5 mg/ml). 
Undigested [1251]-labelled fbg is indicated in the track marked Std. 
I 
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5.A.2.5. H.p.Lc. analysis of the trichloracetic acid-soluble fibrinogen degradation products 
Hp.le. analysis of the TCA-soluble peptides, formed from a 20 hr digestion offbg by PMA-
stimulated neutrophil conditioned medium, was performed in order to identify N-terminal or C-
terminal Aa and Bf3 and y chain released peptides (Fig 18). C-terminal y chain peptides were 
sought as the peptides produced by the action of the neutrophil conditioned medium were shown to 
lack anticoagulant activity. Based on the known elution time of synthetic peptides corresponding to 
the amino acid sequence at positions 397-411, 400-411 and 402-411 from the N-terminus of they 
chain, peptides eluting between 23 and 27 min were identified. A peptide eluting at 25 min was 
found to have an amino acid composition corresponding to the amino acid sequence from position 
395-411 from the N-terminus of they chain (Table 12) (Fig 18A). This peptide was observed after 
a 5 min incubation of fbg with the neutrophil conditioned medium and reached a peak following a 3 
hr incubation period. 
Table 12. Amino acid analysis of the peptide with an elution time of 25 min. Gly-Glu-Gly-Gln-Gln-His-
His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val. This corresponds to residues 395-411 from the 
N-terminus of they chain offbg. 
Amino acid Residues found Theoretical value 
Asp 1.2 1 
Glu 4.3 4 
Gly 5.1 5 
Ala 2.0 2 
Val 1.0 1 
Leu 1.0 1 
Lys 1.3 1 
His 2.2 2 
Co-injection of synthetic FPA (Aa 1-16 peptide) and FPB (Bf3 1-14 peptide) with the TCA-soluble 
peptides revealed the absence of peptides with similar retention times to FPA and FPB in the 
peptide mixture (Fig 18A). The presence ofFPA- and PPB-containing fragments was determined 
by adding thrombin to the peptide mixture. Treatment of the TCA soluble peptides with thrombin 
resulted in the cleavage of three peptides with retention times of 37.6, 38.3 and 38.8 min and the 
generation of a peptide with a retention time equivalent to that ofFPA (Fig l8B). No generation of 
FPB was observed during this treatment with thrombin (Fig l 8B ). When the degradation mixture, 
prior to the precipitation of the larg~ molecular mass degradation products with TCA, was treated 
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with thrombin, peptides with equivalent retention times to both FP A and FPB were generated (Fig 
18C). The amount ofFPA generated in this manner (as judged by peak heights and area under the 
peak) appeared to equal the amount ofFPA generated when the TCA-soluble mixture was treated 
with thrombin (Fig 18B). When the peptides, from the TCA-soluble mixture, with retention times 
of37.6, 38.3 and 38.8 min were individually isolated and treated with thrombin, only the peptide 
with the retention time of38.3 min could generate FPA This peptide was observed in the TCA-
soluble peptide mixture after a 5 min incubation of fbg with the PMA-stimulated conditioned 
medium The amino acid composition of this peptide, with a retention time of38.3 min, was found 
to be identical to that of peptide Aal-21, based on the known amino acid sequence data for amino 
acids at positions 1-21 from the N-terminus of the Aa chain (Table 13). Due to the present 
supposition that the release of the Aal-21 peptide is a specific characteristic of the action of 
neutrophil granule elastase (Weitz et al., 1986) it was necessary to conduct further experiments to 
confirm that the Aal-21 peptide is also generated by a neutral membrane-associated neutrophil 
protease, distinct from granule elastase. Treatment of the TCA-soluble peptide mixture with HNE 
showed many of the peptides to be HNE sensitive, including those with the retention times of 37.6 
and 38.8 min (Fig l8D). The peptide with the retention time of 38.3 min was, however, resistant to 
digestion by HNE (Fig l8D). This was further confirmed by the isolation of this peptide and 
subsequent treatment with HNE. When the elastase specific inhibitor, MeO-Suc-(Ala)i-Pro-
ValCH2Cl (0.1 M), known to block Aal-21 formation by HNE (Weitz et al., 1986), was included 
in the reaction with neutrophil conditioned medium, several peptides, including the one with the 
retention time of38.3 min, were observed (Fig 18E). The amino acid composition of this peptide 
(eluted at 38.3 min) was confirmed to be that of Aal-21 (Table 13) and the yield of the peptide, 
determined by peak heights and area under the peak, was more than 98% of that in the absence of 
the inhibitor. In contrast, MeO-Suc-(Ala)i-Pro-ValCH2Cl (0.1 M) completely inhibited fbg 
digestion by HNE (Fig 18F). When undigested fbg was treated with HNE, many peptides were 
generated (Fig 18G) with retention times different to those generated by the neutrophil conditioned 
medium (Fig 18A). When these HNE generated peptides were treated with thrombin a peptide with 
a retention time of 38.3 min was cleaved and a peptide with a retention time equivalent to that of 
pure FPA was generated (Fig 18H). This HNE generated peptide, when isolated, co-eluted with 
the peptide with a retention time of38.3 min produced by neutrophil conditioned medium 
degradation offbg pre-(Fig ISA) and post-(Fig l8D) HNE treatment. 
Results identical to those described above were achieved when the enzyme source used to degrade 
fbg was either neutrophil cytoskeleton or neutrophil membrane preparations (not shown). 
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Table 13. Amino acid analysis of the peptide with an elution time of 38.3 min. Amino acid sequence: Ala-Asp-
Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg-Gly-Pro-Arg-Val-Val. This corresponds to 
residues 1-21 from the N-terminus of the Aa chain offbg. 
Amino acid Residues found Theoretical value 
Asp 1.9 2 
Ser 1.3 1 
Glu 2.1 2 
Pro 1.3 1 
Gly 6.2 6 
Ala 2.0 2 
Val 3.0 3 
Leu 1.0 1 
Phe 1.0 1 
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Figure 18. H.p.l.c. separation of the trichloractic acid-soluble fibrioogeo peptides. Unlabelled fbg (2 mg) was 
incubated (37oc, 20 hr) with conditioned medium from 5x106 PMA-stimulated neutrophils (a-e) or 
HNE (2 µg/rnl) (f-h) and the TCA-soluble peptides obtained were separated using a Cl8 reverse phase 
column (flow rate 1 ml/min) (as described in the Materials and methods section). An asterisk indicates 
the peptide with an elution time of 38.3 min containing a thrombin sensitive site. (a) Peptides generated 
by a 20 hr digestion period. ( J..) indicates the position at which a peptide with an amino acid composition 
corresponding to the amino acid sequence between positions 395-411 from the N-terminus of the y chain 
was eluted. (b) Effect of treating the peptides shown in (a) with thrombin (2 i.u./rnl, 1 hr, 37°C). FPA 
indicates the position at which the synthetic fibrinopeptide A would elute when co-injected with this 
peptide mixture. (c) Nature of the peptides generated by treating the 20 hr degradation mixture with 
thrombin (2 i.u./ml, 1 hr, 37°C) before stopping the reaction with TCA. FPA and FPB indicate the 
positions at which the synthetic fibrinopeptide A and B would be eluted when co-injected with the 
peptide mixture. (d) Treatment of the peptides shown in (a) with HNE (2 µg/rnl, 2 hr, 37°C). (e) 
Peptides generated [as described in (a)] in the presence of Me0-Suc-(Ala)2-Pro-ValCH2Cl (0.1 M). (f) 
Profile when the reaction contained HNE (2 µg/rnl) and MeO-Suc-(Ala)2-Pro-Va!CH2Cl (0.1 M). (g) 
Nature of the peptides generated by HNE during a 2 hr digestion period. (h) Treatment of the peptides in 
(g) with thrombin (2 i.u./ml, 1 hr, 37°C). FPA indicates the position at which a synthetic fibrinopeptide 
A would be eluted when co-injected with this peptide mixture. 
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5.A.3. DISCUSSION 
This study demonstrates the ability of a neutral, serine protease, associated with isolated 
neutrophil membranes, cytoskeletons and the conditioned medium from PMA-stimulated 
neutrophils, to cleave fbg, time and concentration dependently, to a non-clottable form. The fbg-
degrading protease within each of these three neutrophil fractions was found to migrate on SOS-
PAGE as four discrete bands of molecular mass values 209 k.Da, 316 k.Da, 398 k.Da and 501 k.Da. 
It has been proposed from our studies characterising this protease (see Chapter 4) that it may be 
located at sites of interaction of the membrane and the cytoskeleton. 
The high molecular mass fbg products generated by the action of this neutral protease from the 
three neutrophil fractions were found to be distinctly different, on the basis of molecular mass, to 
the fbg products generated by plasmin, neutrophil lysosomal enzymes and pure HNE. In addition, 
the terminal fbg products generated by the PMA-stimulated neutrophil conditioned medium were 
sensitive to plasmin digestion. In contrast to plasmin degradation, the generation of the terminal fbg 
products by the neutrophil conditioned medium was insensitive to the presence or absence of ca2+. 
Fibrinogenolysis by the three neutrophil fractions appeared to be a result of elastase-like proteolytic 
activity as this degradation was partially inhibited by the elastase inhibitors, MeO-Suc-(Ala)i-Pro-
ValCH2Cl and a 1AT. These inhibitors completely inhibited elastase degradation offbg (Weitz et 
al., 1986; Wright et al., 1988; Weitz et al., 1987; Weitz et al., 1992). No inhibition of the 
fibrinogenolytic activity of the neutrophil membranes, cytoskeleton and conditioned medium could 
be achieved with other elastase inhibitors or inhibitors of plasmin and cathepsin G. 
In the presence or absence of Ca Cl 2, simultaneous early cleavage of all three constituent chains of 
fbg, by the proteolytic activity associated with neutrophil membrane, cytoskeleton and conditioned 
medium fractions, gave rise to unclottable fbg products which do not exhibit anticoagulant activity. 
The initial prolongation ofthrombin clotting time was exhibited by a fbg degradation product with 
an apparent molecular mass of 330 k.Da which retains a partial capacity to form crosslinked fibrin. 
The prolongation of clotting time of this 330 k.Da fbg product appears to result from the 
degradation of the Aa chain to a molecular mass of 45 kDa, and partial cleavage of the Bf3 and y 
chains to molecular mass values of 48 k.Da and 38 k.Da, respectively. The inability to form y-y 
dimers and loss of coagulability, that is characteristic of the fbg degradation product with an 
apparent molecular mass of290 k.Da, is the result of extensive cleavage of the Aa, Bf3 and y chains 
to apparent molecular mass values of 42 k.Da, 48 k.Da and 32 k.Da respectively. This is in contrast 
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to tbg degradation by plasmin where the Aa chain is degraded rapidly followed by the BP chain 
and they chain is relatively resistant to degradation, especially in the presence of CaCl2. Also, the 
plasmin generated tbg terminal products exht'bit prolonged clotting times but are still able to form 
y-y dimers (Pizzo et al., 1972). 
As mentioned above, the tbg products generated by the neutrophil membrane-associated protease 
do not possess anticoagulant activity. Release of an Aal-21 peptide within 5 min of digestion 
suggests that degradation of the Aa chain occurs from the N-terminus. On the other hand, the 
observation that FPB can be released from the high molecular mass split products at the end point 
of digestion and the detection of a 17 amino acid C-terminus y chain peptide indicates 
fibrinogenolysis to occur from the C-terminal regions of the Bf3 and y chains. Such proteolysis of 
the Aa chain could account for the products lacking anticoagulant activity as the Aal-21 peptide 
does not act as a competitive inhibitor of the action ofthrombin on intact fbg (Larrieu et al., 1972) 
and the C-terminal Gly-Pro-Arg-Val-Val sequence of the peptide has been shown to bind poorly to 
the primary polymerisation site on intact fbg (Laudano and Doolittle, 1980). l11e release of the 17 
amino acid y chain peptide was achieved by the cleavage of the bond between amino acids Ile and 
Gly at positions 394 and 395 from the N-terminus of they chain by the neutrophil membrane-
associated protease. Although no attempt was made to detect other y chain peptides released, 
particularly a peptide containing the primary fibrin polymerisation site at y-363 (Shimizu et al., 
1992; Yamazumi and Doolittle, 1992), such a peptide may have been proteolytically removed. This 
is tenable since the neutrophil membrane protease has been shown to cleave bonds between Ala and 
Ser (Shephard et al., 1990) which are found at positions 357 and 358 from the N-terminus of they 
chain. It is possible, however, that removal of the 17 amino acid peptide may be sufficient for loss 
of the appropriate structural configuration required for binding of they chain to complementary 
sites on the E domain of the fibrin monomer (Olexa et al., 1981), which would account for the lack 
of anticoagulant activity of the degradation products. It has been shown that y chain peptides 3 7 4-
411 and 374-396 do not act as anticoagulants (Varadi and Scheraga, 1986). 
In contrast, plasmin mediated fibrinogenolysis occurs from the C-terminus of the Aa chain, the N-
terminus of the Bf3 chain, with they chain being relatively resistant to degradation, and generates 
products with anticoagulant activity (Pizzo et al., 1972; Doolittle, 1984; Ferguson et al., 1975; 
Yamazumi and Doolittle, 1992; Varadi and Scheraga, 1986). Degradation offbg by the neutrophil 
membrane-associated proteas~ is also in contrast with that of neutrophil lysates and purified HNE 
which cleave all three fbg chains from the N-terminus. Fbg products generated by the neutrophil 
lysate were also able to inhibit fibrin polymerisation (Bilezikian and Nossel, 1977; Gramse et al., 
1977; Plow and Edgington, 1975). 
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Several studies have concluded that HNE is solely responsible for the formation of an Aa 1-21 
peptide found in the serum of normal individuals and patients with a 1 AT deficiency and this 
peptide has since been used as an assay for HNE activity in these a 1 AT deficient patients (Weitz et 
al., 1986; Weitz et al., 1987; Weitz et al., 1992). This study confirms the ability of pure HNE to 
generate this thrombin sensitive FPA-containing peptide and also demonstrates that an identical 
peptide can be generated by the proteolytic activity associated with the neutrophil membrane. The 
formation of this peptide by the neutrophil membrane-associated protease was insensitive to the 
inhibitor MeO-Suc-(Ala )z-Pro-ValCH2Cl that has been shown in several studies, and now 
confirmed here, to completely inhibit HNE formation of the Aal-21 peptide (Weitz et al., 1986; 
Wright et al., 1988; Weitz et al., 1987; Weitz et al., 1992). The study of Weitz et al. (1987) also 
showed the generation of the Aal-21 peptide, via an HNE-insensitive pathway, when non-
stimulated neutrophils were incubated with fbg coated filters. This may be due to the action of the 
neutrophil membrane protease as it exhibits activity in non-stimulated neutrophils (Shephard et al., 
1989 ). It is, therefore, tenable that the existence of the Aa 1-21 peptide in plasma may not be a 
specific marker of neutrophil granule associated elastase as previously believed (Weitz et al., 1986; 
Wright et al., 1988; Weitz et al., 1987). 
Only the bond between amino acids Val-21 and Glu-22 from the N-terminus of the Aa chain seems 
to be sensitive to both HNE and the proteolytic activity of the neutrophil membrane. Other elastase 
specific sites in fbg appear to be markedly different to those susceptible to cleavage by the 
neutrophil membrane-associated protease. This is concluded from the finding that the size of the 
high molecular mass degradation products and the h.p.lc. profiles of the low molecular mass 
peptides, generated by each of these two proteases, are different. 
5.B. ASSOCIATION OF FIBRINOGEN WITH NEUTROPHILS AND THE 




The interaction ofneutrophils with fbg, which is associated with the process of fibrin deposition, 
is regulated by membrane cytoadhesive receptors of the P2 and p3 integrin families (Wright et al., 
1988; Loike et al., 1991; Diamond and Springer, 1993; Gresham et al., 1992; Zhou and Brown, 
1993 ). The integrin adhesion molecules are composed of non-covalently associated subunit pairs, 
designated a and P, that mediate cell-matrix and cell-cell adhesion processes (Smyth et al., 1993). 
The integrins are classified according to the P subunit which may associate with one or more a 
subunits. The leukocyte specific or P2 integrins have a common P subunit (CD18) which may 
associate with one of three a subunits, CD 11 a, CD 11 b and CD 11 c, to form the heterodimers 
CDI la/CD18 (LFA-1), CDl lb/CD18 (CR3, Mac-1) and CD1 lc/CD18 (pl50,95) (Fig 4) (Smyth 
et al., 1993). Recently neutrophils have been shown to possess a novel integrin receptor described 
as the leukocyte response integrin (LRI) which is most immunologically related to the p3 integrin 
family (Gresham et al., 1992; Zhou and Brown, 1993). Depending on the stimulus, different 
integrin receptors on the neutrophil may interact with different specific fbg recognition sequences 
contained within both soluble and immobilised fbg. Various stimuli which have been investigated 
include TNF-a and FMLP (Wright et al., 1988; Loike et al., 1991; Diamond and Springer, 1993; 
Zhou and Brown, 1993). Fbg recognition sequences which bind to these integrin receptors have 
thus far been identified to include R-G-D, G-P-R and K-Q-A-G-D-V (Wright et al., 1988; Loike et 
al., 1991; Gresham et al., 1992; Altieri et al., 1988; Altieri et al., 1993). 
This study attempts to identify the neutrophil receptor which interacts with fbg leading to its 
degradation by a neutrophil membrane-associated protease. The association of fbg with the 
neutrophil surface, with concomitant degradation, will be characterised and the nature of the fbg 
associated with the neutrophil and the consequence of such association on subsequent neutrophil 
interactions with immobilised fbg will also be examined: 
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5.B.2. RESULTS 
5.B.2.1. Degradation of [1251]-labelled fibrinogen by neutrophils 
Degradation of [ 1251]-labelled fbg was obseived upon incubation with both PMA-stimulated and 
non-stimulated neutrophils (5x106) and the conditioned medium from PMA-stimulated and non-
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Figure 19. Degradation of [1251)-labelled fibrinogen by neutrophils and neutrophil conditioned medium. 
Reactions ( I ml) contained [ 1251]-labelled fbg (1 mg) and either PMA-stimulated (0) or non-
stimulated neutrophils (5xl06) (0) or the conditioned medium from PMA-stimulated (•) or non-
stimulated neutrophils (5xl06) (•). Degradation ·was measured as 10% (w/v) TCA-soluble peptides at 
the indicated time points and was expressed as µg [ 1251]-labelled fbg/ml. Ten experiments gave results 
within 10% of these. 
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The generation ofTCA-soluble [1251]-labelled fbg peptides by PMA-stimulated neutrophils at 60 
min was, however, 3.6 times greater than that by the PMA-stimulated neutrophil conditioned 
medium while non-stimulated neutrophils generated approximately 9 times more TCA-soluble 
products than the conditioned medium from these cells at 60 min (Fig 19). Neutrophil-mediated 
degradation offbg was increased 1.3 times by stimulating the cells with PMA and the generation of 
TCA-soluble [ 1251]-labelled fbg peptides by the PMA-stimulated conditioned medium at 60 min 
was 3 times greater than that of the conditioned medium generated from non-stimulated cells (Fig 
19). Incubation of [1251]-labelled fbg with PMA-stimulated neutrophils or the conditioned medium 
from these cells yielded TCA-soluble [ 1251]-labelled fbg degradation products within 2 min (Fig 
19). Results within 1 % of those shown in Fig 19 were found with 10 different batches of 
neutrophils. The neutrophil-mediated degradation occurred faster in the presence of Ca2+ whereas 
the conditioned medium degradation was not affected by the chelation of ca2+ (Table 14 ). SDS-
PAGE (5-20% non-reduced and 5-20% reduced) analysis revealed that the apparent molecular 
mass of the [1251]-labelled fbg products generated by PMA-stimulated and non-stimulated 
neutrophils were identical to those generated by the neutrophil conditioned medium from PMA-
stimulated and non-stimulated cells (Fig 20A and B) The time course of [ 125 I]-labelled fbg 
degradation depicted in Fig 20B confirms the increased degradation rate of [ 1251]-labelled fbg in 
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Figure 20. The nature of [1251]-labelled fibrinogen degradation products generated by neutrophils and 
neutrophil conditioned medium in the presence and absence of PMA [125I)-labelled fbg (1 mg) was 
incubated (37°C) with either PMA-stimulated or non-stimulated neutrophils (5x106) or the conditioned 
medium from either PMA-stimulated or non-stimulated neutrophils (5x106). The [125I]-labelled fbg 
products thus generated were analysed by SOS-PAGE followed by autoradiography, as described in the 
Materials and methods. (A) SOS-PAGE (5-20% non-reduced) indicating [125I]-labelled fbg 
degradation at 30 min. Track 1: non-stimulated neutrophil-mediated degradation, track 2: PMA-
stimulated neutrophil-mediated degradation, track 3: non-stimulated conditioned medium degradation 
and track 4: PMA-stimulated conditioned medium degradation. Track 5: Undigested [125I]-labelled fbg. 
(B) SOS-PAGE (5-20% reduced) indicating PMA-stimulated neutrophil-mediated degradation and 
PMA-stimulated neutrophil conditioned medium degradation of ( 1251)-labelled fbg occurring over a 
period of 30 min to 3 hr. Undigested [ 1251)-labelled fbg is indicated in the track marked Std. 
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Table 14. The influence of ca2+ on the degradation of [1251)-labelled fibrinogen. PMA-stimulated and non-
stimulated neutrophils (5x106) and the conditioned medium from 5xl0
6 PMA-stimulated and non-
stimulated neutrophils were incubated (37°C) with [ 1251]-labelled fbg (1 mg) in the absence or 
presence of EGI' A (10 mM). Degradation was measured at 30 min and 3 hr as 100/o (w/v) TCA 
[ 1251]-labelled fbg peptide formation and was expressed as µg/ml. 
Degraded [1261]-labelled fibrinogen (µg/ml) 
NEUTROPHILS 
+PMA -PMA 
Time (min) + Ca2+ - Ca
2
+ + Ca2+ C 2+ - a 
30 83 29 54 18 
180 420 280 300 53 
CONDITIONED MEDIUM 
30 36 35 13 18 
180 180 170 25 26 
Degradation of [1251]-labelled fbg by PMA-stimulated neutrophils was inhibited by 86%, 50% and 
98% by a1AT (1.5 mg/ml), MeO-Suc-(Ala)z-Pro-ValCHzCl (lmM) and AEBSF (lmM), 
respectively, within a 30 min period (Table 15). No inhibition of [1251]-labelled fbg by PMA-
stimulated neutrophils was noted with leupeptin (20 µM) (Table 15). A similar inhibition of 
degradation by non-stimulated neutrophils was obtained with these inhibitors (not shown). 
Table 15. Influence of inhibitors on the degradation of [1251]-labelled fibrinogen by PMA-stimulated 
neutrophils. PMA-stimulated neutrophils (5xl0
6
) were preincubated (37°C, 15 min) with various 
enzyme inhibitors whereafter the neutrophils were incubated (37°C, 30 min) with [ 
1251]-labelled 
fbg (1 mg). Degradation was measured as 100/o (w/v) TCA [ 1251]-labelled fbg peptide formation 
and was expressed in µglml. 
Degraded (1261]-labelled fibrinogen (µg/ml) 
Inhibitor Concentration Time 30 min 
None 138 
Me0SucA1a2Pr0ValCH2CI 1mM 69 
a1-antitrypsin 1.5 mg/ml 19 
Leupeptin 20µM 138 
AEBSF 1 mM 2 
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The rate of PMA-stimulated neutrophil-mediated degradation of [1251]-labelled fbg was reduced, 
at 30 min, by 75% by the kinase inhibitors TFP (20 µM) and H7 (50 µM) (Table 16). The 
generation of [ 1251]-labelled fbg degradation products by PMA-stimulated neutrophils was 
inhibited by 65% by 1-(5-chloronaphthalene-1 sulphonyl)-lH-hexahydro-1,4-diazepine (ML-9, 20 
µM) (Table 16). No inhibition of PMA-stimulated neutrophil-mediated degradation of [1251]-
labelled fbg was obseived with the protein kinase C inhibitor, bisindolylmaleimide (Table 16). 
These inhibitors did not affect the viability of the cells. 
The percentage inhibition of [ 1251]-labelled fbg degradation by non-stimulated neutrophils was 
identical to that obseived with the PMA-stimulated cells, for all the kinase inhibitors tested (Table 
16). 
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Table 16. Influence of kinase inhibitors on neutrophil-mediated degradation of [ ll
5IJ-labelled fibrinogen. 
Reactions (1 ml) contained (1251]-labelled fbg (1 mg) and either PMA-stimulated or non-stimulated 
neutrophils (5xI06) that had been preincubated (37°C) for 15 min with or without the indicated 
inhibitor. Degraded fbg, measured at the indicated times as 10% (w/v) TCA-soluble peptides, was 
expressed as µg degraded ( 1251]-labelled fbg/ml. Results are from a representative experiment. 
Degraded fibrinogen (µg/ml) 
+PMA -PMA 
Time (min) 2 10 30 2 10 30 
Inhibitor 
None 20 60 138 16 34 95 
ML-9 (20 µM) 15 20 48 8 11 32 
TFP (20 µM) 5 12 35 4 7 24 
H7 (50 µM) 6 13 34 5 5 23 
Bisindolylmaleimide (2 µM) 20 60 138 16 34 95 
5.B.2.2. Influence of [1251]-labelled fibrinogen on proteolytic activity in the extracellular 
medium during cellular degradation. 
Degradation of [125I]-labelled tbg by both PMA-stimulated and non-stimulated neutrophils is 
notably faster than that of the conditioned medium prepared from these cells (Fig 19). A release of 
proteolytic activity into the extracellular medium during the incubation of neutrophils with tbg 
could account for this obseIVation. To investigate this possibility, the rate at which [125I]-labelled 
tbg continues to degrade, following the removal of the cells, was compared with that by PMA-
stimulated cells and PMA-stimulated neutrophil conditioned medium. When the incubation period 
of PMA-stimulated neutrophils with [ 125I]-labelled tbg was less than 30 min, degradation of 
[ 125I]-labelled tbg in the extracellular medium was slower than that in the presence of cells, but 
faster than that by PMA-stimulated neutrophil conditioned medium (Table 17). However, if the 
incubation period of cells with [ 125I]-labelled tbg was longer than 30 min, prior to removal of the 
cells, the rate of extracellular degradation was equal to that in the presence of cells (Table 17). 
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Similarly, [ 1251]-labelled fbg is able to mediate the release of fbg-degracling activity from non-
stimulated neutrophils. As for the stimulated cells, a 30 min incubation period of [ 1251]-labelled fbg 
with non-stimulated neutrophils resulted in the degradation of [ 1251]-labelled fbg in the cell free 
medium being equal to that in the presence of non-stimulated neutrophils and greater than that of 
the conditioned medium from non-simulated neutrophils (Table 17). 
Table 17. Proteolysis of [1251]-labelled fibrinogen in the extracellular medium during neutrophil 
association with fibrinogen. Reactions (1 ml) contained [ 1251)-labelled fbg (1 mg) and either the 
conditioned medium from 5x l 06 neutrophils (PMA-stimulated and non-stimulated) or 5x l 06 
neutrophils (PMA-stimulated or non-stimulated). Degradation was measured as l 0% (w/v) TCA-
soluble peptides and expressed as µg [ 1251]-labelled fbg/rnl. Neutrophil-mediated or conditioned 
medium degradation was measured at the indicated times ( .. ). Degradation in the extracellular 
medium, obtained by removing the cells from the neutrophil-mediated reaction at various times 
(••), was measured at the indicated times (*). 
Degraded fibrinogen (µg/ml} 
+PMA 
Conditioned Neutrophil Extracellular Medium 
Medium Mediated 
Time 20* 30 40 60 90 
2 .. 6 12 60 70 90 120 130 
10 18 60 80 100 120 140 170 
20 25 110 - 120 130 160 190 
30 32 140 - - 170 210 240 
40 44 170 - - - 220 240 
60 60 220 - - - - 240 
-PMA 
2 5 10 40 45 60 80 110 
10 8 35 50 80 90 130 150 
20 11 77 - 90 90 130 160 
30 14 90 - - 120 140 190 
40 18 120 - - - 180 210 
60 20 180 - - - - 210 
148 
5.B.2.3. Influence of AEBSF on the association of [1251]-labelled fibrinogen with neutrophils 
The association of [ 125I]-labelled fbg with non-stimulated and PMA-stimulated neutrophils 
was investigated in the presence and absence of the inhibitor AEBSF. The serine protease 
inhibitor, AEBSF (1 mM), has been demonstrated to inhibit neutrophil-mediated degradation of 
[1251]-labelled fbg by 98% (see above). 
In the absence of AEBSF, the association of [1251]-labelled fbg with neutrophils (5x106) was fast, 
occurring as early as 2 min (Fig 21). The association of [1251]-labelled fbg with PMA-stimulated 
neutrophils was far greater than the association with non-stimulated neutrophils and reached a 
steady state within 30 min (Fig 21) via a saturable process, as shown by concentration dependence 
cmves (Fig 22A). Over the concentration range of [1251]-labelled fbg offered to the neutrophils, 
the non-specific association of [ 1251]-labelled fbg with the neutrophils, in the presence of a 100 
fold molar excess of unlabelled fbg, varied from 2-11 % of the total [ 1251]-labelled fbg associated 
with the cells. Specific association was calculated by subtracting the non-specific association from 
the total [ 1251]-labelled fbg associated with the cell. When 1 mg of [ 1251]-labelled fbg was offered 
to 5xl06 non-stimulated or PMA-stimulated cells in 1 ml and in the presence of Ca2\ the specific 
association reached a steady state. At saturation 600 ng [1251]-labelled fbg was associated with 
5xl 06 PMA-stimulated neutrophils with half-maximal saturation occurring at 200 µg [ 1251]-
labelled fbg/ml (Fig 22A). This association of [1251]-labelled fbg with PMA-stimulated neutrophils, 
was not influenced in the absence of Ca2+·. By contrast, at 30 min only 290 ng [ 1251]-labelled fbg 
was associated with 5xl06 non-stimulated neutrophils at saturation and in the presence of Ca2\ 
with half-maximal saturation occurring at 260 µg [ 1251]-labelled fbg/ml (Fig 22A). These results 
varied by less than 10% for 10 different experiments. 
In the presence of the serine protease inhibitor AEBSF (lmM) less [1251]-labelled fbg associated 
specifically and saturably with PMA-stimulated neutrophils than in the absence of AEBSF (Fig 
22A). Similar to the situation in the absence of AEBSF, a steady state was reached in 30 min, but 
in the presence of AEBSF (1 mM) only 400 µg [1251]-labelled fbg/ml was required to reach this 
saturation. At saturation 80 ng [1251]-labelled fbg was associated with 5x106 PMA-stimulated 
neutrophils with half-maximal saturation occurring at-78 µg [1251]-labelled fbg/ml (Fig 22A). By 
contrast, association of [1251]-labelled fbg with the non-stimulated neutrophils, in the presence of 
AEBSF (1 mM), reached saturation at 1 mg [1251]-labelled fbg, but at saturation the amount of fbg 
bound was only marginally less than that with the PMA-stimulated neutrophils (Fig 22A). 75 ng 
[1251]-labelled fbg was associated with 5xl06 non-stimulated neutrophils at saturation with half.. 
maximal saturation occurring at 330 µg [1 251]-labelled fbg/ml (Fig 22A). Four different experiments 
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Figure 21. Specific association of [1251]-labelled fibrinogen with neutropbils occurring over time. [1251]-
labelled fbg (I ml) was incubated (37°C) with either PMA-stimulated (•) or non-stimulated (0) 
neutrophils (5xl0 ). At the indicated times over a period from 2 to 60 min, the reactions were stopped 
and the specific association of [ l251]-labelled fbg was calculated as described in the Materials and 
methods. Each value is the mean of duplicates which did not differ by more than 10%. Ten experiments 
gave results within 10% of these. 
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Figure 22. Specific association of i1251]-labelled fibrinogen with PMA-stimulated neutrophils as a function of 
concentration. A. [ 12 !]-labelled fbg was incubated (37°c, 30 min) with either PMA-stimulated 
neutrophils (5xl06) in the absence (0) or presence (0) of the inhibitor AEBSF (1 mM) or non-
stimulated neutrophils 1sxl06) in the absence (• ) or presence (• ) of the inhibitor AEBSF (1 mM). Specific association of [ 25I]-labelled tbg was calculated as described in Methods. Each value is a mean 
of duplicates which did not differ by more than 10%. B. PMA-stimulated neutrophils (5x106) were 
incubated (37oC) with [ 125I]-labelled fbg (1 mg) in a final volume of 1 ml and the cell associated 
[ 1251]-labelled fbg was analysed by SDS-PAGE (5-20% non-reduced) at 2, 12 and 30 min. 
5.B.2.4. Nature of the [1251]-labelled fibrinogen degradation products associated with the 
neutrophil 
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The nature of the [1251]-labelled fbg degradation products associated with PMA-stimulated 
neutrophils, in the absence of AEBSF, was ascertained by SOS-PAGE (5-20%, non-reduced) 
followed by autoradiography. No intact fbg was found to be associated with the cell. The [ 1251]-
labelled fbg degradation products observed to be associated with the neutrophil appeared to have 
apparent molecular mass values of 30 k.Da or less (Fig 22B ). Products with identical molecular 
mass values were found to associate with the non-stimulated neutrophils (not shown). 
5.B.2.5. Influence of fibrinogen degradation products on the association of [1251]-labelled 
fibrinogen with PMA-stimulated neutrophils 
Since the size of the degradation products associated with non-stimulated and PMA-stimulated 
neutrophils were identical, the specificity of the interaction of the neutrophil derived [1251]-labelled 
fbg degradation products, with apparent molecular mass values of 30 k.Da and less, with PMA-
stimulated neutrophils was investigated. To accomplish this, the ability of TCA-soluble fbg 
products to competitively inhibit the association of [1251]-labelled fbg with PMA-stimulated 
neutrophils, in the absence of AEBSF, was assessed. It was found that, when used at a 
concentration of25 µg/ml, the unlabelled fbg degradation products inhibited the association of 
[1251]-labelled fbg (600 ng/5xl06 cells) with PMA-stimulated neutrophils by 50% (Fig 23). The 
fbg degradation products were, however, not shown to have any effect on the degradation of the 
intact [1251]-labelled fbg. 
In an attempt to identify specific fbg sequences capable of associating with the neutrophil surface, 
various synthetic fbg peptides were included in the incubation of [ 1251]-labelled fbg with PMA-
stimulated neutrophils, in the absence of AEB SF. No modulation of the association of ( 1251]-
labelled fbg degradation products with neutrophils was observed when the synthetic peptides ( all at 
1 mg/ml) G-P-R-P, R-G-D-S, and HlO, Hl2 or Hl5 (corresponding to residues 399-411, 400-411 
and 398-411 of they chain respectively, all including the K-Q-A-G-D-V sequence), FPA (Aa 1-16) 
and FPB (B ~ 1 -14) were present in the reaction. 
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Figure 23. Influence of the neutrophil-derived fibrinogen degradation products on the association of [
12511-
labelled fibrinogen with PMA-stimulated neutrophils. PMA-stimulated neutrophils (5x 106) were 
incubated (37°c, 30 min) with [ 1251]-labelled fbg (I mg) in the absence and presence of neutrophil-
derived fbg products (0-100 µg) in a final volume of 1 ml. Neutrophil associated [1251]-labelled fbg in 
the presence of fbg products is expressed as a percentage of neutrophil-associated [ 1251]-labelled fbg in 
the absence offbg degradation products (control, 600 ng/5x106 cells, 30 min). Values are the mean of 
duplicates which did not differ by more than 10%. This experiment is representative of three separate 
experiments. 
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5.B.2.6. Influence of monoclonal antibodies on PMA-stimulated neutrophil association and 
degradation of [1251]-labelled fibrinogen 
In order to elucidate the neutrophil receptor involved in the association of [ 1251]-labelled fbg and 
neutrophil-derived [1251]-labelled fbg degradation products with PMA-stimulated neutrophils, 
monoclonal antibodies directed against known neutrophil receptors were investigated. These 
experiments were conducted in the absence and presence of AEBSF ( I mM). The monoclonal 
antibodies used were directed against CD16 (the neutrophil low avidity Fe receptor), CDI la, 
CDI lb, CDI le, CD18 and the intact gpllb/illa complex (CD4la). The concentration of 
monoclonal antibodies required to saturate these receptors on PMA-stimulated neutrophils was 
determined by flow cytometry. 
When saturating concentrations of the monoclonal antibodies against CD 16, CD 11 a, CD 11 b, 
CDI lc and CD18 were preincubated with PMA-stimulated neutrophils, in the absence of AEBSF, 
inhibition of the association of[125I]-labelled fbg with the neutrophils was noted (Table 18). The 
monoclonal antibodies ( obtained from Sanbio) directed against CD 16, CD 11 a, CD 11 b, CD I le and 
CD18 inhibited the specific association of [1251]-labelled fbg (600 ng/5xlo6 cells at 30 min, Fig 
22) by 25%, 31 %, 35%, 46% and 10%, respectively. The monoclonal antibodies directed against 
CD 11 a, CD 11 c and CD 18 (manufactured by Serotec) inhibited the specific association of [ 125 !]-
labelled fbg with PMA-stimulated neutrophils by 40%, 30% and 10%, respectively (Table 18). 
Monoclonal antibodies OKM 1 and OKM IO ( directed against CD 11 b) inhibited this specific 
association by 22% and 18%, respectively, and no inhibition was achieved with saturating 
concentrations of monoclonal antibodies directed against CD41a (Sanbio) (Table 18). Two 
different monoclonal antibodies recognising two different epitopes of CD41 a gave the same result. 
A combination of OKMl, OKMlO and antibodies to CD18, CDl la, CDI lb and CDl lc inhibited 
the association of [1251]-labelled fbg with the neutrophils by 60% (Table 18). 
No modulation of the association of [ 1251]-labelled fbg with either non-stimulated or PMA-
stimulated neutrophils in the presence of AEBSF (1 mM) (80 ng/5xl06 neutrophils in 30 min, Fig 
22) could be achieved with any of the monoclonal antibodies tested. 
Only the monoclonal antibody directed against CDllc (from Sanbio and Serotec) was shown to 
have any modulatory effect on the degradation of [1251]-labelled fbg by the PMA-stimulated 
neutrophils (Table 18). In the absence of the anti-CDllc and AEBSF, 140 µg TCA-soluble [1251]-
labelled fbg peptides were generated from 1 mg [1251]-labelled fbg by 5xlo6 PMA-stimulated 
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neutrophils, in 30 min. In the presence of the anti-CD1 le (and the absence of AEBSF), 30 µg 
TCA-soluble [1251]-labelled fbg peptides were generated by 5x106 PMA-stimulated neutrophils, in
 
30 min (Table 18). Thus, in the presence of the monoclonal antibody directed against CD1 le the 
PMA-stimulated neutrophil-mediated degradation of[l25I]-labelled fbg is reduced to a rate similar
 
to that of neutrophil conditioned medium (Fig 19 ). When the antibody to CD 11 c and AEB SF 
(lmM) were both present in the reaction, degradation of[l25I]-labelled fbg by PMA-stimulated 
neutrophils was inhibited by 100%. None of the other monoclonal antibodies tested altered the rate
 
ofneutrophil-mediated [1251]-labelled fbg degradation (Table 18). 
Table 18. Influence of monoclonal antibodies, directed against various neutrophil receptors, on
 PMA-
stimulated neutrophil association and degradation of [1251]-labelled fibrinogen. [1251]-
labelled fbg (1 mg) was incubated (37°C, 15 min) with PMA-stimulated neutrophils (5xl06) and 
monoclonal antibodies (from Sanbio or Serotec) to various neutrophil receptors, in the presence 
and absence of the inhibitor AEBSF (l mM). In one instance (*) a combination of antibodies 
directed against CD1 la, CDllb, CDllc and CD18 were used (as described in the Materials and 
methods). The specific association of [ 1251]-labelled fbg with the neutrophils was expressed in 
ng/5xl06 neutrophils and the degradation was measured as 10% (w/v) TCA-soluble [1251]-
labelled fbg peptide formation and expressed as µg/ml. 
ng bound fibrinogen bound degraded fibrinogen 
/5x106 cells {µg/ml} 
+AEBSF -AEBSF +AEBSF -AEBSF 
Monoclonal Serotec Serotec Sanbio Serotec or Serotec or 
Antibody or Sanbio Sanbio Sanbio 
anti-CD11a 80 360 414 3 140 
anti-CD11 b 80 - 390 3 140 
anti-CD11 c 80 420 325 0 30 
anti-CD18 80 540 540 3 140 
OKM1 80 - 468 3 140 
OKM10 80 - 492 3 140 
All of above * 80 - 240 3 140 
anti-CD41a 80 - 600 3 140 
anti-CD16 80 - 450 3 140 
None 80 600 600 3 140 
5.B.2. 7. The effect of the neutrophil-derived fibrinogen products on PMA-stimulated 
neutrophil adherence to immobilised fibrinogen 
In the absence of AEBSF, and any neutrophil derived fbg products, 60% of the total number of 
neutrophils offered (2xl06) adhered to the immobilised fbg. The neutrophil-derived fbg products, 
of molecular mass 30 kDa and less, concentration dependently inhibited the adherence of [51 Cr]-
labelled neutrophils to immobilised fbg. Half maximal inhibition was achieved with 25 µg 
peptide/ml (Fig 24). 
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Figure 24. Influence of the neutrophil-derived fibrinogen degradation products on the adherence of [SlcrJ-
labelled neutrophils to immobilised fibrinogen. [5 1cr]-labelled neutrophils (2x 106) were 
preincubated (37°C, 30 min) with TCA-soluble fbg peptides at a concentration range of 0-50 µg/ml, as 
described in the Materials and methods. The neutrophils (2xl06) were stimulated with PMA (5 ng/ml) 
and incubated (37°C, 30 min) with immobilised fbg. In the absence of the fbg degradation products 
O. llxl06 PMA-stimulated neutrophils attached/fbg coated well and association, in the presence of the 
fbg products, was expressed as a percentage of this control figure. Values are the mean of quadruplicates 




The interaction of neutrophils with immobilised and soluble fbg has been the topic of a
 number of 
investigations (Wright et al., 1988; Loike et al., 1991; Diamond and Springer, 1993; Gres
ham et 
al., 1992; Zhou and Brown, 1993). A major feature of the interaction ofneutrophils with 
immobilised fbg is the cleavage of the N-terminus of the Aa chain by elastase to gener
ate the Aal-
21 peptide (Wright et al., 1988). Studies describing the interaction of neutrophils with solu
ble fbg 
have not addressed concomitant degradation of this ligand. 
This study demonstrates that fbg is degraded during an incubation of soluble [ l 25I]-lab
elled fbg 
with neutrophils. A neutrophil-mediated proteolytic process appears to contribute sign
ificantly to 
this process since fibrinogenolysis in the presence of cells was consistently faster than t
hat by the 
neutrophil conditioned medium. As degradation of the ligand could be detected as earl
y as 2 min 
upon incubation of fbg with neutrophils, the neutrophil-mediated fibrinogenolysis is lik
ely to be due 
to a membrane-associated protease rather than internal cellular metabolism. Incubation
 of fbg with 
neutrophils caused considerable activation of the membrane-associated proteolytic acti
vity per se 
with further activation being achieved by stimulating the cells with PMA. By contrast, 
CRP, which 
is another substrate for this membrane-associated protease (see Chapter 4, Shephard e
t al., 1989), 
did not significantly upregulate this protease during association of CRP with non-stimu
lated 
neutrophils. Considerable activation was, however, observed during association of CR
P with PMA-
stimulated cells (see Chapter 4, Shephard et al., 1989). Upregulation of the activity of a ne
utrophil 
surface-associated protease by both acute-phase and normal HDL has been demonstra
ted in a study 
investigating the interaction of HDL with neutrophils (Shephard et al., 1987). 
The apparent molecular mass of the fbg degradation products generated by neutrophils
 and 
neutrophil conditioned medium were similar. The fibrinogenolytic activity of the neutro
phil 
conditioned medium has been shown (Chapter 5.A.) to be due to a high molecular mas
s membrane-
associated protease which is released from the cell during the preparation of the condit
ioned 
medium (Chapter 4). Thus, degradation offbg during_its incubation with neutrophils is
 more than 
likely the result of the activation of this membrane-associated protease. The results in C
hapter 4 
suggested that the membrane-associated protease may be a submembrane protease loc
alised at sites 
of attachment of the cytoskeleton with the cell membrane. 
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The up regulation of the activity of the neutrophil membrane-associated protease, that occurs 
following the interaction of fbg with neutrophils, appears to be the result of the activation of 
cellular kinases. It does not appear as if PKC is involved in this process as the specific PKC 
inhibitor, bisindolylmaleimide (Toullec et al., 1991), did not inhibit neutrophil-mediated 
degradation offbg. However, inhibition offbg degradation by H7, TFP and ML-9, suggests that 
Ca2+/calmodulin-dependent kinases, which are sensitive to these inhibitors, may be activated by fbg 
interaction with the neutrophil membrane. The inhibition of neutrophil-mediated fibrinogenolysis in 
Ca2+ depleted media may support the participation of Ca
2+/calmodulin-dependent kinases in the 
activation of the membrane-associated protease. However, the decreased neutrophil-mediated 
degradation offbg in the absence of Ca
2+ might reflect possible Ca
2+ dependent binding of fbg to 
neutrophils. This does not, however, appear to be the case since neutrophil-mediated 
fibrinogenolysis is not reduced to that of conditioned medium in the absence of Ca
2+ and association 
of fbg with PMA-stimulated neutrophils is not influenced in the absence of Ca 2, indicating Ca
2+ 
independent binding of fbg to neutrophils. ML-9 inhibits actin-myosin interactions by the inhibition 
of phosphorylation of the myosin light chain by the myosin light chain kinase (MLCK) (Ito et al., 
1989). Thus, microfilament assembly may be important for the upregulation of the neutrophil 
membrane-associated proteolytic activity following the interaction of fbg with the neutrophil 
surface. An identical inhibition profile with these inhibitors, for both PMA-stimulated neutrophils 
and non-stimulated neutrophils, substantiates the findings that fbg association with the neutrophil 
per se, results in significant upregulation of the membrane associated protease. By contrast, the 
interaction of CRP with non-stimulated neutrophils did not activate cellular kinases. The observed 
activation of kinases during the incubation of CRP with PMA-stimulated neutrophils appears to be 
due to the action of PMA on the neutrophil (see Chapter 4, Shephard et al., 1989). 
The association offbg with the neutrophil membrane of both non-stimulated and PMA-stimulated 
neutrophils occurred in a saturable and specific manner although stimulation with PMA appeared to 
increase the affinity offbg binding. The association of fbg with neutrophils occurred at a position in 
close proximity to the CD1 le, 132 integrin receptor and resulted in, not only the upregulation of the 
membrane-associated protease, but also a time dependent release of this protease into the 
extracellular medium. The period required for maximal release of the protease may relate to the 
time required for the association of fbg with the neutrophil to reach equilibrium. Degradation of fbg 
by neutrophils, thus occurs both at the cell surface and in the extracellular medium. 
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Intact fbg could not be detected in association with the neutrophil as a result
 of neutrophil surface 
and subsequent extracellular-mediated degradation offbg. The fbg products
 (of30 kDa and less), 
however, associated specifically with the neutrophil Fe receptor, CD16 and 
the '32 integrins, 
CD1 la/CD18, CD1 lb/CD18 and CD1 lc/CD18. Although receptors recogn
ised by monoclonal 
antibodies directed against the gpllb/Illa ((33) receptor were expressed durin
g PMA-stimulation 
(data not shown) no interaction of the degradation products with this recept
or could be detected. 
The amino acid sequences within these fbg derived peptides do not appear h
omologous with K-Q-
A-G-D-V or G-P-R, which are known to be ligand recognition sequences fo
r CD1 lb/CD18 and 
CD1 lc/CD18, respectively (Wright et al., 1988; Loike et al., 1991), or R-G-D w
hich is recognised 
as a common ligand recognition sequence for integrins (Smyth et al., 1993). A 3
0 kDa plasmin-
derived peptide (fragment D) has been shown to bind to the CD1 lb/CD18 r
eceptor via a sequence 
within they chain (Gly-190 to Val-200) which does not contain any of the k
nown ligand 
recognition sequences (Altieri et al., 1988; Altieri et al., 1993). The possibility e
xists that this 
sequence is present within the 30 kDa degradation product described in this 
study, but this was not 
explored. 
The observed inhibition of neutrophil adherence to immobilised fbg by the n
eutrophil-derived fbg 
degradation products could modulate neutrophil interactions with extracellu
lar matrix components 
as well as neutrophil '32 integrin interactions with endothelial counter recept
ors ICAM-1 and 
ICAM-2. In addition, the interaction of the neutrophil-derived fbg degradati
on products with CD16 
may modulate neutrophil Fe receptor function. When this is considered, toge
ther with the results 
which show that neutrophil fibrinogenolysis generates non-clottable fbg, it is
 tenable that neutrophil 
proteolysis offbg could play an important role in the modulation of inflamm
atory processes 
through the regulation of fibrin deposition, neutrophil adhesion and migrator
y processes. 
CHAPTER6 
SUMMARY AND CONCLUSION 
The association of CRP with neutrophils and the concomitant degradation of this ligan
d by a 
PMA-upregulatable membrane-associated neutral protease has been shown in previous
 studies 
(Shephard et al., 1989). The aim of this study has been to identify the cellular distributi
on ofthis 
protease and the mechanism of neutrophil-mediated degradation of CRP and another a
cute phase 
protein, fibrinogen, during association of these ligands with neutrophils. 
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A non-ionic detergent insoluble neutrophil fraction, containing proteins of the neutroph
il 
cytoskeleton was found to contain this neutral protease. lhis may suggest that the enz
yme is 
located within the cell as a submembrane protease, localised at sites of interaction of th
e 
cytoskeleton with the membrane. Size exclusion chromatography showed the protease
 to be of the 
approximate molecular mass 600 k.Da and SOS-PAGE dissociated this protease into fo
ur distinct 
enzymatic species migrating to positions corresponding to the apparent molecular mas
s values of 
209 k.Da, 316 k.Da, 398 k.Da and 501 k.Da. 
Fibrinogen was also found to be a substrate for this protease. Degradation of fibrinoge
n by this 
neutrophil membrane-associated protease occurred in a manner distinct from other kno
wn 
fibrinogenolytic systems, including that of plasmin and neutrophil lysosomal enzymes. 
Fibrinogenolysis by this neutrophil membrane protease rendered the fibrinogen non-clo
ttable by 
thrombin, through cleavage from the N-terminus of the Aa chain and the C-terminus o
f the Bf3 and 
y chain. Cleavage of the Aa chain from the N-terminus by the neutrophil membrane pr
otease 
resulted in a 21 amino acid peptide, Aa 1-21, which has previously been reported to be
 a 
, characteristic of the action of elastase on fibrinogen. This protease was found to degr
ade fibrinogen 
during incubation with both non-stimulated neutrophils and neutrophils stimulated with
 PMA at a 
concentration which does not release proteases from the azurophil granules. Thus, this
 study 
presents an alternative mechanism for the generation of the Aa 1-21 peptide which cou
ld contribute 
to the reported plasma levels of this peptide and may also account for the levels of Aa
l-21 seen 
with non-stimulated neutrophils (Weitz et al., 1987). 
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The results of experiments investigating the mechanism of neutrophil-mediated processing of CRP 
and fibrinogen indicate that degradation occurs as a consequence of these ligands interacting with 
the neutrophil membrane. In the case offibrinogen, and possibly CRP, this interaction was 
concluded to occur at a position in close proximity to the CD l lc receptor of the f32 integrin family. 
The inability of the association of radio labelled CRP with neutrophils to be inhibited by unlabelled 
CRP, in the presence of inhibitors to the membrane protease, would not allow for accurate 
assessment of the position on the neutrophil surface to which CRP binds. The interaction of both 
CRP and fibrinogen with the neutrophil resulted in a time dependent egress of the protease from 
the cell, thus promoting the degradation of these ligands in the extracellular medium The products 
generated were found to associate with the neutrophil surface and in the case of fibrinogen 
degradation products this association was with the receptors of the f32 integrin family and the IgG 
Fe receptor, CD16. The CRP degradation products did not appear to bind to receptors of the f32 or 
f33 integrin family or the IgG Fe receptor. 
Although maximum degradation of both CRP (Shephard et al., 1989) and fibrinogen by the 
neutrophil membrane-associated preotease was achieved by stimulating the cells with PMA, these 
ligands could be degraded in the presence of non-stimulated cells. This was especially so in the case 
offibrinogen degradation. The interaction of fbg could activate cellular kinase activity per se while 
lcinase activation during the interaction of CRP with neutrophils required stimulation with PMA. 
The increase in proteolytic activity of the membrane-associated protease following ligand binding 
and PMA activation involves both H7 and TFP inhibitable kinases in addition to alterations in the 
micro filament structure of the cytoskeletal network. Protein kinase C does not, however, appear to 
be involved in the upregulation of this enzyme. 
Although the exact structure and sequence ofthis neutrophil membrane protease was not 
determined, it appears to be distinct from the only other serine protease (300 kDa) which has been 
described to be associated with the neutrophil membrane and cytoskeleton (Pontremoli et al., 1986; 
Pontremoli et al., 1990). This 300 kDa protease is involved in the downregulation of protein kinase 
Candis completely released into the extracellular medium as a result of PMA activation and 
protein kinase C stimulation (Melloni et al., 1986). A membrane bound form ofproteinase 3 as 
well as elastase and cathepsin G have recently been discovered (Csernok et al., 1994; Bangalore 
and Travis, 1994). These proteases within the neutrophil granules have considerable amino acid 
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sequence homology and all possess elastase-lik:e activity (Rao et al., 1991 ). They are, however, 
distinct on the basis of their specific catalytic properties and sensitivity to certain inhibitors. The 
protease descnoed here may represent another member of this family of elastase-like proteases. The 
fact that this enzyme exists as a large molecular weight complex may account for it behaving 
differently from elastase, with respect to cleavage specificity and sensitivity to inhibition by elastase 
inhibitors. 
The generation ofnon-clottable fibrinogen through the action of a membrane associated protease 
could well influence the extent of fibrin deposition at sites of inflammation. In addition, the ability 
of fibrinogen degradation products of less than 30 kDa to associate with receptors important for 
neutrophil function, could influence neutrophil adhesive and phagocytic processes. When this is 
considered together with the previously observed generation of bioactive CRP peptides which 
inhibit neutrophil inflammatory functions by this neutrophil membrane enzyme (Shephard et al., 
1989; Shephard et al., 1990; Shephard et al., 1992), it is tenable that activated neutrophils may 
play an important role generating products which limit the extent of an inflammatory reaction. 
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